

**THE FREQUENCY OF APPEARANCE
OF
EVALUATIVE CRITERIA IN POLYGRAPH CHARTS**

A RESEARCH REPORT

by

**Norman Ansley
Forensic Research, Inc.
35 Cedar Road
Severna Park, Maryland 21146-3715**

for

**Defense Personnel Research Center
99 Pacific Street
Building 455-E
Monterey, California 93940-2481**

**Office of Naval Research
Grant No. N00014-98-1-0863**

1999

DTIC QUALITY INSPECTED 2

DISTRIBUTION STATEMENT A
Approved for Public Release
Distribution Unlimited

19990802 046

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave Blank)		2. REPORT DATE July 1999		3. REPORT TYPE AND DATES COVERED Final Report, July 1999	
TITLE AND SUBTITLE The Frequency of Appearance of Evaluative Criteria in Polygraph Charts, A Research Report				5. FUNDING NUMBERS G No. N00014-98-1-0863	
6. AUTHOR(S) Norman Ansley				AGO Code N66020 PR No. 98PR07549-00 PR Code 822 Dispersing Code N68892	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Forensic Research, Inc. 35 Cedar Road Severna Park, MD 21146				8. PERFORMING ORGANIZATION REPORT NUMBER FRI 99-1	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Personnel Security Research Program Defense Personnel Research Center 99 Pacific Street, Bldg 455-E, Monterey, CA 93940-2481				10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES Prepared in cooperation with Donald J. Krapohl, Research Division, Department of Defense Polygraph Institute.					
12a. DISTRIBUTION/AVAILABILITY STATEMENT Department of Defense Polygraph Institute Fort Jackson, S.C. <i>Approved for public release Distribution unlimited</i>				12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) FRI recorded on forms the deception related reactions found on 616 polygraph charts from 174 criminal cases in which ground truth was known. Using the Department of Defense guide to chart interpretation to define reactions, the extracted data was sorted and counted. The frequency of each of the 22 evaluative criteria was rank ordered, ranging from 5 to 4,793. The rank order pattern stayed remarkably constant across questions, gender, and truth or deception status. Recommendations were made with respect to scoring generic zone comparison tests and the elimination of some currently listed deception criteria.					
14. SUBJECT TERMS Deception criteria, Polygraph charts, distribution of reactions, zone comparison test formats.				15. NUMBER OF PAGES 348	
				16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT unclassified	20. LIMITATION OF ABSTRACT UL		

TABLE OF CONTENTS

Abstract	1
Background	
Background to the Research	2
Background to this Research	2
Method	
Database	3
Definitions of Evaluative Criteria	4
Organization of the Data on FRI Form 1	5
Form 1 sample	6
Question Numbers and Question Types	7
Organization of Reaction Data From Questions	8
Organization of the Data for Comparison Purposes	9
Table 2, sample page	10
Table 3, bar charts	12
Reaction Types - Rank Order by Frequency	13
Two Cardio Frequency Studies	14
Chart Serial Effect by Channel	15
Organization of the Data by Sets of Charts	16
Sample and Instructions for Form 4 Series	18
Results	
Basic Data	19
Total and Average Reactions	20

Results by Question Number	20
Results by Type of Reaction	22
Results by Physiological Channel	22
Comparisons of Men and Women	23
Position Effect by Question Number	25
Comparisons by DI and NDI Status	27
Table 2-Q1-C and Table 1-5	28
Heart Rates and Respiration Rates	31
Table 1-3	32
Tables 1-7A to 7K	34
Table 1-8	46
Table 1-7	47
Discussion	48
Electrodermal	48
Table 5-1	49
Table 5-2	50
Table 5-3	51
Table 5-11	52
Table 5-8	53
Cardio	54
Table 5-12	56
Table 1-3	57
Table 5-10	59

Table 5-11	60
Respiration	61
Table 1-2	62
Table 1-8	63
Table 1-4A	64
Table 1-4	65
Table 5-11	66
Table 5-9	67
Chart Serial Effect By Channel	68
Table 5-11	69
Table 5-8	70
Table 5-10	71
Table 5-7	72
Table 5-6	73
Table 5-13	74
Recommendations	78
Appendix	79

LIST OF TABLES

Data Evaluation Form 1. 1a through 207C. Not with final report as there is no end user value.
All the data is in series 2 and series 4.

Table 1-1, Questions and Reactions

Table 1-2, Distribution of Reactions by Channel

Table 1-3, Heart Rates - tonic

Table 1-4, Reaction types - Rank Order by Frequency

Table 1-4A, Respiration - Rank Order by Frequency

Table 1-5, Number of Reactions by Question Number and by Reaction Type

Table 1-6, Respiration Rates from the Charts, in Sequence

Table 1-7A through 7F, Heart Rates of First Three Charts

Table 2 Q1 A through 2 Q10 N. 14 tables for each of the ten Questions

Table 3-1 through 3-6, bar-chart comparisons

Table 4AA through 4GG, 174 tables of data on sets of charts

Table 5-1, Electrodermal amplitude reactions and percent of questions asked

Table 5-2, Electrodermal duration reactions and percent of questions asked

Table 5-3, Electrodermal complex reactions and percent of questions asked

Table 5-4, Frequency of Electrodermal Responses

Table 5-5, Average Heart Rate by Gender and Race

Table 5-6, Gender and Outcome of Tests

Table 5-7A, Deceptive Charts: Distribution of Responses by Percentage

Table 5-7B, Non-Deceptive Charts: Distribution of Responses by Percentage

Table 5-8, Chart Serial Effect - Electrodermal

Table 5-9, Chart Serial Effect - Respiration

Table 5-10, Chart Serial Effect - Cardio

Table 5-11, Chart Serial Effect by Channel

Table 5-12, Two Cardio Frequency Tables

Table 5-13, Percentage Profile of Q.5 from 1st, 2nd, and 3rd charts

Tables 6-1 through 6-8 are rearranged data from the 2 and 4 series, and have no end user value. They are not included in the final report.

Abstract

Forensic Research, Inc. recorded on forms all the deception related reactions found on the polygraph charts in 174 criminal cases in which ground truth was known. The guide for categorizing the reactions as deception criteria was an illustrated paper on chart interpretation published by the Department of Defense Polygraph Institute, and recently published by the journal *Polygraph*. Federal examiners conducted these tests, with Axciton computer instruments and a variety of formats featuring juxtaposition of relevant and comparative questions which might be described as generic zone comparison formats. The frequency of appearance of each of the 22 criteria was tabulated and they were put in rank order, ranging from the five appearances of one reaction type to 4,793 appearances of another reaction. The rank order stayed remarkably constant across questions, gender, and truth or deception status. There was a reduction in the number of reactions in second and third charts of NDI examinees in all three physiological channels and a similar reduction in the electrodermal and cardio channels of DI examinees. However, the respiratory pattern showed an increase in reactions in successive charts.

Although we found more reactions and a higher tonic heart rate for the deceptive than the non-deceptive examinees, FRI recommends that scoring methods for these test formats and instruments include amplitude and duration as in a 7-position scale, and avoid the 3-position scale and rank ordering. FRI recommends combining four pairs of reactions, and eliminating PCVs. Last, FRI recommends that a study replicating this one be done with charts from laboratory simulations of examinations.

Key Words: Deception criteria, distribution of reactions, research, zone comparison test formats

BACKGROUND

Background to the Research

In teaching deception test criteria the Department of Defense Polygraph Institute (DoDPI) needs to know the frequency of the appearance of each type of reaction in their criteria list. Instructors know there are reactions on the list that they seldom see, but they cannot say they appear so seldom that they have no utility. We know from a Capps & Ansley study in 1992 what criteria examiners do use in their analyses, but that study does not tell us what reactions were available and not used. In a small study by Jensen of the cardio reactions on his charts, his numbers were sufficiently robust that the distribution could be compared to the results in this research.

Purpose of This Research

This study was planned to be large enough to answer a major question: What is the frequency of appearance on the charts of each of the deception test criteria that appear on the DoDPI list? In addition, the research was to address some issues on habituation, tonic heart rate, serial position effect, and gender effect.

We were able to answer the basic question. Some of the secondary projects could not be done for a lack of information.

We did obtain information on tonic heart rate. Deceptive examinees have a faster heart rate than non-deceptive examinees. Women have a faster heart rate than men.

There seemed to be no serial effect as we tested, asking questions one through ten. However, we found a general decline of reactivity in successive charts, with an anomaly. Comparative chart data gave us good data on gender effect. Most important, we obtained hard data on the frequency of appearance of listed deception test criteria. Based on the results of the research, a number of recommendations have been made.

METHOD

DATABASE

The database provided by DoDPI consisted of 207 sets of polygraph charts from real cases, confirmed as to truth or deception, conducted on Axciton computer polygraph instruments, and conducted with some form of zone format test featuring pairs of relevant and comparison questions. For various reasons some sets could not be used at all, and some could be used for limited purposes. We did use 176 sets of charts, plus 16 sets for limited purposes. There were 616 polygraph charts with seven to ten relevant questions on each. There were sixteen different formats, of which the most common (n.118) had 10 questions including 3 relevant, 3 comparison, and 4 technical questions. Technical questions include irrelevant, symptomatic, sacrifice relevant, and similar questions.

METHOD

DEFINITIONS OF EVALUATIVE CRITERIA

For definitions of terminology and scoring criteria, the reference was "Instructions for the Manual Evaluation of Charts Recorded During the Psychophysiological Detection of Deception," issued by the Department of Defense Polygraph Institute on 26 January 1998. The supplementary drawings of scoring criteria were also consulted.

The definitions of terminology and scoring criteria have been published. See Swinford, Jimmy (1999) Manually scoring polygraph charts utilizing the seven-position numerical analysis scale at the Department of Defense Polygraph Institute. *Polygraph* 28(1) 10-27. The Institute criteria list was placed on the left side of FRI Form 1, in the same order.

METHOD

ORGANIZATION OF THE DATA ON FRI FORM 1

FRI Form 1 was designed to match the DoD Polygraph Institute criteria list. The Form covers up to 10 questions, plus totals for all questions, totals for comparative questions, and totals for all relevant questions. These individual forms are the basis for most of the data and tables in this study. After a form had been completed for each chart, the DoDPI sent to FRI the conclusion of DI or NDI for each set, and that was marked on the lower right side of Form 1. For some forms they sent the gender and race of the examinee, but that data was far from complete.

File Name: _____

Chart: _____ of _____

Test Format: _____

Heart Rate - Beginning: _____

End: _____

PVCs useful? Yes No Other: _____

	1	2	3	4	5	6	7	8	9	10	T	TC	TR
RESPIRATION													
1. Rate Decrease													
2. Rate Increase													
3. I/E Ratio Change													
4. Amplitude Increase													
5. Amplitude Decrease/Suppression													
6. Progressive Increase/Decrease													
7. Progressive Increase & Return													
8. Progressive Decrease & Return													
9. Baseline Change - Temporary													
10. Baseline Change - Permanent													
11. Apnea - Holding (Inspiration)													
12. Apnea - Blocking (Exhalation)													
ELECTRODERMAL													
1. Amplitude Change													
2. Complex Response													
3. Response Duration & Return													
CARDIOVASCULAR													
1. Baseline Increase & Decrease													
2. Baseline Increase													
3. Baseline Decrease													
4. Amplitude Increase													
5. Amplitude Decrease													
6. Rate Increase													
7. Rate Decrease													
8. P.V.C.													

Gender: Male Female

Race:

Caucasian

African American

Hispanic

Asian

Age: _____

Comments: _____

METHOD

QUESTION NUMBER AND QUESTION TYPE

In most instances, when you know the name of the test format you know what kind of questions are at each location. The charts supplied by DoDPI for this project were labeled MGQT, but were actually generic zone comparison tests with several different sequences, varying from 7 to 10 questions. Question 1 was in all cases an irrelevant question. We were able to reconstruct the test format because examiners marked their charts with letters next to the question numbers that identified the type of question by type. Charts not so marked had to be rejected from the study. For example, if you relied on the conventional numbering, Question 7 is a relevant question, but among the sets of charts we used, in 20 it was a comparison question, and in ten sets it was a technical question. Question 8, usually a technical question (symptomatic), was a comparison question in 23 sets, and a relevant question in 19 sets. We are unaware of how DoDPI selected the charts.

METHOD

ORGANIZATION OF REACTION DATA FROM QUESTIONS ONE THROUGH TEN

The reactions caused by each of the ten questions was entered in the appropriate reaction category on the left side of the table. Tables were prepared for the various pairings of information. There are 14 tables for each of the ten questions, and each set of tables has the following headings:

Table 2 is the series, Q1 through Q10 are the questions, and the letter is the specific table - with the title.

Table 2-Q1-A Reactions from the First Three Charts DI - NDI

Table 2-Q1-B Reactions to the First Three Charts Men - Women

Table 2-Q1-C First Chart Reactions DI - NDI

Table 2-Q1-D First Chart Reactions Men - Women

Table 2-Q1-E First Chart Reactions DI Men - DI Women

Table 2-Q1-F First Chart Reactions NDI Men - NDI Women

The Second Chart Reactions are also on four forms, as above.

The Third Chart Reactions are also on four forms, as above.

For a sample table, see the next page. The numbers of reactions are in the left two columns, the percentages which show distribution, are in the right two columns.

Other pairings are possible by taking data from these tables, but there does not seem to be much use in comparing, for example, DI men with NDI women.

METHOD

ORGANIZATION OF THE DATA FOR COMPARISON PURPOSES

The Series 2 tables are organized by question number, with 14 tables for each question. Each table lists numbers and percentages. See a table, attached. The tables for comparison are:

Reactions from the first three charts [of that set] DI and NDI

Reactions from the first three charts, Men and Women

First chart reactions, DI and NDI

First chart reactions, Men and Women

First chart reactions, DI Men and DI Women

First chart reactions, NDI Men and NDI Women

The same series of sub-charts are made for the second charts and again for the third charts.

The Series 3 tables provide bar graphs to compare reaction data from the three sources:

Respiration, electrodermal, and cardio, compare heart rate data, and compare data from comparison questions with that of relevant questions.

The Series 4 tables provide the data so it may be used for comparative purposes, and the heart rate data is set up with some comparisons already done.

The Series 5 tables are those developed for use in the discussion section.

Title:

Q 1, Reactions from the First Three Charts

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	13	5	1	1
2. Rate Increase	5	0	0	0
3. I/E Ratio Change	3	3	0	0
4. Amplitude Increase	43	28	4	4
5. Amplitd Decrease/Suppression	16	31	1	4
6. Progressive Increase/Decrease	6	4	1	1
7. Progressive Increase & Return	6	8	1	1
8. Progressive Decrease & Return	8	8	1	1
9. Baseline Change - Temporary	40	16	4	2
10. Baseline Change - Permanent	21	19	2	3
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	12	7	1	1
ELECTRODERMAL				
1. Amplitude Change	312	188	29	26
2. Complex Response	31	22	2	3
3. Response Duration & Return	290	186	27	26
CARDIOVASCULAR				
1. Baseline Increase & Decrease	144	89	13	12
2. Baseline Increase	59	52	5	7
3. Baseline Decrease	17	15	2	2
4. Amplitude Increase	1	0	0	0
5. Amplitude Decrease	55	31	5	4
6. Rate Increase	3	1	0	0
7. Rate Decrease	2	0	0	0
8. ETC.				

1087 713

Table 2-26-A

Title: Q 6 , Reactions from the First Three Charts

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI	NDI	DI	NDI
	1	2	3	4
	no.	no.	%	%
RESPIRATION				
1. Rate Decrease	27	11	2	1
2. Rate Increase	21	2	2	0
3. I/E Ratio Change	7	5	1	1
4. Amplitude Increase	51	19	4	3
5. Amplitude Decrease/Suppression	20	19	2	3
6. Progressive Increase/Decrease	4	2	0	0
7. Progressive Increase & Return	6	8	0	1
8. Progressive Decrease & Return	11	11	1	1
9. Baseline Change - Temporary	40	38	3	5
10. Baseline Change - Permanent	32	15	3	2
11. Apnea - Holding (inspiration)	2	2	0	0
12. Apnea - Blocking (Exhalation)	12	5	1	1
ELECTRODERMAL				
1. Amplitude Change	307	188	25	25
2. Complex Response	70	57	6	8
3. Response Duration & Return	296	180	24	24
CARDIOVASCULAR				
1. Baseline Increase & Decrease	183	105	15	14
2. Baseline Increase	29	13	2	2
3. Baseline Decrease	43	32	4	4
4. Amplitude Increase	1	0	0	0
5. Amplitude Decrease	50	39	4	5
6. Rate Increase	1	0	0	0
7. Rate Decrease	0	0	0	0
	1213	751		

Average Reactions
on DI and NDI Sets
of Charts

Source of Reactions
on DI and NDI Sets
of Charts

DI/NDI

Average Heart Rate
Response on DI and NDI
Sets of Charts




Table 1-4

Reaction Types - Rank Order by Frequency

E1	Amplitude change	4793	26%
E3	Duration	4496	24%
C1	Baseline increase & decrease	2778	15%
E2	Complex response	1051	6%
C5	Amplitude decrease	940	5%
R4	Amplitude increase	704	4%
R9	Baseline change - temporary	683	3%
C2	Baseline increase	578	3%
R5	Amplitude decrease/suppression	476	3%
C3	Baseline decrease	400	2%
R10	Baseline change - Permanent	389	2%
R1	Rate decrease	318	1%
R8	Progressive decrease & return	265	1%
R12	Apnea - (exhalation)	182	1%
R2	Rate increase	154	1%
R7	Progressive increase & return	107	1%
R6	Progressive increase/decrease	102	1%
R3	I/E Ratio change	62	Under ½ of 1 percent
C6	Rate increase	25	
C7	Rate decrease	23	
R11	Apnea - Holding (inspiration)	9	
C4	Amplitude increase	5	

Table 5-12

TWO CARDIO FREQUENCY TABLES

This is a comparison of Carl Jensen's study of the frequency of cardio responses taken from 66 specific issue tests in his files with the frequency of cardio responses from the 176 specific issue sets of files in this study. The lists are in descending order. We have changed his terminology to match our.

THIS STUDY		JENSEN'S STUDY	
Baseline increase & decrease	2778	Baseline increase & decrease	363
Pulse amplitude decrease	940	Pulse amplitude decrease	326
Baseline increase	578	Baseline increase	172
Baseline decrease	400	Pule amplitude increase	52
Pulse rate increase	25	Baseline decrease	48
Pulse rate decrease	23	Pulse rate increase	43
Pulse amplitude increase	5	Baseline decrease	42
		Pulse rate decrease	20

See Jensen, Carl W. (1981). Frequency of occurrence of specific reaction criteria as observed in the cardio tracing. *Academy Journal* 4(2), 5, 7.

TABLE 5-11

CHART SERIAL EFFECT BY CHANNEL

DI charts	1st	2d	3d	NDI charts	1st	2d	3d
Respiration	745	761	802		448	335	364
Electrodermal	2221	2081	1960		1490	1259	1098
Cardiovascular	1076	1063	984		681	667	495
Average	1347	1302	1249		873	754	652

Data from tables in 2 Series

METHOD

ORGANIZATION OF THE DATA BY SETS OF CHARTS

The 176 sets of charts are described by the tables in series 4. Most of that information came from Forms 1 and 1a. However, information on case outcome, DI or NDI, gender, and race was provided by DoDPI after FRI had extracted all the data from Forms 1 and 1a. Data on case outcome was the only complete list.

A sample of table 4 entries and an explanation of the entries are on the following pages.

TABLE 4 SERIES

DATA FROM THE SETS OF CHARTS

Note on the tables. The \$\$ number/letter group is the Axciton/DoD number; the set number is the FRI file; 10, 8, 7, etc. with Q is the number of questions on a chart; 3C means 3 comparative questions, 3R is the number of relevant questions on a chart, 3 charts is the number of charts run but not counting stim charts; DI is deception indicated; NDI is no deception indicated (both confirmed by independent means; M and F for Male and Female; under Asked is R for Relevant questions, C for comparative questions and T is for technical questions (irrelevant, symptomatic, sacrifice relevant) and the total number of questions asked in that set; (from the left) T is the total number of reactions on each chart and in the set; TR is the total number of reactions in each chart and the set to relevant questions; TC is the same but reactions to the comparative questions; R is the number of reactions by chart and set from the respiration channels; GSR is the number of reactions by chart and set from the electrodermal channel; C is the number of reactions by chart and set from the cardio channel; HR is the heart rate from the beginning and end of each chart and below the average rates for the charts; RR is the respiration rates from the beginning and end of each chart and below the average rate for the charts in the set (not all sets have the RR data on the form); stim data on the lower left if known; notes on fast or slow HR or RR.

Table 4DF\$\$\$57991K Set no. 103 10 Q Test, 3 C 3 R, 3 charts DI / NDI M / F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	36	9	16	2	20	8	96/86	17/18	9 R
b.	27	7	7	3	22	2	90/88	14/17	9 C
c.	26	7	9	3	21	2	88/88	15/16	12 T
T.	<u>83</u>	<u>23</u>	<u>26</u>	<u>8</u>	<u>63</u>	<u>12</u>	<u>91/87</u>	<u>15/17</u>	<u>30</u>

STIM 86/88, 17/15

Table 4DG\$\$\$V#V7M Set no. 105 10 Q Test, 3 C 3 R, 3 charts DI / NDI M / F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	37	12	13	4	21	12	84/76	20/16	9 R
b.	42	16	11	6	17	19	78/74	19/16	9 C
c.	47	16	15	8	19	20	76/76	17/16	12 T
T.	<u>126</u>	<u>44</u>	<u>39</u>	<u>18</u>	<u>57</u>	<u>51</u>	<u>79/75</u>	<u>19/16</u>	<u>30</u>

Note: large output of cardio channel

STIM 70/26, 19/20

RESULTS

Basic Data

The 1,780 relevant questions produced 6,453 reactions, for an average of 3.6 per question. The 1,932 comparison questions produced 6,777 reactions, for an average of 3.1 per question. The 2,154 technical questions produced 7,484 reactions, for an average of 3.5 per person.

In terms of questions asked, of the total, 31% were relevant, 33% were comparison, and 36% were technical. See Table 1-1.

Of the 20,714 reactions, 3,848 or 19% from the pneumograph, 11,414, or 55%, were from the electrodermal, and 5,453, or 26%, were from the cardiosphymograph. See Table 1-2.

RESULTS

TOTAL AND AVERAGE REACTIONS

1,780 relevant questions asked during the examinations caused 6,453 reactions, averaging 3.6 per question. 1,932 comparison questions caused 6,777 reactions, averaging 3.1 per question. 2,154 technical questions caused 7,484 reactions, averaging 3.5 reactions per question. See Table 1-1.

Of those 20,714 reactions, 3,848, or 19%, came from the pneumograph channel. 11,414, or 55% of the reactions, came from the electrodermal channel. 2,154, or 26% of the reactions, came from the cardio channel. See Table 1-2.

The average heart rate during the examinations was 90 beats per minute. Pairings for twelve sets of information are listed on Table 1-3. For example, the average heart rate at the ending of NDI charts was 87 [paired with]; the average heart rate at the end of DI charts was 92.

On Table 1-4 each type of reaction is rank ordered by frequency of appearance on the charts. The range is from electrodermal amplitude change which appeared 4,793 times to cardio amplitude increase which occurred 5 times.

Results by Question Number

Tables in the 2 series display information by question number. For each of the ten question numbers there are 14 tables. Each of these presents a pairing of information for analysis. For example, Table 2-Q1-A is Reactions from the 1st three charts [of each set] pairing reactions on DI charts with information on NDI charts, by reaction type and by channel [pneumo, electrodermal, cardio]. The researcher with a special interest may design his own table from these tables. For example, he can compare the reactions on DI charts with those on NDI charts, question by question, then with totals. See Table 6-1, attached.

Result

DI 1st Charts

Table 6-1

Questions	Resp	Elect.	Cardio	Totals			
1	56	15%	222	58%	105	27%	383
2	63	15%	234	57%	114	28%	411
3	77	19%	231	56%	103	25%	411
4	69	20%	185	53%	98	28%	352
5	62	15%	223	53%	136	32%	421
6	81	19%	247	58%	96	22%	424
7	75	17%	234	53%	134	30%	443
8	76	19%	203	57%	79	22%	358
9	73	18%	225	56%	105	26%	403
0	83	20%	217	53%	106	26%	406
T	715	18%	2221	55%	1076	27%	4012

NDI 1st Charts

	Resp	Elect.	Cardio	Totals			
1	39	17%	136	58%	61	26%	236
2	46	17%	155	58%	67	28%	268
3	48	16%	172	57%	83	27%	303
4	56	20%	141	51%	77	28%	274
5	47	17%	155	57%	68	25%	270
6	50	17%	180	60%	72	24%	302
7	47	17%	163	57%	74	26%	284
8	41	18%	124	55%	61	27%	226
9	34	15%	136	59%	59	26%	229
10	41	18%	128	56%	59	26%	228
T	449	17%	1490	57%	681	26%	2620

RESULTS

Results by Type of Reaction

The distribution of reactions by type, can be shown by numbers or by percentages. The numbers for the types of reactions are found on Table 1-5. Percentages may be found on the 2 series of tables, and for NDI charts on Table 5-7A, and for DI charts on Table 5-7B.

Results by Physiological Channel

The information on the number of reactions by physiological channel is in bar-graph format in the 3 series tables, and by chart sets in the 4 series tables.

RESULTS

COMPARISONS OF MEN AND WOMEN

In the 2 series of tables, for each question number there are comparisons of men and women for:

- a. Reactions from the first three charts [of each set]
- b. First chart reactions
- c. First chart reactions - DI Men and DI Women
- d. First chart reactions - NDI Men and NDI Women
- e. Second and third chart reactions with the same sub-sets as above

From information on 2 series tables other tables can be made.

In comparing results from testing men and women, keep in mind that of 177 examinees, the gender of 16 was not recorded. There were 115 men tested, and 36 women tested. So of the 161 tested whose gender is known, 115 (71%) are men and 46 (29%) are women.

See Table 5-6, attached.

Using the rules in Table 5-6, here is a sampling comparing the average number of reactions per question of men and women.

	DI Men	DI Women	NDI Men	NDI Women
Q1	3.3	3.5	2.4	2.9
Q4	3.9	4.6	4.6	3.2
Q7	4.1	4.0	4.3	4.5

Note that on Table 1-1, the average reactions to a technical question is 3.5 (compare to Q1 above), 3.1 to a comparison question (Q4 above) and 3.6 to a relevant question (Q7 above).

TABLE 5-6
GENDER AND OUTCOME OF TESTS

Men Tested	115	DI	71 (62%)	NDI	44 (38%)
Women Tested	46	DI	31 (67%)	NDI	15 (39%)
Gender Unknown	16	DI	9 (56%)	NDI	7 (44%)
Total Tested	177	DI	111 (63%)	NDI	66 (37%)

Of 161 tested whose gender is known, 115 are men (71%) and 46 are women (29%). To compare reactivity of men and women on question 2 of the first chart, you divide the total number of reactions by men, 449, by the number of men tested and get 3.9. The total for women is 182, divided by 46, and get 4.0. These are reasonable results, see Table 1-1. If you are going to compare reactivity on DI Men with DI Women, you divide by 71 for Men and 31 for Women, from Table 5-6 (*supra*).

RESULTS

POSITION EFFECT BY QUESTION NUMBER

Look at Table 1-5, Number of reactions by question and by reaction type, and look at Table 1-8, Rank order of frequency of criteria by question, both attached. Table 1-5 shows a rather consistent pattern of numbers across the Question numbers. No position effect appears.

On the Rank Order Table, 1-8, reactions stay in the rank order across the question numbers with fair consistency, moving up or down a line or two. No position effect can be attributed to those changes in the order. There are exceptions, the most startling is R9 that starts at level 8 and is there or at 7 or 6 for all of the numbers except Question 6, where it drops to level 14.

RESULTS

CHART SERIAL EFFECT

The question here was to determine if the number of reactions varied with the chart, first, second or third chart in a test. We drew on the data in the number two series, those forms comparing DI with NDI on charts, one, two and three. New tables were created by channel, but separated into DI and NDI. (See 5-8 through 5-11).

General results are apparent on Table 5-11. Declining numbers of reactions are seen in the NDI charts for the three channels, and in the average of the three channels for NDI charts. That is true for the electrodermal and cardio channels of DI charts. However, the respiration channel with DI charts presents an anomaly, instead of reactions declining on the second and third charts, they increased. (See 5-11).

RESULTS

COMPARISONS BY DI AND NDI STATUS

In the 2 series of tables, for each question number there are comparison of DI and NDI for:

- a. Reactions from the first three charts [of each set]
- b. First chart reactions
- c. Second chart reactions
- d. Third chart reactions

From the data in these tables one can make other tables of interest. See for example Table 6-1 comparing data from the first charts of all ten questions. From this table for each question you have the number of reactions from the pneumo, electrodermal, and cardio channels, and the total number of reactions for that question. You also have by percentage what the numbers represent in relation to the total number. At the bottom of Table 6-1 are the total number of reactions from each channel for all ten questions. For the DI First charts the total number of reactions was 4,012 of which 18% came from the pneumo, 55% from electrodermal, and 27% from the cardio. The NDI total reactions are 2,620 of which 17% came from the pneumo, 57% from the electrodermal, and 26% from the cardio.

Table 2-Q1-c

● title: Q 1, First Chart Reactions

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	2	1	1	0
2. Rate Increase	2	0	1	0
3. I/E Ratio Change	2	1	1	0
4. Amplitude Increase	14	8	4	3
5. Amplitd Decrease/Suppression	5	5	1	2
6. Progressive Increase/Decrease	1	2	0	1
7. Progressive Increase & Return	2	2	1	1
8. Progressive Decrease & Return	1	3	0	1
9. Baseline Change - Temporary	19	7	5	3
10. Baseline Change - Permanent	6	9	2	4
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	2	1	1	0
ELECTRODERMAL	56	39		
1. Amplitude Change	108	66	28	28
2. Complex Response	8	5	2	2
3. Response Duration & Return	106	65	28	28
CARDIOVASCULAR	222	136		
1. Baseline Increase & Decrease	53	33	14	14
2. Baseline Increase	17	10	4	4
3. Baseline Decrease	7	8	2	3
4. Amplitude Increase	1	0	0	0
5. Amplitude Decrease	25	10	7	4
6. Rate Increase	1	0	0	0
7. Rate Decrease	1	0	0	0
8. P.V.C.				

105 383 61 236

Result

DI 1st Charts

Table 6-1

resting	Resp	Elect.	Cardio	Totals			
1	56	15%	222	58%	105	27%	383
2	63	15%	234	57%	114	28%	411
3	77	19%	231	56%	103	25%	411
4	69	20%	185	53%	98	28%	352
5	62	15%	223	53%	136	32%	421
6	81	19%	247	58%	96	22%	424
7	75	17%	234	53%	134	30%	443
8	76	19%	203	57%	79	22%	358
9	73	18%	225	56%	105	26%	403
10	83	20%	217	53%	106	26%	406
T	715	18%	2221	55%	1076	27%	4012

NDI 1st Charts

	Resp	Elect.	Cardio	Totals			
1	39	17%	136	58%	61	26%	236
2	46	17%	155	58%	67	28%	268
3	48	16%	172	57%	83	27%	303
4	56	20%	141	51%	77	28%	274
5	47	17%	155	57%	68	25%	270
6	50	17%	180	60%	72	24%	302
7	47	17%	163	57%	74	26%	284
8	41	18%	124	55%	61	27%	226
9	34	15%	136	59%	59	26%	229
10	41	18%	128	56%	59	26%	228
T	449	17%	1490	57%	681	26%	2620

Table 1-5
NUMBER OF REACTIONS BY QUESTION
AND BY REACTION TYPE

	1	2	3	4	5	6	7	8	9	10	T	TC	TR
RESPIRATION													
1. Rate Decrease	22	36	32	40	24	34	37	32	27	24	318	105	48
2. Rate Increase	6	15	26	19	11	19	18	12	20	8	154	70	35
3. I/E Ratio Change	6	5	6	7	11	10	6	5	6	3	62	29	18
4. Amplitude Increase	61	86	74	87	78	82	76	53	60	53	764	223	223
5. Amplitd Decrease/Suppression	42	44	61	46	48	46	38	55	47	44	476	148	132
6. Progressive Increase/Decrease	14	10	10	13	13	8	9	14	7	4	102	27	37
7. Progressive Increase & Return	13	9	11	15	12	11	11	15	3	7	107	28	35
8. Progressive Decrease & Return	22	20	28	30	32	26	31	23	32	21	265	94	81
9. Baseline Change - Temporary	59	72	72	73	75	71	79	66	59	57	683	216	222
10. Baseline Change - Permanent	36	31	44	42	50	43	44	41	35	23	364	132	128
11. Apnea - Holding (Inspiration)	0	1	0	1	0	2	1	1	2	1	9	5	2
12. Apnea - Blocking (Exhalation)	17	23	16	23	21	15	18	20	13	16	182	57	58
ELECTRODERMAL													
1. Amplitude Change	504	503	492	489	506	462	493	450	440	439	4793	1439	1414
2. Complex Response	54	117	128	122	162	140	109	95	105	74	1051	409	284
3. Response Duration & Return	489	479	454	451	481	458	463	413	406	412	4496	1334	1344
CARDIOVASCULAR													
1. Baseline Increase & Decrease	231	277	273	307	372	269	312	257	274	256	2778	971	1005
2. Baseline Increase	102	85	64	62	57	44	45	37	46	33	578	160	154
3. Baseline Decrease	25	36	37	56	41	64	35	41	39	26	460	151	14
4. Amplitude Increase	2	2	-	-	-	2	-	1	-	-	5	2	-
5. Amplitude Decrease	87	103	104	109	117	84	117	66	78	75	940	312	326
6. Rate Increase	4	3	3	3	3	2	3	1	1	2	25	5	8
7. Rate Decrease	2	4	1	2	4	1	3	3	3	-	23	8	8
8. P.V.C.	3	5	3	1	4	2	4	4	3	1	30	6	8

RESULTS

HEART RATES AND RESPIRATION RATES

Heart rates were taken from the beginning and end of each chart. Using that data a number of combinations are made on Table 1-3, attached. Note that wherever DI and NDI are compared, the DI will have the faster heart rate. Wherever men and women are compared, women will have the faster heart rate.

The respiration rate was taken from the beginning and ending of 110 sets of charts. The rates are set forth in Table 1-6 attached. The respiration data has been plotted on six graphs in Table 1-6, attached. Similarly, the heart rate data has been plotted on six graphs on Table 1-7A to 1-7F.

TABLE 1-3

Heart Rates

Average HR for Women at beginning of charts:	94
Average HR for Men at beginning of charts:	86
Average HR for Women at ending of charts:	94
Average HR for Men at ending of charts:	86
Average HR for DI Women at beginning of charts:	98
Average HR for DI Men at beginning of charts:	89
Average HR for DI Women at ending of charts:	97
Average HR for DI Men at ending of charts:	88
Average HR for NDI Women at beginning of charts:	91
Average HR for NDI Men at beginning of charts:	84
Average HR for NDI Women at ending of charts:	91
Average HR for NDI Men at ending of charts:	84
Average HR for NDI Women at beginning of charts:	91
Average HR for DI Women at beginning of charts:	98
Average HR for NDI Women at ending of charts:	91
Average HR for DI Women at ending of charts:	97

Average HR of NDI Men at beginning of charts:	84
Average HR of DI Men at beginning of charts:	89
Average HR of NDI Men at ending of charts:	84
Average HR of DI Men at ending of charts:	88
Average HR at beginning of 1 st chart:	92
Average HR at end of 1 st chart:	91
Average HR at beginning of 2d chart:	90
Average HR at ending of 2d chart:	90
Average HR at beginning of 3d chart:	89
Average HR at ending of 3d chart:	88
Overall average HR:	90
Average HR at beginning of NDI charts:	87
Average HR at beginning of DI charts:	94
Average HR at ending of NDI charts:	87
Average HR at ending of DI charts:	92

HR DATA Beginning of lot chat

Average 91.6
mode 72 (n. 13)
range 48-146
n. 206

Table
1-7A

[illegible]

Average	91.1
mode	78 (n")
Range	48-144
n	206

[illegible]

36

Average	90.0
Mode	90 (n=14)
Range	50 - 144
N _n	201

7.

[illegible]

HR Data Beginning of 3rd Chart

Average	88.6
Mode	84 (n.13)
Range	50 - 144
No.	196

2

[illegible]

HR Data	End of 3rd Chart
1	1
2	2
3	3
4	4
5	5
6	6
7	7
8	8
9	9
10	10
11	11
12	12
13	13
14	14
15	15
16	16
17	17
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31
32	32
33	33
34	34
35	35
36	36
37	37
38	38
39	39
40	40
41	41
42	42
43	43
44	44
45	45
46	46
47	47
48	48
49	49
50	50
51	51
52	52
53	53
54	54
55	55
56	56
57	57
58	58
59	59
60	60
61	61
62	62
63	63
64	64
65	65
66	66
67	67
68	68
69	69
70	70
71	71
72	72
73	73
74	74
75	75
76	76
77	77
78	78
79	79
80	80
81	81
82	82
83	83
84	84
85	85
86	86
87	87
88	88
89	89
90	90
91	91
92	92
93	93
94	94
95	95
96	96
97	97
98	98
99	99
100	100

Average
Mode


88, 3
76 (n. 13)
84 (n. 13)
90 (n. 13)
92 (n. 13)
48, 144
196

Range No.

42


Respiration
Average 17.7
Mode 17
Range 8-28

Beginning of 1st Charts
Table 1-7F



Average: 17.5 Respiration
 Mode: 16 Ending of lot charts
 Range: 8-35

Table 1.76



Cycles Per Minute

6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40

Respiration


Average 16.4

Mode 17

Range 9-31

Beginning of 2nd Chart

Table D-74




Cycles per minute 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40

Respiration Ending of 2nd Chute

Table 1-71

Respiration
Average 17.1
Mode 17
Range 7-30



Cycles per minute: 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35



Respiration: Beginning of 3rd Chart


Respiration

Average 16.7 Beginning of 3d Chart

Mode 16

Range 9-32

Table 125



6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35

Cycles Per minute

Respiration


Ending of 3d Chart

Table L7K

Average 17.4

Mode 16.218 (trial)

Range 8-34



5 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35

Circles per minute

TABLE 1-8

RESPIRATION RATES FROM THE CHARTS

The respiration cycles per minute were taken from the beginning and ending of each chart in 110 sets of charts.

Beginning of 1st charts: 17.7 c.p.m., range 8-28, mode 17

Ending of 1st charts: 17.5 c.p.m., range 9-35, mode 16

Beginning of 2nd charts: 16.4 c.p.m., range 9-31, mode 17

Ending of 2nd charts: 17.1 c.p.m., range 7-30, mode 17

Beginning of 3rd charts: 16.7 c.p.m., range 9-32, mode 16

Ending of 3rd charts: 17.4 c.p.m., range 8-34, mode 16 and 18

TABLE 1-7

HEART RATE DATA FROM CHARTS

HR at beginning of 1st chart: av. 91.6, mode 72, range 48-146

HR at end of 1st chart: av. 91.1, mode 78, range 48-144

HR at beginning of 2nd chart: av. 90.0, mode 94, range 48-152

HR at end of 2nd chart: av. 90.0, mode 90, range 50-144

HR at beginning of 3rd chart: av. 88.6, mode 84, range 50-144

HR at end of 3rd chart: av. 88.3, mode tied*, range 48-144

* mode tied by 76, 84, 90 and 92

HR at beginning of stim charts: 86.5, end 87.3 (n. 30)

DISCUSSION

Electrodermal

In regard to the frequency of reactions, the electrodermal channel is the most productive. DoDPI lists three electrodermal reactions in the evaluative criteria: amplitude, duration and complex pattern. Of the 22 criteria on the DoDPI list, electrodermal amplitude and electrodermal duration are the two most productive, and the complex reaction is fourth.

There are more electrodermal reactions in deceptive sets of charts than there are in non-deceptive sets of charts. In this study there was an average of 56 in the deceptive sets, 50 in the nondeceptive sets. Sets from deceptive women averaged 55, truthful women averaged 47. Sets of charts from deceptive men averaged 58 electrodermal reactions, while truthful sets from men averaged 54 electrodermal reactions.

There appears to be a small lessening of production of electrodermal reactions over the span of ten questions, after allowance is made for the fact that questions 8, 9, and 10 were asked less often than the other seven. Some sets of charts had only seven questions, some sets had only eight, and some only had nine questions in the format (see Table 5-1). More pronounced is the reduction in electrodermal responses in second and third charts, see Tables 5-8 and 5-11.

TABLE 5-1

Electrodermal

Q.	1.	509 reactions/amplitude	590 questions asked	86%
Q.	2.	503 reactions/amplitude	590 questions asked	85%
Q.	3.	492 reactions/amplitude	590 questions asked	83%
Q.	4.	489 reactions/amplitude	590 questions asked	83%
Q.	5.	506 reactions/amplitude	590 questions asked	86%
Q.	6.	482 reactions/amplitude	590 questions asked	82%
Q.	7.	493 reactions/amplitude	590 questions asked	84%
Q.	8.	450 reactions/amplitude	585 questions asked	77%
Q.	9.	440 reactions/amplitude	579 questions asked	76%
Q.	10.	439 reactions/amplitude	572 questions asked	77%

TABLE 5-2

Electrodermal

Q.	1.	489 reactions/duration	590 questions asked	83%
Q.	2.	479 reactions/duration	590 questions asked	81%
Q.	3.	454 reactions/duration	590 questions asked	77%
Q.	4.	451 reactions/duration	590 questions asked	76%
Q.	5.	481 reactions/duration	590 questions asked	82%
Q.	6.	458 reactions/duration	590 questions asked	78%
Q.	7.	463 reactions/duration	590 questions asked	78%
Q.	8.	450 reactions/duration	585 questions asked	77%
Q.	9.	440 reactions/duration	579 questions asked	76%
Q.	10.	439 reactions/duration	572 questions asked	77%

TABLE 5-3**Electrodermal**

Q.	1.	59 Reactions/Complex	590 Questions asked	10%
Q.	2.	117 Reactions/Complex	590 Questions asked	20%
Q.	3.	128 Reactions/Complex	590 Questions asked	22%
Q.	4.	122 Reactions/Complex	590 Questions asked	21%
Q.	5.	102 Reactions/Complex	590 Questions asked	17%
Q.	6.	170 Reactions/Complex	590 Questions asked	29%
Q.	7.	109 Reactions/Complex	590 Questions asked	18%
Q.	8.	95 Reactions/Complex	585 Questions asked	16%
Q.	9.	105 Reactions/Complex	579 Questions asked	18%
Q.	10.	74 Reactions/Complex	572 Questions asked	13%

TABLE 5-11
CHART SERIAL EFFECT BY CHANNEL

DI charts	1st	2nd	3rd	NDI	1st	2nd	3rd
Respiration	745	761	802		448	335	364
Electrodermal	2221	2081	1960		1490	1259	1098
Cardiovascular	1076	1063	984		681	667	495
Average	1347	1302	1249		874	754	652

Data from tables in 2 Series

TABLE 5-8

CHART SERIAL EFFECT - ELECTRODERMAL

DI						NDI				
	1 st	2 nd		3 rd	chart	1 st	2 nd		3 rd	chart
1.	222	210	-12	191	-31	136	136	0	120	-16
2.	234	213	-21	216	-18	155	137	-18	120	-35
3.	231	221	-10	190	-41	172	131	-41	94	-78
4.	185	199	+14	193	+8	141	129	-12	121	-20
5.	223	229	+6	224	+1	155	125	-30	141	-14
6.	247	215	-32	209	-38	180	136	-44	132	-48
7.	234	230	-4	214	-20	163	120	-43	111	-52
8.	203	190	-13	192	-11	124	110	-14	97	-27
9.	225	189	-36	149	-76	136	175	+39	114	-22
10.	217	185	-32	182	-35	128	60	-68	48	-80
	2221	2081	-140	1960	-261	1490	1259	-231	1098	-392

DISCUSSION

Cardio

In terms of frequency, the cardio contributed 29% of the reactions, in seven categories. The increase and decrease reaction appeared 2,778 times, while pulse amplitude appeared only five times. Pulse rate increase (n.25) and pulse rate decrease (n.23) contributed less than one percent of the cardio reactions. Those three low-production patterns could be footnoted but should be deleted from the deception criteria list.

The similar but smaller study by Jensen in 1981 is particularly interesting in that his hierarchy of appearances of the reaction types is much like our study. Proportionately, Jensen has higher incidents of pulse amplitude increases. His instrument might have had a mechanical cardio, and those required a much higher operating pressure. When the operating pressure is above the midway point between systolic and diastolic you get pulse amplitude increase instead of a pulse amplitude decrease. For a comparison of this study and Jensen see Table 5-12.

The tonic heart rate of deceptive examinees was consistently faster than the tonic heart rate of non-deceptive examinees; and the tonic heart rate of women was consistently faster than the tonic heart rate of men. There does not appear to be any way to capitalize on the tonic rate difference between truth and deception. Subtle differences in heart rate as phasic changes might be made visible to examiners with a cardio tachometer. See Table 1-3.

With the increase and decrease pattern a frequently appearing reaction, a question about its accuracy is appropriate. In Capps & Ansley (1992) the examiners used the pattern in 36% of their decisions, and their spot analysis were correct in 81% of their decisions. The increase without the decrease reaction was used in 22% of the spot analyses and was correct in 81% of their decisions.

The most accurate feature in detecting deception was the pulse amplitude decrease, used in 9% of their decisions, correct in 93%.

There does not appear to be any serial effect by question sequence. See Table 5-10. However, the repetition over three charts did have an effect, with a reduction in the number of cardio reactions in both DI and NDI sets. See Table 5-11. In the DI charts, the second chart had 45 fewer cardio reactions than the first, and the third had 53 fewer than the second. In the NDI sets, the second is 119 fewer than the first, and the 3rd is 102 less than the 2nd. The other two channels had similar drops in the NDI sets, and the electrodermal decline was similar in the DI sets. The Respiration data for the DI sets is anomalous, increasing 16 after the first chart, and increasing 19 after the 2nd. Since the distribution is fairly constant, no practical problem seems to arise. Also, if the third chart was seriously deficient in reactivity, that would have been noticed years ago in quality control.

TABLE 5-12

TWO CARDIO FREQUENCY TABLES

This is a comparison of Carl Jensen's study of the frequency of cardio responses taken from 66 specific issue tests in his files with the frequency of cardio responses from the 176 specific issue sets of files in this study. The lists are in descending order. We have changed his terminology to match ours.

THIS STUDY		JENSEN'S STUDY	
Baseline increase & decrease	2778	Baseline increase & decrease	363
Pulse amplitude decrease	940	Pulse amplitude decrease	326
Baseline increase	578	Baseline increase	172
Baseline decrease	400	Pulse amplitude increase	52
Pulse rate increase	25	Baseline decrease	48
Pulse rate decrease	23	Pulse rate increase	43
Pulse amplitude increase	5	Baseline decrease	42
		Pulse rate decrease	20

See Jensen, Carl W. (1981). Frequency of occurrence of specific reaction criteria as observed in the cardio tracing. *Academy Journal* 4(2) 5, 7.

TABLE 1-3

Heart Rates

Average HR for Women at beginning of charts:	94
Average HR for Men at beginning of charts:	86
Average HR for Women at ending of charts:	94
Average HR for Men at ending of charts:	86
Average HR for DI Women at beginning of charts:	98
Average HR for DI Men at beginning of charts:	89
Average HR of DI Women at ending of charts:	97
Average HR of DI Men at ending of charts:	88
Average HR of NDI Women at beginning of charts:	91
Average HR of NDI Men at beginning of charts:	84
Average HR of NDI Women at ending of charts:	91
Average HR of NDI Men at ending of charts:	84
Average HR of NDI Women at beginning of charts:	91
Average HR of DI Women at beginning of charts:	98
Average HR of NDI Women at ending of charts:	91
Average HR of DI Women at ending of charts:	97

Average HR of NDI Men at beginning of charts:	84
Average HR of DI Men at beginning of charts:	89
Average HR of NDI Men at ending of charts:	84
Average HR of DI Men at ending of charts:	88
 Average HR at beginning of 1 st chart:	 92
Average HR at end of 1 st chart:	91
 Average HR at beginning of 2 nd chart:	 90
Average HR at ending of 2 nd chart:	90
 Average HR at beginning of 3 rd chart:	 89
Average HR at ending of 3 rd chart:	88
 Overall average HR:	 90
 Average HR at beginning of NDI charts:	 87
Average HR at beginning of DI charts:	94
 Average HR at ending of NDI charts:	 87
Average HR at ending of DI charts:	92

TABLE 5-10

CHART SERIAL EFFECT - CARDIO

DI						NDI				
	1 st	2 nd	3 rd			1 st	2 nd	3 rd		
1.	105	106	+1	77	-28	61	71	+10	55	-6
2.	114	112	-2	99	-15	67	64	-3	56	-11
3.	103	101	-2	98	-5	83	72	-11	50	-33
4.	98	119	+21	122	+24	77	63	-14	50	-27
5.	136	129	-7	101	-35	68	62	-6	63	-5
6.	96	103	+7	105	+9	72	65	-7	60	-12
7.	134	113	-21	123	-11	74	59	-15	40	-34
8.	79	87	+8	83	+4	61	50	-11	44	-17
9.	105	93	-12	76	-29	59	133	+74	51	-8
10.	106	100	-6	100	-6	59	28	-31	26	-33
	1076	1063	-13	984	-92	681	667	-14	495	-186

TABLE 5-11**CHART SERIAL EFFECT BY CHANNEL**

DI charts	1st	2nd	3rd	NDI	1st	2nd	3rd
Respiration	745	761	802		448	335	364
Electrodermal	2221	2081	1960		1490	1259	1098
Cardiovascular	1076	1063	984		681	667	495
Average	1347	1302	1249		873	754	652

Data from tables in 2 Series

DISCUSSION

Respiration

Although respiration has the largest number of types of reactions, it is the least productive, providing only 19% of the reactions. The most productive reaction was R4, Amplitude increase, which appeared 704 times. The least productive in the respiration list was R11, apnea (inspiration), which appeared nine times. It would make sense to put the apnea reactions together. R9 and R10 could also be combined into one item on base line shift, dropping the temporary or permanent difference. Separating them makes sense only if you give different scores or use them differently. In their study of what examiners really do, Capps & Ansley found apnea to be the most accurate of the respiratory reactions at 93%. Capps & Ansley found the accuracy of change (temporary) to be 76%, and used in 11% of the decisions. The accuracy of loss (permanent) was 73%.

There was no serial effect found in following 1 through 10 through the charts. However, there was a reduction in reactions in the second and third charts of all the NDI sets; and in the electrodermal and cardio reactions to the DI charts. However, the respiratory responses increased in the second and third charts. An inexplicable anomaly. See Table 5-11.

TABLE 1-2

DISTRIBUTION OF REACTIONS BY CHANNEL

Channel	Number of Reactions	Percentage of Total
Pneumograph	3,848	19%
Electrodermal	11,414	55%
Cardio	5,453	26%
Total:	20,714	

TABLE 1-8

RESPIRATION RATES FROM THE CHARTS

The respiration cycles per minute were taken from the beginning and ending of each chart in 110 sets of charts.

Beginning of 1st charts: 17.7 c.p.m., range 8-28, mode 17

Ending of 1st charts: 17.5 c.p.m., range 9-35, mode 16

Beginning of 2nd charts: 16.4 c.p.m., range 9-31, mode 17

Ending of 2nd charts: 17.1 c.p.m., range 7-30, mode 17

Beginning of 3rd charts: 16.7 c.p.m., range 9-32, mode 16

Ending of 3rd charts: 17.4 c.p.m., range 8-34, modes 16 and 18

TABLE 1-4A

RESPIRATION - RANK ORDER BY FREQUENCY OF REACTIONS

R4	Amplitude increase	704
R9	Baseline change - temporary	683
R5	Amplitude decrease/suppression	476
R10	Baseline change - permanent	389
R1	Rate decrease	318
R8	Progressive decrease & return	265
R12	Apnea (exhalation)	182
R2	Rate increase	154
R7	Progressive increase and return	107
R6	Progressive increase/decrease	102
R3	I/E ratio change	62
R11	Apnea (inspiration)	9

TABLE 1-4

REACTION TYPES - RANK ORDER BY FREQUENCY

E1	Amplitude change	4793	26%
E3	Duration	4496	24%
C1	Baseline increase & decrease	2778	15%
E2	Complex response	1051	6%
C5	Amplitude decrease	940	5%
R4	Amplitude increase	704	4%
R9	Baseline change - temporary	683	4%
C2	Baseline increase	578	3%
R5	Amplitude decrease/suppression	476	3%
C3	Baseline increase	400	2%
R10	Baseline change - Permanent	389	2%
R1	Rate decrease	318	2%
R8	Progressive decrease & return	265	1%
R12	Apnea - (exhalation)	182	1%
R2	Rate increase	154	1%
R7	Progressive increase & return	107	1%
R6	Progressive increase/decrease	102	1%
R3	I/E Ratio change	62	under ½ of 1 percent
C6	Rate increase	25	"
C7	Rate decrease	23	"
R11	Apnea - Holding (inspiration)	9	"
C4	Amplitude increase	5	"

TABLE 5-11

CHART SERIAL EFFECT BY CHANNEL

DI charts	1st	2nd	3rd	NDI	1st	2nd	3rd
Respiration	745	761	802		448	335	364
Electrodermal	2221	2081	1960		1490	1259	1098
Cardiovascular	1076	1063	984		681	667	495
Average	1347	1302	1249		873	754	652

Data from tables in 2 Series

TABLE 5-9

CHART SERIAL EFFECT - RESPIRATION

DI						NDI				
	1 ST	2 ND		3 RD	chart	1 st	2 nd		3 rd	
1.	56	54	-2	60	+4	38	41	+3	38	0
2.	63	73	+10	77	+14	46	42	-4	47	+1
3.	77	86	+9	89	+12	48	33	-15	40	-8
4.	59	86	+17	92	+13	56	43	-13	38	-18
5.	82	84	+2	97	+15	47	38	-9	37	-10
6.	81	88	+7	91	+10	50	44	-6	34	-16
7.	75	87	+12	93	+18	47	32	-15	38	-9
8.	76	78	+2	83	+7	41	29	-12	33	-8
9.	73	70	-3	59	-14	34	7	-27	37	+3
10.	83	55	-28	61	-22	41	26	-15	22	-19
	745	761	+26	802	+57	448	335	-113	364	-84

CHART SERIAL EFFECT BY CHANNEL

The data shows for five of six groupings, there is a decline in the number of reactions with each chart. Electrodermal has long been known to habituate to repetitions of a signal, but the varied questions in a polygraph test may prevent habituation. The literature is incomplete on habituation of cardio and respiratory reactions. We are also at a loss to explain the anomaly of the number of reactions increasing from chart to chart, but only for DI charts. For the time, all we can do is note the general decline and the anomaly, and see if this matches data from future studies.

TABLE 5-11

CHART SERIAL EFFECT BY CHANNEL

DI charts	1st	2nd	3rd	NDI	1st	2nd	3rd
Respiration	745	761	802		448	335	364
Electrodermal	2221	2081	1960		1490	1259	1098
Cardiovascular	1076	1063	984		681	667	495
Average	1347	1302	1249		873	754	652

Data from tables in 2 Series

TABLE 5-8

CHART SERIAL EFFECT - ELECTRODERMAL

DI						NDI				
	1 st	2 nd		3 rd	chart	1 st	2 nd		3 rd	
1.	222	210	-12	191	-31	136	136	0	120	-16
2.	234	213	-21	216	-18	155	137	-18	120	-35
3.	231	221	-10	190	-41	172	131	-41	94	-78
4.	185	199	+14	193	+8	141	129	-12	121	-20
5.	223	229	+6	224	+1	155	125	-30	141	-14
6.	247	215	-32	209	-38	180	136	-44	132	-48
7.	234	230	-4	214	-20	163	120	-43	111	-52
8.	203	190	-13	192	-11	124	110	-14	97	-27
9.	225	189	-36	149	-76	136	175	+39	114	-22
10.	217	185	-32	182	-35	128	60	-68	48	-80
	2221	2081	-140	1960	-261	1490	1259	-231	1098	-392

TABLE 5-10

CHART SERIAL EFFECT - CARDIO

DI						NDI				
	1 st	2 nd		3 rd	chart	1 st	2 nd		3 rd	
1.	105	106	+1	77	-28	61	71	+10	55	-6
2.	114	112	-2	99	-15	67	64	-3	56	-11
3.	103	101	-2	98	-5	83	72	-11	50	-33
4.	98	119	+21	122	+24	77	63	-14	50	-27
5.	136	129	-7	101	-35	68	62	-6	63	-5
6.	96	103	+7	105	+9	72	65	-7	60	-12
7.	134	113	-21	123	-11	74	59	-15	40	-34
8.	79	87	+8	83	+4	61	50	-11	44	-17
9.	105	93	-12	76	-29	59	133	+74	51	-8
10.	106	100	-6	100	-6	59	28	-31	26	-33
	1076	1063	-13	984	-92	681	667	-14	495	-186

	1	2	3	4	5	6	7	8	9	10	TAV	IC	IR
RESPIRATION													
1. Rate Decrease	1	2	2	2	2	2	2	3	2	2	2	2	
2. Rate Increase	0	1	2	1	0	2	1	1	1	1	1	1	
3. I/E Ratio Change	0	0	1	1	1	1	1	0	0	0	1.5	1.3	
4. Amplitude Increase	4	4	4	4	4	4	3	3	3	3	3.6	3.3	
5. Amplitd Decrease/Suppression	1	2	3	3	2	2	2	4	4	3	2.6	2.6	
6. Progressive Increase/Decrease	1	0	1	1	1	0	1	1	0	0	1.7	1.6	
7. Progressive Increase & Return	1	0	1	1	0	0	0	1	0	0	1.4	1.8	
8. Progressive Decrease & Return	1	1	1	1	2	1	1	1	2	2	1.3	1.7	
9. Baseline Change - Temporary	4	3	5	4	4	3	4	4	4	4	4	3.2	
10. Baseline Change - Permanent	2	2	2	2	2	3	2	2	3	2	2.2	2.6	
11. Apnea - Holding (inspiration)	0	0	0	0	0	0	0	0	0	0	0	1	
12. Apnea - Blocking (Exhalation)	1	2	1	2	1	1	1	1	1	1	1.2	1.5	
ELECTRODERMAL													
1. Amplitude Change	29	26	25	24	24	25	25	26	26	26	26.6	25.2	
2. Complex Response	2	5	5	5	5	6	4	4	4	4	4.4	6.1	
3. Response Duration & Return	27	25	23	21	23	24	23	24	24	24	23.8	24.1	
CARDIOVASCULAR													
1. Baseline Increase & Decrease	13	15	13	16	18	15	17	15	16	17	15.5	15.5	
2. Baseline Increase	5	5	4	3	2	2	2	2	2	2	2.9	3.0	
3. Baseline Decrease	2	1	2	3	2	4	2	2	3	2	2.3	2.9	
4. Amplitude Increase	0	0	0	0	0	0	0	0	0	0	0	0	
5. Amplitude Decrease	5	6	5	7	6	4	7	4	5	6	5.5	4.5	
6. Rate Increase	0	0	0	0	0	0	0	0	0	0	0	0	
7. Rate Decrease	0	0	0	0	0	0	0	0	0	0	0	0	
											96.2	100.3	
											26.2	25.9	
											Age:		

Comments:

5-7

Deceptive Charts: Distribution of responses by Percentage

	1	2	3	4	5	6	7	8	9	10	11	12
RESPIRATION												
1. Rate Decrease	1	1	1	1	1	1	1	1	1	2	1	MD1
2. Rate Increase	0	1	0	1	1	0	1	0	2	1	1	1.7
3. I/E Ratio Change	0	0	0	0	0	1	1	1	0	1	1	1.3
4. Amplitude Increase	4	4	2	4	2	3	3	3	3	5	5	3.3
5. Amplitude Decrease/Suppression	4	3	4	2	2	3	2	2	2	2	2	2.6
6. Progressive Increase/Decrease	1	1	0	1	0	0	1	1	0	1	1	1.6
7. Progressive Increase & Return	1	1	1	1	1	1	0	1	0	1	1	1.8
8. Progressive Decrease & Return	1	2	2	2	2	1	2	2	2	1	1	1.7
9. Baseline Change - Temporary	2	3	4	3	4	5	3	4	2	2	2	3.2
10. Baseline Change - Permanent	3	2	2	3	3	2	3	3	2	3	3	2.6
11. Apnea - Holding (Inspiration)	0	0	0	0	0	0	0	0	0	1	1	1.1
12. Apnea - Blocking (Exhalation)	1	1	0	1	0	1	0	1	0	0	0	1.5
ELECTRODERMAL												17.5
1. Amplitude Change	26	25	24	24	26	25	26	25	26	25	25	25.2
2. Complex Response	3	1	8	7	6	8	6	7	7	8	7	6.1
3. Response Duration & Return	26	25	23	23	25	24	25	24	24	22	22	24.1
CARDIOVASCULAR												55.4
1. Baseline Increase & Decrease	12	14	17	15	17	14	17	15	17	17	17	15.5
2. Baseline Increase	7	3	3	4	3	2	2	3	2	1	1	3.0
3. Baseline Decrease	2	3	2	3	3	4	2	3	2	5	5	2.9
4. Amplitude Increase	0	0	0	0	0	0	0	0	0	0	0	0
5. Amplitude Decrease	4	5	5	5	5	5	4	5	4	3	3	4.5
6. Rate Increase	0	0	0	0	0	0	0	0	0	0	0	0
7. Rate Decrease	0	1	0	0	0	0	0	0	0	0	0	1.1
												25.9

Age: _____

Comments: _____

Table 5-6

Non-deceptive charts: Distribution of responses by percentage.

TABLE 5-13

PERCENTAGE PROFILE OF Q.5 FROM 1ST, 2ND & 3RD CHARTS

Respiration	1 st DI	2 nd DI	3 rd DI
	%	%	%
R1	2	2	2
R2	1	0	0
R3	0	1	2
R4	6	4	3
R5	1	1	4
R6	0	1	2
R7	0	0	0
R8	2	2	1
R9	3	4	4
R10	3	2	3
R11	0	0	0
R12	0	1	2

ELECTRODERMAL**1ST DI****2ND DI****3RD DI**

E1

24

24

24

E2

4

5

5

E3

23

23

22

CARDIO

C1

19

19

16

C2

3

1

2

C3

1

2

1

C4

0

0

0

C5

7

7

5

C6

0

0

0

C7

0

0

0

RESPIRATION

	1 ST NDI	2 ND NDI	3 RD NDI
	%	%	%
R1	0	1	0
R2	1	1	1
R3	0	0	0
R4	2	4	2
R5	4	0	1
R6	0	1	1
R7	1	0	1
R8	2	2	2
R9	4	3	3
R10	2	4	3
R11	0	0	0
R12	0	0	1

ELECTRODERMAL**1ST NDI****2ND NDI****3RD NDI****%****%****%**

E1

26

25

2

E2

7

5

6

E3

24

24

25

CARDIO

C1

16

17

18

C2

3

3

1

C3

3

3

3

C4

0

0

0

C5

4

5

4

C6

0

0

0

C7

0

0

0

RECOMMENDATIONS

Considering that the average relevant question generates 3.6 reactions, the average comparison question 3.1 reactions, and the average technical question (irrelevant, sacrifice relevant, symptomatic, etc.) generates 3.5 reactions; FRI recommends that any scoring method applied with these generic zone comparison formats use more than mere rank ordering or three-position scales. The research results suggest the examiner needs the extra discriminating power to avoid a high inconclusive rate.

FRI recommends that DoDPI delete the two kinds of baseline changes and combine them into one, called respiration baseline change.

FRI recommends that DoDPI combine cardio amplitude increase with cardio amplitude decrease. The former appeared only 5 times and the latter 940 times. It would be called cardio amplitude change.

FRI recommends that DoDPI combine Apnea holding, appearance 9 times, with Apnea blocking, 182 times; and call it apnea.

FRI recommends that premature ventricular contractions be removed from the list of deceptive criteria. They appeared only 30 times in this research, and 18 of those from one examinee. Given the restrictive rule on their use, the utility is so low that PCVs should not be on the list of deceptive criteria.

APPENDIX

PREMATURE VENTRICULAR CONTRACTIONS (PVCs)

The author of this research is of the opinion that the premature ventricular contraction has no more business being listed in the deceptive criteria than a hiccup or sneeze. The DoDPI Scoring Criteria states:

Medically, this is a ventricular contraction which occurs between two sinus cycles without a compensatory pause. In the PDD tracings, it is an absent systole, followed immediately by a diastolic point that is below the remaining diastoles. PVCs are only evaluated when they occur following the relevant question(s), but not the comparison question(s)--or following comparison question(s), but not relevant question(s). PVCs are fairly common, but rarely given any weight during the scoring process.

How common are they? The charts in this research include 5,866 questions, and in response PVCs occurred 30 times. Moreover, 18 of those PVCs were on set FRI no. 111, DoDPI number \$\$1A4GZg, with 9 on chart one, 5 on chart 2, and 4 on chart three. In cardio reactions, 30 puts it in company with pulse amplitude increase 5, pulse rate decrease 23, and pulse rate increase 25; but not in company with the next cardio reaction, baseline increase at 400. The most frequent cardio reaction was the baseline increase and decrease at 2,778. At the rate of .005, or 5 per thousand charts, it lacks utility and does not merit our attention.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave Blank)		2. REPORT DATE July 1999		3. REPORT TYPE AND DATES COVERED Final Report, July 1999	
4. TITLE AND SUBTITLE The Frequency of Appearance of Evaluative Criteria in Polygraph Charts, A Research Report				5. FUNDING NUMBERS G No. N00014-98-1-0863	
6. AUTHOR(S) Norman Ansley				AGO Code N66020 PR No. 98PR07549-00 PR Code 822 Dispersing Code N68892	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Forensic Research, Inc. 35 Cedar Road Severna Park, MD 21146				8. PERFORMING ORGANIZATION REPORT NUMBER FRI 99-1	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Personnel Security Research Program Defense Personnel Research Center 99 Pacific Street, Bldg 455-E, Monterey, CA 93940-2481				10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES Prepared in cooperation with Donald J. Krapohl, Research Division, Department of Defense Polygraph Institute.					
12a. DISTRIBUTION/AVAILABILITY STATEMENT Department of Defense Polygraph Institute Fort Jackson, S.C. <i>Approved for Public Release Distribution Unlimited</i>				12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) FRI recorded on forms the deception related reactions found on 616 polygraph charts from 174 criminal cases in which ground truth was known. Using the Department of Defense guide to chart interpretation to define reactions, the extracted data was sorted and counted. The frequency of each of the 22 evaluative criteria was rank ordered, ranging from 5 to 4,793. The rank order pattern stayed remarkably constant across questions, gender, and truth or deception status. Recommendations were made with respect to scoring generic zone comparison tests and the elimination of some currently listed deception criteria.					
14. SUBJECT TERMS Deception criteria, Polygraph charts, distribution of reactions, zone comparison test formats.				15. NUMBER OF PAGES 348	
				16. PRICE CODE	
7. SECURITY CLASSIFICATION OF REPORT unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT unclassified	20. LIMITATION OF ABSTRACT UL		

TABLES

THE FREQUENCY OF APPEARANCE
of
EVALUATIVE CRITERIA IN POLYGRAPH CHARTS

A RESEARCH REPORT

by

Norman Ansley
Forensic Research, Inc.
35 Cedar Road
Severna Park, Maryland 21146-3715

for

Defense Personnel Research Center
99 Pacific Street
Building 455-E
Monterey, California 93940-2481

Office of Naval Research
Grant No. N00014-98-1-0863

1999

TABLE OF CONTENTS

Abstract

Background

Background to the Research

Background to This Research

Method

Data Base

Definitions of Evaluative Criteria

Organization of the Data on FRI Form 1

Form 1 sample

Question Numbers and Question Types

Organization of Reaction Data From Questions

Table 2, sample page

Organization of the Data for Comparison Purposes

Table 2, sample page

Table 3, bar charts

Reaction Types - Rank Order by Frequency

Two Cardio Frequency Studies

Chart Serial Effect by Channel

Organization of the Data by Sets of Charts

Sample and Instructions for Form 4 Series

Results

Basic Data

Total and Average Reactions

Results by Question Number

Results by Type of Reaction

Results by physiological channel

Comparisons of Men and Women

Position Effect by Question Number

Comparisons by DI and NDI status

Table 2-Q1-C and Table 1-5

Heart Rates and Respiration Rates

Table 1-3

Tables 1-7A to 7K

Table 1-7

Table 1-8

Discussion

Electrodermal

Table 5-1

Table 5-2

Table 5-3

Table 5-11

Discussion

Cardio

Table 5-12

Table 1-3

Table 5-10

Respiration

Table 1-2

Table 1-8

Table 4 series

Table 1-4

Table 5-11

Table 1-7

Chart Serial Effect by Channel

Table 5-8

Table 5-11

Table 5-10

Table 5-9

Table 5-8

Table 5-7

Table 5-6

Table 5-13

Recommendations

Appendix

LIST OF TABLES

Data Evaluation Form 1. 1a through 207c. Not with final report as there is no end user value. All the data is in series 2 and series 4.

Table 1-1, Questions and Reactions

Table 1-2, Distribution of Reactions by Channel

Table 1-3, Heart Rates - tonic

Table 1-4, Reaction types - Rank Order by Frequency

Table 1-4A Respiration - Rank Order by Frequency

Table 1-5, Number of Reactions by Question Number and by Reaction Type

Table 1-6, Respiration Rates from the Charts, in Sequence

Table 1-7A through 7F, Heart Rates of first three charts

Tables 2 Q1 A through 2 Q10 N. 14 tables for each of the ten Questions

Tables 3-1 through 3-6, bar-chart comparisons

Tables 4AA through 4GG, 174 tables of data on sets of charts

Table 5-1, Electrodermal amplitude reactions and percent of questions asked

Table 5-2, Electrodermal duration reactions and percent of questions asked

Table 5-3, Electrodermal complex reactions and percent of questions asked

Table 5-4, Frequency of Electrodermal Responses

Table 5-5, Average Heart Rates by Gender and Race

Table 5-6, Gender and Outcome of Tests

Table 5-7A, Deceptive Charts: Distribution of Responses by Percentage

Table 7B, Non-Deceptive Charts: Distribution of Responses by Percentage

List of Tables 0 2

Table 5-8, Chart Serial Effect - Electrodermal

Table 5-9, Chart Serial Effect - Respiration

Table 5-10, Chart Serial Effect - Cardio

Table 5-11, Chart SErial Effect by Channel

Table 5-12, Two Cardio Frequency Tables

Table 5-13, Percentage Profile of Q.5 from 1st, 2nd, and 3rd charts

Tables 6-1 through 6-8 are rearranged data from the 2 and 4 series, and have no end user value. They are not included in the final report.

Table 1 - 1

QUESTIONS AND REACTIONS

Question Type	Questions	Reactions	Percent of reactions	Average per question
Relevant Questions	1,780	6,453	31%	3.6
Comparison Questions	1,932	6,777	33%	3.1
Technical Questions	2,154	7,484	36%	3.5
		20,714		

Note: Comparison questions were formerly called control questions.
Technical questions include irrelevant, sacrifice relevant and symptomatic questions.

Table 1 - 2

DISTRIBUTION OF REACTIONS BY CHANNEL

Channel	Number of Reactions	Percentage of Total
Pneumograph	3,848	19%
Electrodermal	11,414	55%
cardio	5,453	26%
	20,714	

Table 1-3

Heart Rates

Average HR at beginning of 1st chart:	92
Average HR at end of 1st chart:	91
Average HR at beginning of 2d chart:	90
Average HR at end of 2d chart:	90
Average HR at beginning of 3d chart:	89
Average HR at end of 3d chart:	88
Overall average HR	90
Average HR at beginning of NDI charts:	87
Average HR at beginning of DI charts:	94
Average HR at ending of NDI charts:	87
Average HR at ending of DI charts:	92

Table 1-3

Heart Rates

Average HR for Women at beginning of charts:	94
Average HR for Men at beginning of charts:	86
Average HR for Women at ending of charts:	94
Average HR for Men at ending of charts:	86
Average HR for DI Women at beginning of charts	98
Average HR of DI Men at beginning of charts:	89
Average HR of DI Women at ending of charts:	97
Average HR of DI Men at ending of charts:	88
Average HR of NDI Women at beginning of charts	91
Average HR of NDI Men at beginning of charts:	84
Average HR of NDI Women at ending of charts:	91
Average HR of NDI Men at ending of charts:	84
Average HR of NDI Women at beginning of charts	91
Average HR of DI Women at beginning of charts	98
Average HR of NDI Women at ending of charts	91
Average HR of DI Women at ending of charts	97
Average HR of NDI Men at beginning of charts:	84
Average HR of DI Men at beginning of charts:	89
Average HR of NDI Men at ending of charts:	84
Average HR of DI men at ending of charts:	88

Table 1-4A

RESPIRATION - RANK ORDER BY FREQUENCY OF REACTIONS

R4	Amplitude increase	704
R9	Baseline change - temporary	683
R5	Amplitude decrease/suppression	476
R10	Baseline change - Permanent	389
R1	Rate decrease	318
R8	Progressive decrease & return	265
R12	Apnea (exhalation)	182
R2	Rate increase	154
R7	Progressive increase and return	107
R6	Progressive increase/decrease	102
R3	I/E ratio change	62
R11	Apnea (inspiration)	9

Table 1-4

Reaction Types - Rank Order by Frequency

E1	Amplitude change	4793	26%
E3	Duration	4496	24%
C1	Baseline increase & decrease	2778	15%
E2	Complex response	1051	6%
C5	Amplitude decrease	940	5%
R4	Amplitude increase	704	4%
R9	Baseline change - temporary	683	4%
C2	Baseline increase	578	3%
R5	Amplitude decrease/suppression	476	3%
C3	Baseline decrease	400	2%
R10	Baseline change - Permanent	389	2%
R1	Rate decrease	318	2%
R8	Progressive decrease & return	265	1%
R12	Apnea - (exhalation)	182	1%
R2	Rate increase	154	1%
R7	Progressive increase & return	107	1%
R6	Progressive increase/decrease	102	1%
R3	I/E Ratio change	62	under $\frac{1}{2}$ of
C6	Rate increase	25	1 percent
C7	Rate decrease	23	
R11	Apnea - Holding (inspiration)	9	
C4	Amplitude increase	5	

Table 1-5

NUMBER OF REACTIONS BY QUESTION
AND BY REACTION TYPE

	1	2	3	4	5	6	7	8	9	10	T	TC	TR
RESPIRATION													
1. Rate Decrease	22	36	32	40	29	39	37	32	27	24	318	105	98
2. Rate Increase	6	15	26	19	11	19	18	12	20	8	154	70	35
3. I/E Ratio Change	6	5	6	7	11	10	6	5	6	3	62	29	18
4. Amplitude Increase	61	86	74	87	78	82	76	53	60	53	704	223	223
5. Amplitude Decrease/Suppression	42	49	61	46	48	46	38	55	47	44	476	148	132
6. Progressive Increase/Decrease	14	10	10	13	13	8	9	14	7	4	102	27	37
7. Progressive Increase & Return	13	9	11	15	12	11	11	15	3	7	107	28	35
8. Progressive Decrease & Return	22	20	28	30	32	26	31	23	32	21	265	99	81
9. Baseline Change - Temporary	59	72	72	73	75	71	79	66	59	57	683	216	222
10. Baseline Change - Permanent	36	31	44	42	50	43	54	41	35	23	384	132	128
11. Apnea - Holding (Inspiration)	0	1	0	1	0	2	1	1	2	1	9	5	2
12. Apnea - Blocking (Exhalation)	17	23	16	23	21	15	18	20	13	16	182	57	58
ELECTRODERMAL													
1. Amplitude Change	509	563	492	489	506	462	493	450	440	439	4793	1439	1414
2. Complex Response	59	117	128	122	162	140	109	95	105	74	1051	409	284
3. Response Duration & Return	489	479	454	451	481	456	463	413	406	412	4496	1334	1344
CARDIOVASCULAR													
1. Baseline Increase & Decrease	231	277	273	307	372	269	312	257	274	256	2778	971	1005
2. Baseline Increase	102	85	69	62	57	44	49	37	46	33	578	160	154
3. Baseline Decrease	25	36	37	56	41	64	35	41	39	26	400	151	114
4. Amplitude Increase	5	2	-	-	-	2	-	1	-	-	5	2	-
5. Amplitude Decrease	87	103	104	109	117	84	117	66	78	75	940	312	326
6. Rate Increase	4	3	3	3	3	2	3	1	1	2	25	5	8
7. Rate Decrease	2	4	1	2	4	1	3	3	3	-	23	8	8
8. P.V.C.	3	5	3	1	4	2	4	4	3	1	30	6	8

Table 1-6

RESPIRATION RATES FROM THE CHARTS

The respiration cycles per minute were taken from the beginning and ending of each chart in 110 sets of charts.

beginning of 1st charts: 17.7 c.p.m., range 8-28, mode 17

ending of 1st charts: 17.5 c.p.m., range 9-35, mode 16

beginning of 2nd charts: 16.4 c.p.m., range 9-31, mode 17

ending of 2nd charts: 17.1 c.p.m., range 7-30, mode 17

beginning of 3d charts: 16.7 c.p.m., range 9-32, mode 16

ending of 3d charts: 17.4 c.p.m., range 8-34 16 and 18

[illegible]

Table 1-7F

HR end of 3d chart

Average Mode	Range	No.
88.3	48-144	196
76 (n.13)		
84 (n.13)		
90 (n.13)		
92 (n.13)		

[illegible]

Average	88.6
Mode	84 (n. 13)
Range	50 - 144
N _{o.}	196

HR Beginning of 3d Chart

[illegible]

[illegible]

Average	90.0
Mode	90 (n. 14)
Range	50 - 144
No.	201

HR End of 2d conf.

Exhib 1-7D

[illegible]

Average	90.0
mode	94 (n.11)
range	48 - 152
n	205

HR Beginning of 2d Chart

Table 1-7C

[illegible]

Average 91.1

made 78 (201)

W. 18-144

202

End of Chart 3 1-7B

[illegible]

HR DATA Beginning of March

916

337

range 48-146

n. 206

HR Beginning of 1st Chart Table 1-4 1-7A

[illegible]

Table 2 Q1-A

Title:

Q 1, Reactions from the First Three Charts

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	13	5	1	1
2. Rate Increase	5	0	0	0
3. I/E Ratio Change	3	3	0	0
4. Amplitude Increase	43	28	4	4
5. Amplitd Decrease/Suppression	16	31	1	4
6. Progressive Increase/Decrease	6	4	1	1
7. Progressive Increase & Return	6	8	1	1
8. Progressive Decrease & Return	8	8	1	1
9. Baseline Change - Temporary	40	16	4	2
10. Baseline Change - Permanent	21	19	2	3
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	12	7	1	1
ELECTRODERMAL	173			
1. Amplitude Change	312	188	29	26
2. Complex Response	31	22	2	3
3. Response Duration & Return	290	186	27	26
CARDIOVASCULAR	633			
1. Baseline Increase & Decrease	144	89	13	12
2. Baseline Increase	59	52	5	7
3. Baseline Decrease	17	15	2	2
4. Amplitude Increase	1	0	0	0
5. Amplitude Decrease	55	31	5	4
6. Rate Increase	3	1	0	0
7. Rate Decrease	2	0	0	0
8. P.V.C.				

281 / 1087 713

Table 2 Q1-B

Title:

Q1, Reactions from the First Three Charts

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	men	women	men	women
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	11	5	1	1
2. Rate Increase	4	1	0	0
3. I/E Ratio Change	0	1	0	0
4. Amplitude Increase	38	18	3	4
5. Amplitude Decrease/Suppression	23	13	2	3
6. Progressive Increase/Decrease	5	5	0	1
7. Progressive Increase & Return	10	2	1	0
8. Progressive Decrease & Return	11	5	1	1
9. Baseline Change - Temporary	37	17	3	4
10. Baseline Change - Permanent	27	7	2	2
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	7	11	1	3
ELECTRODERMAL				
1. Amplitude Change	335	117	29	27
2. Complex Response	33	13	3	3
3. Response Duration & Return	323	116	28	26
CARDIOVASCULAR				
1. Baseline Increase & Decrease	157	57	13	13
2. Baseline Increase	67	21	6	5
3. Baseline Decrease	16	5	1	1
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	57	24	5	5
6. Rate Increase	1	0	0	0
7. Rate Decrease	1	0	0	0
8. P.V.C.				

1163 438

Table 2-Q1-C

Title: Q 1, First Chart Reactions

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	2	1	1	0
2. Rate Increase	2	0	1	0
3. I/E Ratio Change	2	1	1	0
4. Amplitude Increase	14	8	4	3
5. Amplitd Decrease/Suppression	5	5	1	2
6. Progressive Increase/Decrease	1	2	0	1
7. Progressive Increase & Return	2	2	1	1
8. Progressive Decrease & Return	1	3	0	1
9. Baseline Change - Temporary	19	7	5	3
10. Baseline Change - Permanent	6	9	2	4
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	2	1	1	0
ELECTRODERMAL	56	39		
1. Amplitude Change	108	66	28	28
2. Complex Response	8	5	2	2
3. Response Duration & Return	106	65	28	28
CARDIOVASCULAR	222	136		
1. Baseline Increase & Decrease	53	33	14	14
2. Baseline Increase	17	10	4	4
3. Baseline Decrease	7	8	2	3
4. Amplitude Increase	1	0	0	0
5. Amplitude Decrease	25	10	7	4
6. Rate Increase	1	0	0	0
7. Rate Decrease	1	0	0	0
8. P.V.C.				
	105	383	61	236

Table 2 Q1 D

Title: Q 1, First Chart Reactions

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	men	Women	men	Women
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	1	1	0	1
2. Rate Increase	0	1	0	1
3. I/E Ratio Change	0	0	0	0
4. Amplitude Increase	12	6	3	4
5. Amplitd Decrease/Suppression	7	4	2	3
6. Progressive Increase/Decrease	1	1	0	1
7. Progressive Increase & Return	2	1	1	1
8. Progressive Decrease & Return	3	2	1	1
9. Baseline Change - Temporary	14	6	4	4
10. Baseline Change - Permanent	12	2	3	1
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	0	3	0	2
ELECTRODERMAL				
1. Amplitude Change	114	45	29	29
2. Complex Response	8	4	2	3
3. Response Duration & Return	112	44	29	28
CARDIOVASCULAR				
1. Baseline Increase & Decrease	61	18	16	11
2. Baseline Increase	16	7	4	4
3. Baseline Decrease	10	2	3	1
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	24	10	6	6
6. Rate Increase	1	0	0	0
7. Rate Decrease	0	0	0	0
8. P.V.C.				

388 157

Table 2 G1 E

Title: Q 1, First Chart Reactions

Column 1. is: DI Men

Column 2. is: DI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI men	DI Women	DI men	DI Women
	1	2	3	4
RESPIRATION				
			%	%
1. Rate Decrease	1	1	0	1
2. Rate Increase	0	1	0	1
3. I/E Ratio Change	0	0	0	0
4. Amplitude Increase	9	3	4	3
5. Amplitude Decrease/Suppression	1	4	0	4
6. Progressive Increase/Decrease	1	0	0	0
7. Progressive Increase & Return	1	1	0	1
8. Progressive Decrease & Return	2	1	1	1
9. Baseline Change - Temporary	11	3	5	3
10. Baseline Change - Permanent	5	1	2	1
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	0	2	0	2
ELECTRODERMAL				
1. Amplitude Change	67	31	29	28
2. Complex Response	4	3	2	3
3. Response Duration & Return	66	31	28	28
CARDIOVASCULAR				
1. Baseline Increase & Decrease	36	13	15	12
2. Baseline Increase	9	4	4	4
3. Baseline Decrease	4	3	2	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	16	7	7	6
6. Rate Increase	1	0	0	0
7. Rate Decrease	0	0	0	0
8. P.V.C.				

234 109

234 ÷ 71
109 ÷ 31

Table 2 Q1 F

Title: Q. 1, First Chart Reactions

Column 1. is: NDI Men

Column 2. is: NDI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	NDI men	NDI women	NDI men	NDI women
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	0	0	0	0
2. Rate Increase	0	0	0	0
3. I/E Ratio Change	0	0	0	0
4. Amplitude Increase	3	3	2	7
5. Amplitude Decrease/Suppression	6	0	4	0
6. Progressive Increase/Decrease	0	1	0	2
7. Progressive Increase & Return	1	0	1	0
8. Progressive Decrease & Return	1	1	1	2
9. Baseline Change - Temporary	3	3	2	7
10. Baseline Change - Permanent	7	1	4	2
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	0	1	0	2
ELECTRODERMAL				
1. Amplitude Change	47	14	29	32
2. Complex Response	4	1	2	2
3. Response Duration & Return	46	13	28	29
CARDIOVASCULAR				
1. Baseline Increase & Decrease	25	0	15	0
2. Baseline Increase	7	3	4	7
3. Baseline Decrease	6	0	4	0
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	8	3	5	7
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
8. P.V.C.				

104 ÷ 44 2.4
44 ÷ 15 2.9

164 44

Table 2 Q1 G

Title: Q 1, Second Chart Reactions

Column 1. is: NDI Men

Column 2. is: NDI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	NDI Men	NDI Women	NDI men	NDI Women
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	2	1	1	2
2. Rate Increase	0	0	0	0
3. I/E Ratio Change	0	0	0	0
4. Amplitude Increase	3	0	2	0
5. Amplitd Decrease/Suppression	4	1	2	2
6. Progressive Increase/Decrease	2	1	1	2
7. Progressive Increase & Return	2	0	1	0
8. Progressive Decrease & Return	3	0	2	0
9. Baseline Change - Temporary	3	1	2	2
10. Baseline Change - Permanent	4	0	2	0
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	2	3	1	7
ELECTRODERMAL				
1. Amplitude Change	54	12	29	28
2. Complex Response	6	1	3	2
3. Response Duration & Return	53	12	29	28
CARDIOVASCULAR				
1. Baseline Increase & Decrease	22	8	12	19
2. Baseline Increase	13	1	7	2
3. Baseline Decrease	3	0	1	0
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	8	2	4	5
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
8. P.V.C.				

Table 2 Q H

Title: Q 1, SEcond Chart Reactions

Column 1. is: DI Men

Column 2. is: DI Women

Column 3. is: % Distribution 1

Column 4. is: % Distribution 2

	Men	Women	Men	Women
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	4	3	2	3
2. Rate Increase	2	0	1	0
3. I/E Ratio Change	0	1	0	1
4. Amplitude Increase	7	5	3	4
5. Amplitd Decrease/Suppression	5	3	2	3
6. Progressive Increase/Decrease	1	3	0	3
7. Progressive Increase & Return	2	0	1	0
8. Progressive Decrease & Return	0	1	0	1
9. Baseline Change - Temporary	10	6	5	5
10. Baseline Change - Permanent	2	3	1	3
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	2	2	1	2
ELECTRODERMAL				
1. Amplitude Change	61	27	24	24
2. Complex Response	5	2	2	2
3. Response Duration & Return	58	27	28	24
CARDIOVASCULAR				
1. Baseline Increase & Decrease	25	15	12	13
2. Baseline Increase	13	5	6	4
3. Baseline Decrease	2	1	1	1
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	8	9	4	8
6. Rate Increase	0	0	0	0
7. Rate Decrease	1	0	0	0
8. P.V.C.				

Table 2012

Title: Q 1, Second Chart Reactions

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION	%		%	
1. Rate Decrease	5	3	1	1
2. Rate Increase	1	6	0	0
3. I/E Ratio Change	1	1	0	0
4. Amplitude Increase	13	8	4	3
5. Amplitd Decrease/Suppression	1	5	0	2
6. Progressive Increase/Decrease	4	2	1	1
7. Progressive Increase & Return	3	2	1	1
8. Progressive Decrease & Return	1	2	0	1
9. Baseline Change - Temporary	15	2	4	1
10. Baseline Change - Permanent	6	6	2	2
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	4	4	1	2
ELECTRODERMAL	54	40	28	27
1. Amplitude Change	101	65	28	27
2. Complex Response	11	7	3	3
3. Response Duration & Return	98	64	27	26
CARDIOVASCULAR	210	136	13	12
1. Baseline Increase & Decrease	48	30	13	12
2. Baseline Increase	20	26	6	11
3. Baseline Decrease	4	4	1	2
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	19	10	5	4
6. Rate Increase	4	1	1	0
7. Rate Decrease	1	0	0	0
8. P.V.C.	106	71		

360 248

148

Table 2 Q1 J

Title: Q 1, Second Chart Reactions

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	Men	Women	Men	Women
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	6	4	2	3
2. Rate Increase	2	0	0	0
3. I/E Ratio Change	0	1	0	1
4. Amplitude Increase	10	5	3	3
5. Amplitude Decrease/Suppression	9	4	2	3
6. Progressive Increase/Decrease	3	4	1	3
7. Progressive Increase & Return	4	0	1	0
8. Progressive Decrease & Return	3	1	1	1
9. Baseline Change - Temporary	13	7	3	5
10. Baseline Change - Permanent	6	3	2	2
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	4	5	1	3
ELECTRODERMAL				
1. Amplitude Change	115	39	29	26
2. Complex Response	11	3	3	2
3. Response Duration & Return	111	34	28	23
CARDIOVASCULAR				
1. Baseline Increase & Decrease	47	23	12	15
2. Baseline Increase	26	6	7	4
3. Baseline Decrease	5	1	1	1
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	16	11	4	7
6. Rate Increase	0	0	0	0
7. Rate Decrease	1	0	0	0
8. P.V.C.				

392 151

Table 2 Q1 K

Title: Q 1, Third Chart Reactions

Column 1. is: DI Men

Column 2. is: DI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	men		women	
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	5	0	2	0
2. Rate Increase	2	0	1	0
3. I/E Ratio Change	1	0	0	0
4. Amplitude Increase	10	5	4	5
5. Amplitd Decrease/Suppression	7	5	3	5
6. Progressive Increase/Decrease	3	0	1	0
7. Progressive Increase & Return	1	1	0	1
8. Progressive Decrease & Return	5	2	2	2
9. Baseline Change - Temporary	7	3	3	2
10. Baseline Change - Permanent	8	2	3	2
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	3	3	1	2
ELECTRODERMAL				
1. Amplitude Change	75	28	28	26
2. Complex Response	7	5	3	5
3. Response Duration & Return	70	28	26	26
CARDIOVASCULAR				
1. Baseline Increase & Decrease	36	16	13	15
2. Baseline Increase	18	6	7	6
3. Baseline Decrease	0	1	0	1
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	9	2	3	2
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
8. P.V.C.				

267 ÷ 115
107 ÷ 46

267 107

Table 2 Q 1 L

Title: Q 1, Third Chart Reactions

Column 1. is: NDI Men

Column 2. is: NDI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	men	women	men	women
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	0	0	0	0
2. Rate Increase	0	0	0	0
3. I/E Ratio Change	0	0	0	0
4. Amplitude Increase	6	2	5	11
5. Amplitd Decrease/Suppression	1	0	1	0
6. Progressive Increase/Decrease	0	0	0	0
7. Progressive Increase & Return	3	0	3	0
8. Progressive Decrease & Return	0	0	0	0
9. Baseline Change - Temporary	3	1	3	6
10. Baseline Change - Permanent	1	0	1	0
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	0	0	0	0
ELECTRODERMAL				
1. Amplitude Change	31	5	28	28
2. Complex Response	7	1	6	6
3. Response Duration & Return	30	5	27	28
CARDIOVASCULAR				
1. Baseline Increase & Decrease	13	0	12	0
2. Baseline Increase	7	2	6	11
3. Baseline Decrease	1	1	1	6
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	8	1	7	6
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
8. P.V.C.				

Table 201M

Title: Q 1, Third Chart Reactions

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	men	women	men	women
	1	2	3	4
	no.	no.	%	%
RESPIRATION				
1. Rate Decrease	5	0	1	0
2. Rate Increase	2	0	0	0
3. I/E Ratio Change	1	0	0	0
4. Amplitude Increase	16	7	4	6
5. Amplitude Decrease/Suppression	8	5	2	4
6. Progressive Increase/Decrease	3	0	0	0
7. Progressive Increase & Return	4	1	1	0
8. Progressive Decrease & Return	5	3	1	2
9. Baseline Change - Temporary	16	2	3	2
10. Baseline Change - Permanent	9	0	2	0
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	3	3	0	2
ELECTRODERMAL				
1. Amplitude Change	106	33	28	27
2. Complex Response	14	6	4	5
3. Response Duration & Return	100	33	26	27
CARDIOVASCULAR				
1. Baseline Increase & Decrease	49	16	13	13
2. Baseline Increase	25	8	7	7
3. Baseline Decrease	1	2	0	2
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	17	2	4	2
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
8. P.V.C.				

378 121

Table 2Q1 N

Title: Q 1, Third Chart Reactions

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	6	1	2	0
2. Rate Increase	2	0	1	0
3. I/E Ratio Change	0	1	0	0
4. Amplitude Increase	14	11	4	5
5. Amplitd Decrease/Suppression	9	4	3	2
6. Progressive Increase/Decrease	2	1	1	0
7. Progressive Increase & Return	1	4	0	2
8. Progressive Decrease & Return	5	3	2	1
9. Baseline Change - Temporary	6	7	2	3
10. Baseline Change - Permanent	9	4	3	2
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	6	2	2	1
ELECTRODERMAL	60	38		
1. Amplitude Change	94	55	29	26
2. Complex Response	11	10	3	5
3. Response Duration & Return	86	55	26	26
CARDIOVASCULAR	191	120		
1. Baseline Increase & Decrease	42	25	13	12
2. Baseline Increase	19	16	6	8
3. Baseline Decrease	3	3	1	1
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	11	11	3	5
6. Rate Increase	2	0	1	0
7. Rate Decrease	0	0	0	0
8. ...	328	213		

27 56

Table 2-Q2-A

File: Q 2, Reactions from the First Three Charts

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	24	7	2	1
2. Rate Increase	9	6	1	1
3. I/E Ratio Change	4	2	0	0
4. Amplitude Increase	50	29	4	4
5. Amplitd Decrease/Suppression	27	21	2	3
6. Progressive Increase/Decrease	4	9	0	1
7. Progressive Increase & Return	6	5	0	1
8. Progressive Decrease & Return	9	12	1	2
9. Baseline Change - Temporary	39	24	3	3
10. Baseline Change - Permanent	21	15	2	2
11. Apnea - Holding (inspiration)	1	0	0	0
12. Apnea - Blocking (Exhalation)	19	5	2	1
ELECTRODERMAL				
1. Amplitude Change	309	185	26	25
2. Complex Response	57	47	5	1
3. Response Duration & Return	297	180	25	25
CARDIOVASCULAR				
1. Baseline Increase & Decrease	176	103	15	14
2. Baseline Increase	62	20	5	3
3. Baseline Decrease	14	23	1	3
4. Amplitude Increase	1	1	0	0
5. Amplitude Decrease	69	34	6	5
6. Rate Increase	1	1	0	0
7. Rate Decrease	2	4	0	1
8. P.V.C.				

1201 733

Table 2 Q2 B

Title:

Q 2, Reactions from the First Three Charts

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	Men	Women	Men	Women
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	20	9	2	2
2. Rate Increase	5	8	0	2
3. I/E Ratio Change	3	2	0	0
4. Amplitude Increase	53	15	4	3
5. Amplitd Decrease/Suppression	34	12	3	2
6. Progressive Increase/Decrease	11	2	1	0
7. Progressive Increase & Return	6	3	5	1
8. Progressive Decrease & Return	19	1	2	0
9. Baseline Change - Temporary	41	17	3	3
10. Baseline Change - Permanent	21	12	2	2
11. Apnea - Holding (inspiration)	0	1	0	0
12. Apnea - Blocking (Exhalation)	11	12	1	2
ELECTRODERMAL				
1. Amplitude Change	324	124	26	25
2. Complex Response	71	20	6	4
3. Response Duration & Return	310	123	25	25
CARDIOVASCULAR				
1. Baseline Increase & Decrease	182	68	14	14
2. Baseline Increase	59	16	5	3
3. Baseline Decrease	20	11	2	2
4. Amplitude Increase	1	1	0	0
5. Amplitude Decrease	62	32	5	7
6. Rate Increase	2	0	0	0
7. Rate Decrease	4	1	0	0
8. P.V.C.				

1259 440

Table 2 20 C

Title: Q 2. First Chart Reactions

Column 1. is: NDI Men

Column 2. is: NDI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	NDI Men	NDI Women	Men	Women
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	1	0	1	0
2. Rate Increase	1	1	1	1
3. I/E Ratio Change	0	0	0	0
4. Amplitude Increase	8	3	4	4
5. Amplitude Decrease/Suppression	2	2	1	3
6. Progressive Increase/Decrease	2	1	1	1
7. Progressive Increase & Return	2	0	1	0
8. Progressive Decrease & Return	4	1	2	1
9. Baseline Change - Temporary	4	1	5	1
10. Baseline Change - Permanent	5	2	3	3
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	0	0	0	0
ELECTRODERMAL	34	11		
1. Amplitude Change	47	18	24	27
2. Complex Response	13	4	6	6
3. Response Duration & Return	47	17	24	25
CARDIOVASCULAR	107			
1. Baseline Increase & Decrease	22	10	12	15
2. Baseline Increase	7	0	4	0
3. Baseline Decrease	7	3	4	4
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	8	4	4	6
6. Rate Increase	0	0	0	0
7. Rate Decrease	1	0	1	0
8. P.V.C.				

46 186 67 = 253

Table 230 D

Title: Q 2, First Chart Reactions

Column 1. is: DI Men

Column 2. is: DI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	MEN	WOMEN	MEN	WOMEN
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	6	1	2	1
2. Rate Increase	0	2	0	2
3. I/E Ratio Change	1	0	0	0
4. Amplitude Increase	9	4	3	3
5. Amplitd Decrease/Suppression	4	2	2	2
6. Progressive Increase/Decrease	1	0	0	0
7. Progressive Increase & Return	1	1	0	1
8. Progressive Decrease & Return	2	0	1	0
9. Baseline Change - Temporary	9	4	3	3
10. Baseline Change - Permanent	5	2	2	2
11. Apnea - Holding (inspiration)	0	1	0	1
12. Apnea - Blocking (Exhalation)	1	2	0	2
ELECTRODERMAL				
1. Amplitude Change	68	30	26	26
2. Complex Response	17	5	6	4
3. Response Duration & Return	64	32	24	28
CARDIOVASCULAR				
1. Baseline Increase & Decrease	43	18	16	16
2. Baseline Increase	10	1	4	1
3. Baseline Decrease	3	1	1	1
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	19	9	7	8
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
8. P.V.C.				

263 115 378

Table 2 Q26

Title: Q 2, First Chart Reactions

Column 1. is: D I

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	D I	NDI	D I	NDI
	1	2	3	4
RESPIRATION	%			
1. Rate Decrease	7	1	2	0
2. Rate Increase	2	2	0	1
3. I/E Ratio Change	1	1	0	0
4. Amplitude Increase	17	11	4	4
5. Amplitude Decrease/Suppression	6	4	1	1
6. Progressive Increase/Decrease	1	3	0	1
7. Progressive Increase & Return	2	2	0	1
8. Progressive Decrease & Return	2	5	0	2
9. Baseline Change - Temporary	14	10	3	4
10. Baseline Change - Permanent	7	7	2	3
11. Apnea - Holding (inspiration)	1	0	0	0
12. Apnea - Blocking (Exhalation)	3	0	1	0
ELECTRODERMAL	63	46		
1. Amplitude Change	106	69	26	26
2. Complex Response	24	18	6	7
3. Response Duration & Return	104	68	25	25
CARDIOVASCULAR	234	155		
1. Baseline Increase & Decrease	67	36	16	13
2. Baseline Increase	13	7	3	3
3. Baseline Decrease	4	10	1	4
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	30	13	7	5
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	1	0	0
8. P.V.C.	14			

411 268 = 679
67

Table _____

Title:

Q 2, First Chart Reactions

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	Men	Women	Men	Women
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	7	1	2	1
2. Rate Increase	1	3	1	2
3. I/E Ratio Change	1	0	1	0
4. Amplitude Increase	17	7	4	4
5. Amplitude Decrease/Suppression	6	4	1	2
6. Progressive Increase/Decrease	3	1	1	1
7. Progressive Increase & Return	3	1	1	1
8. Progressive Decrease & Return	6	1	1	1
9. Baseline Change - Temporary	18	5	4	3
10. Baseline Change - Permanent	10	4	2	2
11. Apnea - Holding (inspiration)	0	1	0	1
12. Apnea - Blocking (Exhalation)	1	2	0	1
ELECTRODERMAL	73	30		
1. Amplitude Change	115	48	26	26
2. Complex Response	30	9	7	5
3. Response Duration & Return	111	49	25	27
CARDIOVASCULAR	256	106	58	58
1. Baseline Increase & Decrease	65	28	14	15
2. Baseline Increase	17	1	4	1
3. Baseline Decrease	10	4	2	2
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	27	13	6	7
6. Rate Increase	0	0	0	0
7. Rate Decrease	1	0	0	0
8. P.V.C.	120	46		

$$449 \div 115 = 3.9$$

$$182 \div 46 = 4.0$$

$$449 \quad 182$$

Table 202A

Title:

Q2, Second Chart Reactions

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	7	2	2	1
2. Rate Increase	6	2	2	1
3. I/E Ratio Change	2	1	0	6
4. Amplitude Increase	20	6	5	2
5. Amplitude Decrease/Suppression	10	8	3	3
6. Progressive Increase/Decrease	1	6	0	2
7. Progressive Increase & Return	1	1	0	0
8. Progressive Decrease & Return	3	2	1	1
9. Baseline Change - Temporary	11	7	3	3
10. Baseline Change - Permanent	3	4	1	2
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	9	3	3	1
ELECTRODERMAL	5873	412		
1. Amplitude Change	161	60	25	25
2. Complex Response	16	19	4	8
3. Response Duration & Return	96	58	24	24
CARDIOVASCULAR	213	137		
1. Baseline Increase & Decrease	55	35	14	14
2. Baseline Increase	27	7	7	3
3. Baseline Decrease	4	7	1	3
4. Amplitude Increase	0	1	0	0
5. Amplitude Decrease	25	11	6	5
6. Rate Increase	1	0	0	0
7. Rate Decrease	0	2	0	1
8. P.V.C.	112	694		

398 243

Table 222 B

Title: Q 2, Second Chart Reactions

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	M	W	M	W
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	5	3	1	2
2. Rate Increase	2	5	0	3
3. I/E Ratio Change	2	1	0	1
4. Amplitude Increase	18	5	4	3
5. Amplitd Decrease/Suppression	14	3	3	2
6. Progressive Increase/Decrease	6	1	1	1
7. Progressive Increase & Return	0	1	0	1
8. Progressive Decrease & Return	5	0	1	0
9. Baseline Change - Temporary	12	6	3	3
10. Baseline Change - Permanent	4	3	1	2
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	4	7	1	4
ELECTRODERMAL				
1. Amplitude Change	103	46	25	24
2. Complex Response	25	7	6	4
3. Response Duration & Return	99	45	24	24
CARDIOVASCULAR				
1. Baseline Increase & Decrease	56	28	14	15
2. Baseline Increase	20	11	5	6
3. Baseline Decrease	8	1	2	1
4. Amplitude Increase	0	1	0	1
5. Amplitude Decrease	21	14	5	7
6. Rate Increase	1	0	0	0
7. Rate Decrease	1	1	0	1
8. P.V.C.				

406 189

Table 220c

Title:

Q 2, Second Chart Reactions

Column 1. is: NDI Men

Column 2. is: NDI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	NDI Men	NDI Women	Men	Women
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	1	1	1	2
2. Rate Increase	1	1	1	2
3. I/E Ratio Change	1	0	1	
4. Amplitude Increase	5	1	3	2
5. Amplitude Decrease/Suppression	7	1	4	2
6. Progressive Increase/Decrease	5	1	3	2
7. Progressive Increase & Return	0	0	0	0
8. Progressive Decrease & Return	2	0	1	0
9. Baseline Change - Temporary	4	3	2	5
10. Baseline Change - Permanent	3	1	2	2
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	1	2	1	3
ELECTRODERMAL				
1. Amplitude Change	41	15	25	25
2. Complex Response	14	4	8	7
3. Response Duration & Return	34	15	23	25
CARDIOVASCULAR				
1. Baseline Increase & Decrease	24	9	14	15
2. Baseline Increase	5	2	3	3
3. Baseline Decrease	5	0	3	0
4. Amplitude Increase	0	1	0	1
5. Amplitude Decrease	8	3	5	5
6. Rate Increase	0	0	0	0
7. Rate Decrease	1	1	1	2
8. P.V.C.	-	-		

Table 228D

Title:

Q 2 Second Chart Reactions

Column 1. is: DI Men

Column 2. is: DI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI Men	DI Women	DI Men	DI Women
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	4	2	2	2
2. Rate Increase	1	4	0	3
3. I/E Ratio Change	1	1	0	1
4. Amplitude Increase	13	4	6	3
5. Amplitude Decrease/Suppression	7	2	3	2
6. Progressive Increase/Decrease	1	0	0	0
7. Progressive Increase & Return	0	1	0	1
8. Progressive Decrease & Return	3	0	1	0
9. Baseline Change - Temporary	5	3	2	2
10. Baseline Change - Permanent	1	1	0	1
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	3	5	1	4
ELECTRODERMAL				
1. Amplitude Change	62	31	26	25
2. Complex Response	11	3	5	2
3. Response Duration & Return	60	30	25	24
CARDIOVASCULAR				
1. Baseline Increase & Decrease	32	19	14	15
2. Baseline Increase	15	9	6	7
3. Baseline Decrease	3	1	1	1
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	13	11	6	9
6. Rate Increase	1	0	0	0
7. Rate Decrease	0	0	0	0
8. P.V.C.				

Table 2 26 6

Title: Q 2, Third Chart Reactions

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	10	4	3	2
2. Rate Increase	1	2	0	1
3. I/E Ratio Change	1	0	0	0
4. Amplitude Increase	13	12	3	5
5. Amplitude Decrease/Suppression	11	9	3	4
6. Progressive Increase/Decrease	2	0	0	0
7. Progressive Increase & Return	3	2	1	1
8. Progressive Decrease & Return	4	5	1	2
9. Baseline Change - Temporary	14	7	4	3
10. Baseline Change - Permanent	11	4	3	2
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	7	2	2	1
ELECTRODERMAL	77	47		
1. Amplitude Change	102	56	26	25
2. Complex Response	17	10	4	4
3. Response Duration & Return	97	54	25	24
CARDIOVASCULAR	216	120		
1. Baseline Increase & Decrease	54	32	14	14
2. Baseline Increase	22	6	6	3
3. Baseline Decrease	6	6	2	3
4. Amplitude Increase	1	0	0	0
5. Amplitude Decrease	14	10	4	4
6. Rate Increase	0	1	0	0
7. Rate Decrease	2	1	0	0
8. P.V.C.				

99392 223
56

Table _____

Title: Q 2, Third Chart Reactions

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	MEN	WOMEN	MEN	WOMEN
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	8	6	2	4
2. Rate Increase	2	1	0	1
3. I/E Ratio Change	0	1	0	1
4. Amplitude Increase	18	5	4	3
5. Amplitude Decrease/Suppression	14	6	3	4
6. Progressive Increase/Decrease	2	0	0	0
7. Progressive Increase & Return	3	2	1	1
8. Progressive Decrease & Return	8	0	2	0
9. Baseline Change - Temporary	11	9	3	5
10. Baseline Change - Permanent	7	7	2	4
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	6	3	1	2
ELECTRODERMAL				
1. Amplitude Change	106	41	26	24
2. Complex Response	16	7	4	4
3. Response Duration & Return	100	40	25	24
CARDIOVASCULAR				
1. Baseline Increase & Decrease	61	19	15	11
2. Baseline Increase	22	5	5	3
3. Baseline Decrease	2	9	0	5
4. Amplitude Increase	1	0	0	0
5. Amplitude Decrease	14	8	3	5
6. Rate Increase	1	0	0	0
7. Rate Decrease	2	1	0	1
8. P.V.C.				

404 170

Table _____

title:

Q 2, Third Chart Reactions

Column 1. is: DI Men

Column 2. is: DI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	MEN	WOMEN	MEN	WOMEN
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	5	5	2	4
2. Rate Increase	1	0	0	0
3. I/E Ratio Change	0	1	0	1
4. Amplitude Increase	9	3	4	3
5. Amplitude Decrease/Suppression	6	5	2	4
6. Progressive Increase/Decrease	2	0	1	0
7. Progressive Increase & Return	2	1	1	1
8. Progressive Decrease & Return	4	0	2	0
9. Baseline Change - Temporary	7	6	3	5
10. Baseline Change - Permanent	6	5	2	4
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	4	3	2	3
ELECTRODERMAL				
1. Amplitude Change	64	30	27	25
2. Complex Response	10	4	4	3
3. Response Duration & Return	60	29	25	24
CARDIOVASCULAR				
1. Baseline Increase & Decrease	37	12	15	10
2. Baseline Increase	14	4	6	3
3. Baseline Decrease	0	6	0	5
4. Amplitude Increase	1	0	0	0
5. Amplitude Decrease	7	5	3	4
6. Rate Increase	0	0	0	0
7. Rate Decrease	2	0	1	0
8. P.V.C.				

241 119

Table _____

Title: Q 2, Third Chart Reactions

Column 1. is: NDI Men

Column 2. is: NDI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	MEN	WOMEN	MEN	WOMEN
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	3	1	2	2
2. Rate Increase	1	1	1	2
3. I/E Ratio Change	0	0	0	0
4. Amplitude Increase	9	2	6	4
5. Amplitd Decrease/Suppression	8	1	5	2
6. Progressive Increase/Decrease	0	0	0	0
7. Progressive Increase & Return	1	1	1	2
8. Progressive Decrease & Return	4	0	2	0
9. Baseline Change - Temporary	4	3	2	6
10. Baseline Change - Permanent	1	2	1	4
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	2	0	1	0
ELECTRODERMAL				
1. Amplitude Change	42	11	26	22
2. Complex Response	6	3	4	6
3. Response Duration & Return	40	11	25	22
CARDIOVASCULAR				
1. Baseline Increase & Decrease	24	7	15	14
2. Baseline Increase	8	1	5	2
3. Baseline Decrease	2	3	1	6
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	7	3	4	6
6. Rate Increase	1	0	1	0
7. Rate Decrease	0	1	0	2
8. P.V.C.				

Table 2-Q3-A

Title: Q 3, Reactions from the First Three Charts

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	26	7	2	1
2. Rate Increase	20	4	2	0
3. I/E Ratio Change	7	1	1	0
4. Amplitude Increase	47	17	4	2
5. Amplitd Decrease/Suppression	36	27	3	4
6. Progressive Increase/Decrease	7	4	1	0
7. Progressive Increase & Return	6	8	1	1
8. Progressive Decrease & Return	11	14	1	2
9. Baseline Change - Temporary	56	26	5	4
10. Baseline Change - Permanent	20	14	2	2
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	14	0	1	0
ELECTRODERMAL				
1. Amplitude Change	303	176	25	24
2. Complex Response	63	58	5	8
3. Response Duration & Return	276	163	23	23
CARDIOVASCULAR				
1. Baseline Increase & Decrease	167	123	13	17
2. Baseline Increase	44	21	4	3
3. Baseline Decrease	25	17	2	2
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	64	42	5	6
6. Rate Increase	1	2	0	0
7. Rate Decrease	1	0	0	0
	1194	724		

Table 2 Q3-B

Title:

Q 3 Reactions from the First Three Charts

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	Men	Women	Men	Women
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	22	11	2	2
2. Rate Increase	15	7	1	1
3. I/E Ratio Change	5	3	0	1
4. Amplitude Increase	38	20	3	4
5. Amplitude Decrease/Suppression	40	17	3	3
6. Progressive Increase/Decrease	6	4	0	1
7. Progressive Increase & Return	11	2	1	0
8. Progressive Decrease & Return	21	2	2	0
9. Baseline Change - Temporary	57	22	4	4
10. Baseline Change - Permanent	20	14	2	3
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	10	3	1	1
ELECTRODERMAL				
1. Amplitude Change	327	118	26	23
2. Complex Response	84	24	7	5
3. Response Duration & Return	296	113	23	22
CARDIOVASCULAR				
1. Baseline Increase & Decrease	184	80	14	16
2. Baseline Increase	40	20	3	4
3. Baseline Decrease	26	13	2	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	67	28	5	6
6. Rate Increase	1	6	0	1
7. Rate Decrease	1	0	0	0
	1276	507		

Table 2 Q3 c

Title:

Q3, First Chart Reactions

Column 1. is:

DI

Column 2. is:

NDI

Column 3. is:

% Distribution of 1

Column 4. is:

% Distribution of 2

	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	8	2	2	1
2. Rate Increase	3	2	1	1
3. I/E Ratio Change	3	0	1	0
4. Amplitude Increase	18	7	4	2
5. Amplitd Decrease/Suppression	9	10	2	3
6. Progressive Increase/Decrease	1	2	0	1
7. Progressive Increase & Return	2	5	0	2
8. Progressive Decrease & Return	5	3	1	1
9. Baseline Change - Temporary	19	11	5	4
10. Baseline Change - Permanent	6	6	1	2
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	3	0	1	0
ELECTRODERMAL	77	48		
1. Amplitude Change	107	77	26	25
2. Complex Response	23	24	6	8
3. Response Duration & Return	101	71	25	23
CARDIOVASCULAR	231	172		
1. Baseline Increase & Decrease	59	51	14	17
2. Baseline Increase	16	8	4	3
3. Baseline Decrease	6	5	1	2
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	22	19	5	6
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	411	303		

Table 2 Q39

Q3, First Chart Reactions

column 1. is: Men

column 2. is: Women

column 3. is: % Distribution of 1

column 4. is: % Distribution of 2

	Men	Women	Men	Women
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	9	1	2	1
2. Rate Increase	4	1	1	1
3. I/E Ratio Change	2	1	6	1
4. Amplitude Increase	18	4	4	2
5. Amplitude Decrease/Suppression	10	8	2	4
6. Progressive Increase/Decrease	1	2	0	1
7. Progressive Increase & Return	5	2	1	1
8. Progressive Decrease & Return	6	1	1	1
9. Baseline Change - Temporary	20	9	4	5
10. Baseline Change - Permanent	8	3	2	2
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	2	1	0	1
ELECTRODERMAL				
1. Amplitude Change	123	47	26	24
2. Complex Response	24	15	5	8
3. Response Duration & Return	113	46	24	24
CARDIOVASCULAR				
1. Baseline Increase & Decrease	67	34	14	18
2. Baseline Increase	16	6	3	3
3. Baseline Decrease	8	2	2	1
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	28	11	6	6
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
8.	464	194		

Table 2 Q3-E

Title:

Q3, First Chart Reactions

Column 1. is: DI Men

Column 2. is: DI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI Men	DI Women	DI Men	DI Women
RESPIRATION	1	2	3	4
1. Rate Decrease			%	%
2. Rate Increase	7	1	3	1
3. I/E Ratio Change	2	1	1	1
4. Amplitude Increase	2	1	1	1
5. Amplitd Decrease/Suppression	13	2	5	2
6. Progressive Increase/Decrease	5	3	2	2
7. Progressive Increase & Return	0	1	0	1
8. Progressive Decrease & Return	2	0	1	0
9. Baseline Change - Temporary	4	1	2	1
10. Baseline Change - Permanent	13	5	5	4
11. Apnea - Holding (inspiration)	3	3	1	2
12. Apnea - Blocking (Exhalation)	0	0	0	0
2	2	1	1	1
ELECTRODERMAL				
1. Amplitude Change	70	30	27	25
2. Complex Response	16	5	6	4
3. Response Duration & Return	64	31	24	26
CARDIOVASCULAR				
1. Baseline Increase & Decrease	33	22	12	18
2. Baseline Increase	10	4	4	3
3. Baseline Decrease	5	1	2	1
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	13	9	5	7
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	264	121		

Table _____

Title:

Q 3. First Chart Reactions

Column 1. is:

NDI Men

Column 2. is:

NDI Women

Column 3. is:

% Distribution of 1

Column 4. is:

% Distribution of 2

	NDI Men	NDI Women	NDI Men	NDI Women
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	2	0	1	0
2. Rate Increase	2	0	1	0
3. I/E Ratio Change	0	0		0
4. Amplitude Increase	5	2	2	3
5. Amplitude Decrease/Suppression	5	5	2	7
6. Progressive Increase/Decrease	1	1	0	1
7. Progressive Increase & Return	3	2	1	3
8. Progressive Decrease & Return	2	0	1	0
9. Baseline Change - Temporary	7	4	3	5
10. Baseline Change - Permanent	5	0	2	0
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	0	0	0	0
ELECTRODERMAL				
1. Amplitude Change	53	17	26	23
2. Complex Response	13	10	6	14
3. Response Duration & Return	49	15	24	21
CARDIOVASCULAR				
1. Baseline Increase & Decrease	34	12	17	16
2. Baseline Increase	6	2	3	3
3. Baseline Decrease	3	1	1	1
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	15	2	7	3
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	205	73		

Table _____

Title: Q3, Second Chart Reactions

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	10	2	2	1
2. Rate Increase	6	1	1	6
3. I/E Ratio Change	3	0	1	0
4. Amplitude Increase	16	2	4	1
5. Amplitd Decrease/Suppression	10	11	2	5
6. Progressive Increase/Decrease	4	0	1	0
7. Progressive Increase & Return	3	1	1	0
8. Progressive Decrease & Return	2	4	0	2
9. Baseline Change - Temporary	19	7	5	3
10. Baseline Change - Permanent	8	5	2	2
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	5	0	1	0
ELECTRODERMAL	86	33		
1. Amplitude Change	165	57	26	24
2. Complex Response	22	21	5	9
3. Response Duration & Return	94	53	23	22
CARDIOVASCULAR	221	131		
1. Baseline Increase & Decrease	51	42	12	18
2. Baseline Increase	14	7	3	3
3. Baseline Decrease	13	6	3	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	21	12	5	5
6. Rate Increase	1	5	0	2
7. Rate Decrease	1	0	0	0
	408	236		

Table _____

Title: Q3, Second Chart Reactions

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	Men	Women	Men	Women
	1	2	3	4
RESPIRATION			0/6	0/6
1. Rate Decrease	6	6	1	4
2. Rate Increase	4	2	1	1
3. I/E Ratio Change	1	2	0	1
4. Amplitude Increase	11	6	3	4
5. Amplitd Decrease/Suppression	15	4	4	2
6. Progressive Increase/Decrease	3	1	1	1
7. Progressive Increase & Return	4	0	1	0
8. Progressive Decrease & Return	5	1	1	1
9. Baseline Change - Temporary	21	4	5	2
10. Baseline Change - Permanent	4	8	1	5
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	4	1	4	1
ELECTRODERMAL				
1. Amplitude Change	116	38	26	23
2. Complex Response	34	6	8	4
3. Response Duration & Return	99	37	23	22
CARDIOVASCULAR				
1. Baseline Increase & Decrease	58	26	14	15
2. Baseline Increase	12	7	3	4
3. Baseline Decrease	11	6	3	4
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	23	7	5	4
6. Rate Increase	1	5	0	3
7. Rate Decrease	1	0	0	0
	427	167		

Table _____

Title:

Q2 Second Chart Reactions

Column 1. is: DI Men

Column 2. is: DI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI Men	DI Women	DI Men	DI Women
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	4	6	2	5
2. Rate Increase	3	2	1	2
3. I/E Ratio Change	1	2	0	2
4. Amplitude Increase -	9	6	4	5
5. Amplitd Decrease/Suppression	6	2	2	2
6. Progressive Increase/Decrease	3	1	1	1
7. Progressive Increase & Return	3	0	1	0
8. Progressive Decrease & Return	1	1	0	1
9. Baseline Change - Temporary	15	3	6	2
10. Baseline Change - Permanent	3	5	1	4
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	4	1	2	1
ELECTRODERMAL				
1. Amplitude Change	68	28	23	23
2. Complex Response	17	3	7	2
3. Response Duration & Return	61	27	24	22
CARDIOVASCULAR				
1. Baseline Increase & Decrease	31	15	12	12
2. Baseline Increase	7	6	3	5
3. Baseline Decrease	7	5	3	4
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	12	7	5	6
6. Rate Increase	0	1	0	0
7. Rate Decrease	1	0	0	0
	256	121		

Table _____

Title: Q 3 Second Chart Reactions

Column 1. is: NDI Men

Column 2. is: NDI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	NDI Men	NDI Women	NDI Men	NDI Women
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	2	0	1	0
2. Rate Increase	1	0	1	0
3. I/E Ratio Change	0	0	0	0
4. Amplitude Increase	2	0	1	0
5. Amplitd Decrease/Suppression	9	2	5	4
6. Progressive Increase/Decrease	0	0	0	0
7. Progressive Increase & Return	1	0	1	0
8. Progressive Decrease & Return	4	0	2	0
9. Baseline Change - Temporary	6	1	4	2
10. Baseline Change - Permanent	1	3	1	6
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	0	0	0	0
ELECTRODERMAL				
1. Amplitude Change	42	10	25	21
2. Complex Response	17	3	10	6
3. Response Duration & Return	38	10	22	21
CARDIOVASCULAR				
1. Baseline Increase & Decrease	27	11	16	23
2. Baseline Increase	5	1	3	2
3. Baseline Decrease	4	2	2	4
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	11	0	6	0
6. Rate Increase	1	4	1	9
7. Rate Decrease	0	0	0	0
	171	47		

Table _____

Title: Q 3, Third Chart Reactions

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION	% %			
1. Rate Decrease	8	3	2	2
2. Rate Increase	11	1	3	1
3. I/E Ratio Change	1	1	0	1
4. Amplitude Increase	13	8	3	4
5. Amplitd Decrease/Suppression	17	5	5	3
6. Progressive Increase/Decrease	2	2	1	1
7. Progressive Increase & Return	1	1	0	1
8. Progressive Decrease & Return	4	8	1	4
9. Baseline Change - Temporary	18	8	5	4
10. Baseline Change - Permanent	8	3	2	2
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	6	0	2	0
ELECTRODERMAL	89	40		
1. Amplitude Change	91	42	24	23
2. Complex Response	18	13	5	7
3. Response Duration & Return	81	39	21	21
CARDIOVASCULAR	190	94		
1. Baseline Increase & Decrease	57	30	15	16
2. Baseline Increase	14	6	4	3
3. Baseline Decrease	6	6	2	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	21	7	6	4
6. Rate Increase	0	1	0	1
7. Rate Decrease	0	0	0	0
	377	184		
	98	50		

Table _____

Title:

Q3, Third Chart Reactions

Column 1. is:

Men

Column 2. is:

Women

Column 3. is:

% Distribution of 1

Column 4. is:

% Distribution of 2

	Men	Women	Men	Women
	1	2	3	4
RESPIRATION				
1. Rate Decrease			0/6	0/0
2. Rate Increase	7	3	2	3
3. I/E Ratio Change	7	3	2	3
4. Amplitude Increase	2	0	1	0
5. Amplitd Decrease/Suppression	9	7	2	7
6. Progressive Increase/Decrease	15	3	4	3
7. Progressive Increase & Return	2	1	1	1
8. Progressive Decrease & Return	2	0	1	0
9. Baseline Change - Temporary	10	0	3	0
10. Baseline Change - Permanent	16	6	4	6
11. Apnea - Holding (inspiration)	5	2	2	2
12. Apnea - Blocking (Exhalation)	0	0	0	0
ELECTRODERMAL	4	1	1	1
1. Amplitude Change				
2. Complex Response	94	33	25	23
3. Response Duration & Return	26	3	7	2
CARDIOVASCULAR	84	30	22	21
1. Baseline Increase & Decrease				
2. Baseline Increase	59	20	16	14
3. Baseline Decrease	12	7	3	5
4. Amplitude Increase	7	4	2	3
5. Amplitude Decrease	0	0	0	0
6. Rate Increase	10	16	3	7
7. Rate Decrease	0	0	0	0
	0	0	0	0
	380	145		

Table _____

Title: Q3, Third Chart Reactions

Column 1. is: DI Men

Column 2. is: DI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI Men	DI Wm	DI W	DI M
	1	2	3	4
RESPIRATION			7	8%
1. Rate Decrease	4	4	2	4
2. Rate Increase	6	4	3	4
3. I/E Ratio Change	1	0	0	0
4. Amplitude Increase	5	0	2	6
5. Amplitude Decrease/Suppression	11	4	5	4
6. Progressive Increase/Decrease	1	0	0	0
7. Progressive Increase & Return	1	0	0	0
8. Progressive Decrease & Return	3	0	1	0
9. Baseline Change - Temporary	12	5	5	4
10. Baseline Change - Permanent	5	3	2	3
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	4	1	2	1
ELECTRODERMAL				
1. Amplitude Change	61	27	26	24
2. Complex Response	14	3	6	3
3. Response Duration & Return	52	26	22	23
CARDIOVASCULAR				
1. Baseline Increase & Decrease	35	16	15	14
2. Baseline Increase	9	4	4	4
3. Baseline Decrease	3	2	1	2
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	5	8	5	7
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	238	114		

Table _____

Title:

Q 3, Third Chart Reactions

Column 1. is: NDI Men

Column 2. is: NDI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	NDI Men	NDI Women	NDI Men	NDI Women
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	3	0	2	0
2. Rate Increase	1	0	1	0
3. I/E Ratio Change	1	0	1	0
4. Amplitude Increase	4	3	3	10
5. Amplitd Decrease/Suppression	4	7	3	3
6. Progressive Increase/Decrease	1	1	1	3
7. Progressive Increase & Return	1	0	1	0
8. Progressive Decrease & Return	7	0	5	0
9. Baseline Change - Temporary	4	4	3	13
10. Baseline Change - Permanent	3	0	2	0
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	0	0	0	0
ELECTRODERMAL				
1. Amplitude Change	33	6	23	19
2. Complex Response	12	0	8	0
3. Response Duration & Return	32	4	23	13
CARDIOVASCULAR				
1. Baseline Increase & Decrease	24	4	17	13
2. Baseline Increase	3	3	2	10
3. Baseline Decrease	4	2	3	6
4. Amplitude Increase	6	0	0	0
5. Amplitude Decrease	5	2	4	6
6. Rate Increase	0	1	0	3
7. Rate Decrease	0	0	0	0
	142	31		

Table 2-Q4-A

Title: Q4, Reactions from the First Three Charts

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI	NDI	DI	NDI
	1	2	3	4
			%	%
RESPIRATION				
1. Rate Decrease	29	7	2	1
2. Rate Increase	14	5	1	1
3. I/E Ratio Change	7	0	1	0
4. Amplitude Increase	54	30	4	4
5. Amplitude Decrease/Suppression	34	16	3	2
6. Progressive Increase/Decrease	8	7	1	1
7. Progressive Increase & Return	9	5	1	1
8. Progressive Decrease & Return	16	15	1	2
9. Baseline Change - Temporary	46	25	4	3
10. Baseline Change - Permanent	28	21	2	3
11. Apnea - Holding (inspiration)	1	0	0	0
12. Apnea - Blocking (Exhalation)	19	6	2	1
ELECTRODERMAL				
1. Amplitude Change	298	176	24	24
2. Complex Response	62	51	5	7
3. Response Duration & Return	263	169	21	23
CARDIOVASCULAR				
1. Baseline Increase & Decrease	206	107	16	15
2. Baseline Increase	38	26	3	4
3. Baseline Decrease	32	25	3	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	86	37	7	5
6. Rate Increase	3	0	0	0
7. Rate Decrease	0	0	0	0
3.	1253	726		

Table 2-Q4-B

Title:

Q4, Reactions from the First Three Charts

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	Men	Women	Men	Women
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	26	7	2	1
2. Rate Increase	11	8	1	2
3. I/E Ratio Change	5	2	0	0
4. Amplitude Increase	58	19	4	4
5. Amplitd Decrease/Suppression	26	17	2	3
6. Progressive Increase/Decrease	10	4	1	1
7. Progressive Increase & Return	7	3	1	1
8. Progressive Decrease & Return	26	2	2	0
9. Baseline Change - Temporary	56	19	4	4
10. Baseline Change - Permanent	28	18	2	3
11. Apnea - Holding (inspiration)	0	1	0	0
12. Apnea - Blocking (Exhalation)	17	8	1	2
ELECTRODERMAL				
1. Amplitude Change	321	116	24	22
2. Complex Response	76	25	6	5
3. Response Duration & Return	298	102	23	20
CARDIOVASCULAR				
1. Baseline Increase & Decrease	205	82	16	16
2. Baseline Increase	41	21	3	4
3. Baseline Decrease	35	15	3	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	70	45	5	9
6. Rate Increase	1	2	0	0
7. Rate Decrease	0	0	0	0
8. P.V.C.	1311	516	= 1827	

Table 2 Q4-C

Title:

Q4, First Chart Reactions

Column 1. is:

DI

Column 2. is:

NDI

Column 3. is:

% Distribution of 1

Column 4. is:

% Distribution of 2

	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION			72	70
1. Rate Decrease	6	2	2	1
2. Rate Increase	3	3	1	1
3. I/E Ratio Change	2	0	1	0
4. Amplitude Increase	14	11	4	4
5. Amplitude Decrease/Suppression	5	4	1	1
6. Progressive Increase/Decrease	4	4	1	1
7. Progressive Increase & Return	3	3	1	1
8. Progressive Decrease & Return	10	9	3	3
9. Baseline Change - Temporary	13	9	4	3
10. Baseline Change - Permanent	8	11	2	4
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	1	0	0	0
ELECTRODERMAL	69	56		
1. Amplitude Change	88	64	25	23
2. Complex Response	19	14	5	7
3. Response Duration & Return	78	63	22	23
CARDIOVASCULAR	185	141		
1. Baseline Increase & Decrease	54	40	15	14
2. Baseline Increase	11	12	3	4
3. Baseline Decrease	11	8	3	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	22	17	6	6
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
8. I.E.C.	352	274		

498

17

Table 2 Q4 D

Title:

Q4, First Chart Reactions

Column 1. is:

Men

Column 2. is:

Women

Column 3. is:

% Distribution of 1

Column 4. is:

% Distribution of 2

	Men Women		Men Women	
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	26	7	2	1
2. Rate Increase	11	8	1	2
3. I/E Ratio Change	5	2	0	0
4. Amplitude Increase	58	19	4	4
5. Amplitd Decrease/Suppression	26	17	2	3
6. Progressive Increase/Decrease	10	4	1	1
7. Progressive Increase & Return	7	3	1	1
8. Progressive Decrease & Return	26	2	2	0
9. Baseline Change - Temporary	50	19	4	4
10. Baseline Change - Permanent	28	18	2	3
11. Apnea - Holding (inspiration)	0	1	0	0
12. Apnea - Blocking (Exhalation)	17	8	1	2
ELECTRODERMAL				
1. Amplitude Change	321	116	24	22
2. Complex Response	76	25	6	5
3. Response Duration & Return	298	102	23	20
CARDIOVASCULAR				
1. Baseline Increase & Decrease	205	82	16	16
2. Baseline Increase	41	21	3	4
3. Baseline Decrease	35	15	3	3
4. Amplitude Increase	6	0	0	
5. Amplitude Decrease	76	45	5	9
6. Rate Increase	1	2	0	0
7. Rate Decrease	0	0	0	0
8. P.V.B.	1311	516		

Table 2 Q4 E

Title: Q 4 First Chart Reactions

Column 1. is: NDI Men

Column 2. is: NDI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	NDI Men	NDI Women	NDI Men	NDI Women
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	2	0	1	0
2. Rate Increase	3	0	1	0
3. I/E Ratio Change	0	0	0	0
4. Amplitude Increase	9	0	4	0
5. Amplitd Decrease/Suppression	3	1	1	2
6. Progressive Increase/Decrease	2	1	1	2
7. Progressive Increase & Return	1	1	0	2
8. Progressive Decrease & Return	7	0	3	0
9. Baseline Change - Temporary	6	3	3	6
10. Baseline Change - Permanent	7	3	3	6
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	0	0	0	0
ELECTRODERMAL				
1. Amplitude Change	46	12	23	25
2. Complex Response	14	3	7	6
3. Response Duration & Return	46	12	23	25
CARDIOVASCULAR				
1. Baseline Increase & Decrease	29	6	14	12
2. Baseline Increase	9	3	4	6
3. Baseline Decrease	5	1	2	2
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	14	2	7	4
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
5	203	48		

$$203 \div 44 = 4.6$$

$$48 \div 15 = 3.2$$

Table 2-Q4,F

Title:

Q 4, First Chart Reactions

Column 1. is: DI Men

Column 2. is: DI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI Men	DI Women	DI Men	DI Women
RESPIRATION	1	2	3	4
1. Rate Decrease			0/6	0/0
2. Rate Increase	6	4	2	3
3. I/E Ratio Change	3	2	1	1
4. Amplitude Increase	2	0	1	0
5. Amplitd Decrease/Suppression	12	6	4	4
6. Progressive Increase/Decrease	4	4	1	3
7. Progressive Increase & Return	3	1	1	1
8. Progressive Decrease & Return	2	0	1	0
9. Baseline Change - Temporary	8	2	3	1
10. Baseline Change - Permanent	10	5	4	3
11. Apnea - Holding (inspiration)	4	5	1	3
12. Apnea - Blocking (Exhalation)	0	0	0	0
ELECTRODERMAL	1	4	0	3
1. Amplitude Change				
2. Complex Response	70	28	25	19
3. Response Duration & Return	14	10	5	7
CARDIOVASCULAR	61	30	22	21
1. Baseline Increase & Decrease				
2. Baseline Increase	43	22	15	19
3. Baseline Decrease	8	6	3	4
4. Amplitude Increase	8	4	3	3
5. Amplitude Decrease	0	0	0	0
6. Rate Increase	19	10	7	7
7. Rate Decrease	0	1	0	1
TOTAL	0	0	0	0
	278	144		

$$278 \div 71 = 3.9$$

$$144 \div 31 = 4.6$$

Table 2-4Q G

Title: Q4, Second Chart Reactions

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION			0/0	0/0
1. Rate Decrease	9	2	2	1
2. Rate Increase	4	1	1	0
3. I/E Ratio Change	3	0	1	0
4. Amplitude Increase	16	11	4	5
5. Amplitd Decrease/Suppression	10	6	3	3
6. Progressive Increase/Decrease	4	3	1	1
7. Progressive Increase & Return	4	1	1	0
8. Progressive Decrease & Return	4	2	1	1
9. Baseline Change - Temporary	11	9	3	4
10. Baseline Change - Permanent	8	6	2	3
11. Apnea - Holding (inspiration)	6	0	0	0
12. Apnea - Blocking (Exhalation)	7	2	2	1
ELECTRODERMAL	86	43		
1. Amplitude Change	96	58	24	25
2. Complex Response	15	17	4	7
3. Response Duration & Return	88	54	22	23
CARDIOVASCULAR	199	129		
1. Baseline Increase & Decrease	64	34	16	14
2. Baseline Increase	13	9	3	4
3. Baseline Decrease	10	9	3	4
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	24	11	6	5
6. Rate Increase	7	0	2	0
7. Rate Decrease	1	0	0	0
8. Rate	302	235		

119 63
 404

Table 2424

Title: Q4, Second Chart Reactions

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	Men	Women	Men	Women
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	8	2	2	1
2. Rate Increase	0	5	0	3
3. I/E Ratio Change	2	1	0	1
4. Amplitude Increase	19	7	5	4
5. Amplitd Decrease/Suppression	7	4	2	3
6. Progressive Increase/Decrease	5	2	1	1
7. Progressive Increase & Return	3	1	1	1
8. Progressive Decrease & Return	5	0	1	0
9. Baseline Change - Temporary	16	3	4	2
10. Baseline Change - Permanent	6	7	1	4
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	7	2	4	1
ELECTRODERMAL				
1. Amplitude Change	106	35	25	22
2. Complex Response	20	7	5	4
3. Response Duration & Return	101	30	24	19
CARDIOVASCULAR				
1. Baseline Increase & Decrease	64	26	15	17
2. Baseline Increase	13	9	3	6
3. Baseline Decrease	11	5	3	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	22	10	5	6
6. Rate Increase	1	1	0	1
7. Rate Decrease	0	0	0	0
on * R.R.E.	416	157		

Table 2-40-1

Title:

Q 4 Second Chart Reactions

Column 1. is: DI Men

Column 2. is: DI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI Men	DI Women	DI Men	DI Women
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	6	2	2	2
2. Rate Increase	0	4	0	3
3. I/E Ratio Change	2	1	1	1
4. Amplitude Increase	9	7	4	6
5. Amplitd Decrease/Suppression	5	2	2	2
6. Progressive Increase/Decrease	3	1	1	1
7. Progressive Increase & Return	2	1	1	1
8. Progressive Decrease & Return	4	0	2	0
9. Baseline Change - Temporary	9	1	4	1
10. Baseline Change - Permanent	5	3	2	3
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	5	2	2	2
ELECTRODERMAL				
1. Amplitude Change	63	26	25	23
2. Complex Response	8	5	3	4
3. Response Duration & Return	60	22	24	19
CARDIOVASCULAR				
1. Baseline Increase & Decrease	40	19	16	17
2. Baseline Increase	7	6	3	5
3. Baseline Decrease	6	4	2	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	14	8	6	7
6. Rate Increase	1	1	0	1
7. Rate Decrease	0	0	0	0
TOTAL	249	115		

Table 2-48-1

Title: Q 4 Second Chart Reactions

Column 1. is: NDI Men

Column 2. is: NDI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	NDI Men	NDI Women	NDI Men	NDI Women
	1	2	3	4
RESPIRATION			0/0	0/0
1. Rate Decrease	2	0	1	0
2. Rate Increase	0	1	0	2
3. I/E Ratio Change	0	0	0	0
4. Amplitude Increase	10	0	6	0
5. Amplitude Decrease/Suppression	2	2	1	5
6. Progressive Increase/Decrease	2	1	1	2
7. Progressive Increase & Return	1	0	1	0
8. Progressive Decrease & Return	1	0	1	0
9. Baseline Change - Temporary	7	2	4	5
10. Baseline Change - Permanent	1	4	1	10
11. Apnea - Holding (Inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	2	0	1	0
ELECTRODERMAL				
1. Amplitude Change	43	9	26	21
2. Complex Response	12	2	7	5
3. Response Duration & Return	41	8	25	19
CARDIOVASCULAR				
1. Baseline Increase & Decrease	24	7	14	17
2. Baseline Increase	6	3	4	7
3. Baseline Decrease	5	1	3	2
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	8	2	5	5
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
TOTAL	167	42		

Table 2-4Q-L

Title: Q 4, Third Chart Reactions

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	Men	Women	Men	Women
	1	2	3	4
RESPIRATION				
1. Rate Decrease	10	1	2	1
2. Rate Increase	5	1	1	1
3. I/E Ratio Change	1	1	0	1
4. Amplitude Increase	18	6	4	4
5. Amplitd Decrease/Suppression	12	8	3	5
6. Progressive Increase/Decrease	0	0	0	0
7. Progressive Increase & Return	1	1	0	1
8. Progressive Decrease & Return	6	0	1	0
9. Baseline Change - Temporary	18	8	4	5
10. Baseline Change - Permanent	11	3	3	2
11. Apnea - Holding (inspiration)	0	1	0	1
12. Apnea - Blocking (Exhalation)	9	2	2	1
ELECTRODERMAL				
1. Amplitude Change	99	41	24	25
2. Complex Response	28	5	7	3
3. Response Duration & Return	90	30	22	18
CARDIOVASCULAR				
1. Baseline Increase & Decrease	69	28	17	17
2. Baseline Increase	11	3	3	2
3. Baseline Decrease	11	5	3	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	15	23	4	14
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
8. Rate Change	414	167		

Table 240 M

Title: Q 4, Third Chart Reactions

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	9	3	2	1
2. Rate Increase	5	1	1	6
3. I/E Ratio Change	2	0	0	0
4. Amplitude Increase	19	8	5	4
5. Amplitd Decrease/Suppression	16	6	4	3
6. Progressive Increase/Decrease	0	0	0	0
7. Progressive Increase & Return	1	1	0	0
8. Progressive Decrease & Return	21	4	0	2
9. Baseline Change - Temporary	20	7	5	3
10. Baseline Change - Permanent	10	4	2	2
11. Apnea - Holding (inspiration)	1	0	0	0
12. Apnea - Blocking (Exhalation)	7	4	2	2
ELECTRODERMAL	97	38		
1. Amplitude Change	96	54	24	25
2. Complex Response	20	15	5	7
3. Response Duration & Return	77	52	19	24
CARDIOVASCULAR	193	121		
1. Baseline Increase & Decrease	72	33	18	15
2. Baseline Increase	10	0	2	0
3. Baseline Decrease	9	8	2	4
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	31	9	8	4
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
Grand Total	407	244		

122

53
209

Table 242 N

Title:

Q 4 Third Chart Reactions

Column 1. is: DI Men

Column 2. is: DI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI Men	DI Women	DI Men	DI Women
	1	2	3	4
RESPIRATION			%	%
1. Rate Decrease	7	1	3	0
2. Rate Increase	4	1	1	0
3. I/E Ratio Change	1	1	0	0
4. Amplitude Increase	13	4	5	2
5. Amplitude Decrease/Suppression	7	7	5	5
6. Progressive Increase/Decrease	0	0	0	0
7. Progressive Increase & Return	0	1	1	0
8. Progressive Decrease & Return	2	0	4	0
9. Baseline Change - Temporary	12	7	6	5
10. Baseline Change - Permanent	7	3	4	2
11. Apnea - Holding (inspiration)	0	1	0	0
12. Apnea - Blocking (Exhalation)	5	2	4	1
ELECTRODERMAL				
1. Amplitude Change	58	31	41	25
2. Complex Response	13	5	15	3
3. Response Duration & Return	51	20	39	23
CARDIOVASCULAR				
1. Baseline Increase & Decrease	45	21	24	7
2. Baseline Increase	6	3	5	2
3. Baseline Decrease	5	3	6	2
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	9	20	6	3
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	245	167		

Table 2-4Q-0

Title: Q 4, Third Chart Reactions

Column 1. is: NDI Men

Column 2. is: NDI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	NDI Men	NDI Women	NDI Men	NDI Women
	1	2	3	4
RESPIRATION				
1. Rate Decrease	3	0	2	0
2. Rate Increase	1	0	1	0
3. I/E Ratio Change	0	0	0	0
4. Amplitude Increase	5	2	3	6
5. Amplitude Decrease/Suppression	5	1	3	3
6. Progressive Increase/Decrease	0	0	0	0
7. Progressive Increase & Return	1	0	1	0
8. Progressive Decrease & Return	4	0	2	0
9. Baseline Change - Temporary	6	1	4	3
10. Baseline Change - Permanent	4	0	2	0
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	4	0	2	0
ELECTRODERMAL				
1. Amplitude Change	41	10	24	28
2. Complex Response	15	0	9	0
3. Response Duration & Return	39	10	23	28
CARDIOVASCULAR				
1. Baseline Increase & Decrease	24	7	14	19
2. Baseline Increase	5	0	3	0
3. Baseline Decrease	6	2	4	6
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	6	3	4	8
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
8. None	169	36		

Table 2-Q5A

Title: Q 5, Reactions from the First Three Charts

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	25	5	2	1
2. Rate Increase	6	7	0	1
3. I/E Ratio Change	13	2	1	0
4. Amplitude Increase	57	18	4	2
5. Amplitd Decrease/Suppression	28	18	2	2
6. Progressive Increase/Decrease	12	4	1	0
7. Progressive Increase & Return	4	6	0	1
8. Progressive Decrease & Return	23	14	2	2
9. Baseline Change - Temporary	47	27	4	4
10. Baseline Change - Permanent	32	21	2	3
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	16	4	1	0
ELECTRODERMAL				
1. Amplitude Change	315	189	24	26
2. Complex Response	60	46	5	6
3. Response Duration & Return	301	181	23	25
CARDIOVASCULAR				
1. Baseline Increase & Decrease	236	122	18	17
2. Baseline Increase	28	19	2	3
3. Baseline Decrease	22	21	2	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	84	34	6	5
6. Rate Increase	2	0	0	0
7. Rate Decrease	4	0	0	0
	1315	738		

Table 2A5-B

Title:

Q 5 , Reactions from the First Three Charts

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	Men Women		Men Women	
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	9	16	1	3
2. Rate Increase	10	3	1	1
3. I/E Ratio Change	9	3	1	1
4. Amplitude Increase	52	18	4	3
5. Amplitd Decrease/Suppression	30	13	2	2
6. Progressive Increase/Decrease	9	6	1	1
7. Progressive Increase & Return	8	1	1	0
8. Progressive Decrease & Return	27	9	2	2
9. Baseline Change - Temporary	49	21	4	4
10. Baseline Change - Permanent	33	16	2	3
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	8	11	1	2
ELECTRODERMAL				
1. Amplitude Change	338	127	25	23
2. Complex Response	70	25	4	4
3. Response Duration & Return	322	125	24	22
CARDIOVASCULAR				
1. Baseline Increase & Decrease	231	102	17	18
2. Baseline Increase	32	11	2	2
3. Baseline Decrease	22	17	2	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	74	40	6	7
6. Rate Increase	1	0	0	0
7. Rate Decrease	0	0	0	0
	1337	564		

Table 2 Q5 C

Title:

Q 5, First Chart Reactions

Column 1. is:

DI

Column 2. is:

NDI

Column 3. is:

% Distribution of 1

Column 4. is:

% Distribution of 2

	DI	NDI	DI	NDI
	1	2	3	4
	no.	no.	%	%
RESPIRATION				
1. Rate Decrease	9	1	2	0
2. Rate Increase	3	2	1	1
3. I/E Ratio Change	1	1	0	0
4. Amplitude Increase	26	6	6	2
5. Amplitd Decrease/Suppression	6	10	1	4
6. Progressive Increase/Decrease	2	0	0	0
7. Progressive Increase & Return	1	4	0	1
8. Progressive Decrease & Return	7	5	2	2
9. Baseline Change - Temporary	12	12	3	4
10. Baseline Change - Permanent	13	6	3	2
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	2	0	0	0
ELECTRODERMAL	62	47		
1. Amplitude Change	104	70	24	26
2. Complex Response	17	19	4	7
3. Response Duration & Return	102	66	23	24
CARDIOVASCULAR	223	156		
1. Baseline Increase & Decrease	43	42	19	16
2. Baseline Increase	13	9	3	3
3. Baseline Decrease	6	7	1	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	32	10	7	4
6. Rate Increase	1	0	0	0
7. Rate Decrease	1	0	0	0
	441	220	-	-

136

68

Table 2 Q5 E

Title:

Q5, First Chart Reactions

Column 1. is:

Men

Column 2. is:

Women

Column 3. is:

% Distribution of 1

Column 4. is:

% Distribution of 2

	Men	Women	Men	Women
	1	2	3	4
	No.	No.	%	%
RESPIRATION				
1. Rate Decrease	4	4	1	2
2. Rate Increase	3	2	1	1
3. I/E Ratio Change	1	1	0	1
4. Amplitude Increase	19	9	4	5
5. Amplitd Decrease/Suppression	12	4	3	2
6. Progressive Increase/Decrease	2	0	0	0
7. Progressive Increase & Return	3	1	1	1
8. Progressive Decrease & Return	10	1	2	1
9. Baseline Change - Temporary	17	6	4	3
10. Baseline Change - Permanent	9	8	2	4
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	1	1	0	1
ELECTRODERMAL				
1. Amplitude Change	117	44	25	23
2. Complex Response	21	11	4	6
3. Response Duration & Return	113	44	24	23
CARDIOVASCULAR				
1. Baseline Increase & Decrease	87	31	19	16
2. Baseline Increase	14	7	3	4
3. Baseline Decrease	6	5	1	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	28	14	6	7
6. Rate Increase	1	0	0	0
7. Rate Decrease	1	0	0	0
8. P.V.C.	469	193		

Table 2 Q5 F

Title:

Q 5. First Chart Reactions

Column 1. is:

NDI Men

Column 2. is:

NDI Women

Column 3. is:

% Distribution of 1

Column 4. is:

% Distribution of 2

	NDI Men	NDI Women	NDI Men	NDI Women
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	0	1	0	2
2. Rate Increase	2	6	1	0
3. I/E Ratio Change	0	1	0	2
4. Amplitude Increase	3	3	2	5
5. Amplitude Decrease/Suppression	9	1	5	2
6. Progressive Increase/Decrease	0	0	0	0
7. Progressive Increase & Return	2	1	1	2
8. Progressive Decrease & Return	4	0	2	0
9. Baseline Change - Temporary	9	3	5	5
10. Baseline Change - Permanent	3	2	1	3
11. Apnea - Holding (inspiration)	0	6	0	0
12. Apnea - Blocking (Exhalation)	0	0	0	0
ELECTRODERMAL				
1. Amplitude Change	50	14	26	23
2. Complex Response	11	6	6	10
3. Response Duration & Return	47	14	25	23
CARDIOVASCULAR				
1. Baseline Increase & Decrease	36	9	16	15
2. Baseline Increase	7	2	4	3
3. Baseline Decrease	4	2	2	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	9	3	5	5
6. Rate Increase	0	0	0	0
7. Rate Decrease	6	0	0	0
	190	62		

Table 2Q5 G

Title:

Q5, First Chart Reactions

Column 1. is:

DI Men

Column 2. is:

DI Women

Column 3. is:

% Distribution of 1

Column 4. is:

% Distribution of 2

	DI Men	DI Women	DI Men	DI Women
RESPIRATION	1	2	3	4
1. Rate Decrease	40	40	0/	0/
2. Rate Increase	4	3	1	2
3. I/E Ratio Change	1	2	0	2
4. Amplitude Increase	1	0	0	0
5. Amplitd Decrease/Suppression	16	6	6	5
6. Progressive Increase/Decrease	3	3	1	2
7. Progressive Increase & Return	2	0	1	1
8. Progressive Decrease & Return	1	0	0	0
9. Baseline Change - Temporary	6	1	2	2
10. Baseline Change - Permanent	8	3	3	4
11. Apnea - Holding (inspiration)	6	6	2	2
12. Apnea - Blocking (Exhalation)	0	0	0	0
ELECTRODERMAL	1	1	0	1
1. Amplitude Change				
2. Complex Response	67	30	24	23
3. Response Duration & Return	10	5	4	4
CARDIOVASCULAR	66	30	24	23
1. Baseline Increase & Decrease				
2. Baseline Increase	57	22	20	17
3. Baseline Decrease	7	5	2	4
4. Amplitude Increase	2	3	1	2
5. Amplitude Decrease	0	0	0	0
6. Rate Increase	19	11	7	8
7. Rate Decrease	1	0	0	0
	1	0	0	0
	279	131		

Table 2 Q5 H

Title:

Q5, Second Chart Reactions

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	8	3	2	1
2. Rate Increase	1	2	0	1
3. I/E Ratio Change	5	1	1	0
4. Amplitude Increase	19	9	4	4
5. Amplitd Decrease/Suppression	6	1	1	0
6. Progressive Increase/Decrease	3	2	1	1
7. Progressive Increase & Return	1	0	0	0
8. Progressive Decrease & Return	10	5	2	2
9. Baseline Change - Temporary	18	7	4	3
10. Baseline Change - Permanent	7	8	2	4
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	6	1	1	0
ELECTRODERMAL				
1. Amplitude Change	106	55	24	25
2. Complex Response	20	12	5	5
3. Response Duration & Return	103	53	23	24
CARDIOVASCULAR				
1. Baseline Increase & Decrease	82	39	19	18
2. Baseline Increase	6	6	1	3
3. Baseline Decrease	11	6	2	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	30	11	7	5
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	442	220		

Table 2 Q51

Title: Q 5, Second Chart Reactions

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	Men	Women	Men	Women
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	2	7	0	3
2. Rate Increase	3	0	1	0
3. I/E Ratio Change	3	1	1	0
4. Amplitude Increase	20	1	5	0
5. Amplitude Decrease/Suppression	3	3	1	1
6. Progressive Increase/Decrease	1	3	0	1
7. Progressive Increase & Return	1	0	0	0
8. Progressive Decrease & Return	8	7	2	3
9. Baseline Change - Temporary	15	8	4	4
10. Baseline Change - Permanent	9	5	2	2
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	3	4	1	2
ELECTRODERMAL				
1. Amplitude Change	108	39	26	19
2. Complex Response	19	8	5	4
3. Response Duration & Return	104	39	25	19
CARDIOVASCULAR				
1. Baseline Increase & Decrease	73	41	18	20
2. Baseline Increase	12	3	3	1
3. Baseline Decrease	5	6	1	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	19	13	5	6
6. Rate Increase	0	0	0	0
7. Rate Decrease	1	0	0	0
TOTAL	409	202		

Table 2 Q5J

Title:

Q .5 Second Chart Reactions

Column 1. is: DI Men

Column 2. is: DI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI Men	DI Women	DI Men	DI Women
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	2	7	0	4
2. Rate Increase	3	0	1	0
3. I/E Ratio Change	3	1	1	1
4. Amplitude Increase -	20	6	5	3
5. Amplitd Decrease/Suppression	3	3	1	2
6. Progressive Increase/Decrease	1	3	0	2
7. Progressive Increase & Return	1	0	0	0
8. Progressive Decrease & Return	8	7	2	4
9. Baseline Change - Temporary	15	8	4	4
10. Baseline Change - Permanent	9	5	2	3
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	3	4	1	2
ELECTRODERMAL				
1. Amplitude Change	108	39	26	20
2. Complex Response	19	8	5	4
3. Response Duration & Return	104	39	25	20
CARDIOVASCULAR				
1. Baseline Increase & Decrease	73	41	18	21
2. Baseline Increase	8	3	2	2
3. Baseline Decrease	8	6	2	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	25	13	6	7
6. Rate Increase	0	0	0	0
7. Rate Decrease	1	0	0	0
8. P.V.C.	414	193		

Table 2Q5L

Title:

Q 5 Second Chart Reactions

Column 1. is: NDI Men

Column 2. is: NDI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	NDI Men	NDI Women	IVDI Men	IVDI Women
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	0	2	0	5
2. Rate Increase	2	0	1	0
3. I/E Ratio Change	0	0	0	0
4. Amplitude Increase	7	1	5	2
5. Amplitd Decrease/Suppression	0	0	0	0
6. Progressive Increase/Decrease	0	2	0	5
7. Progressive Increase & Return	0	0	0	0
8. Progressive Decrease & Return	4	1	3	2
9. Baseline Change - Temporary	4	2	3	5
10. Baseline Change - Permanent	6	1	4	2
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	0	1	0	2
ELECTRODERMAL				
1. Amplitude Change	42	7	27	17
2. Complex Response	6	3	4	7
3. Response Duration & Return	40	7	26	17
CARDIOVASCULAR				
1. Baseline Increase & Decrease	28	8	18	20
2. Baseline Increase	3	3	2	7
3. Baseline Decrease	3	1	2	2
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	8	2	5	5
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	153	41		

Table 2 Q5 M

Title: ⁵ Q 5 Third Chart Reactions

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI	NDI	DI	DI
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	8	1	2	0
2. Rate Increase	2	3	0	1
3. I/E Ratio Change	7	0	2	0
4. Amplitude Increase	12	4	3	2
5. Amplitd Decrease/Suppression	16	2	4	1
6. Progressive Increase/Decrease	7	2	2	1
7. Progressive Increase & Return	2	2	0	1
8. Progressive Decrease & Return	6	5	1	2
9. Baseline Change - Temporary	17	8	4	3
10. Baseline Change - Permanent	12	7	3	3
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	8	3	2	1
ELECTRODERMAL	97	37		
1. Amplitude Change	105	64	24	26
2. Complex Response	23	15	5	6
3. Response Duration & Return	96	62	22	25
CARDIOVASCULAR	224	141		
1. Baseline Increase & Decrease	69	41	16	17
2. Baseline Increase	10	3	2	1
3. Baseline Decrease	6	8	1	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	23	11	5	4
6. Rate Increase	1	0	0	0
7. Rate Decrease	2	0	0	0
	432	241		

111 63 241

Table 2 Q5 N

Title: Q 5, Third Chart Reactions

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	Men	Women	Men	Women
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	3	5	1	3
2. Rate Increase	4	1	1	2
3. I/E Ratio Change	5	1	1	2
4. Amplitude Increase	13	3	3	2
5. Amplitude Decrease/Suppression	15	6	3	3
6. Progressive Increase/Decrease	6	3	1	2
7. Progressive Increase & Return	4	0	1	0
8. Progressive Decrease & Return	9	1	2	2
9. Baseline Change - Temporary	17	7	4	4
10. Baseline Change - Permanent	15	3	3	2
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	4	6	1	3
ELECTRODERMAL				
1. Amplitude Change	113	44	25	25
2. Complex Response	30	6	7	3
3. Response Duration & Return	105	42	23	24
CARDIOVASCULAR				
1. Baseline Increase & Decrease	71	30	16	17
2. Baseline Increase	10	1	2	2
3. Baseline Decrease	8	6	2	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	21	13	5	7
6. Rate Increase	0	0	0	0
7. Rate Decrease	1	0	0	0
8. Total	454	178		

Table 2 Q5 0

Title:

Q 5, Third Chart Reactions

Column 1. is: DI Men

Column 2. is: DI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI Men	DI Women	DI Men	DI Women
	1	2	3	4
RESPIRATION	No.	No.	%	%
1. Rate Decrease	2	5	1	4
2. Rate Increase	1	1	0	1
3. I/E Ratio Change	5	1	2	1
4. Amplitude Increase	9	3	3	0
5. Amplitd Decrease/Suppression	10	5	4	4
6. Progressive Increase/Decrease	5	2	2	2
7. Progressive Increase & Return	2	0	1	0
8. Progressive Decrease & Return	5	1	2	1
9. Baseline Change - Temporary	14	2	5	2
10. Baseline Change - Permanent	9	2	3	2
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	2	5	1	4
ELECTRODERMAL				
1. Amplitude Change	66	31	24	24
2. Complex Response	18	4	7	14
3. Response Duration & Return	60	29	22	23
CARDIOVASCULAR				
1. Baseline Increase & Decrease	41	21	15	16
2. Baseline Increase	9	0	3	0
3. Baseline Decrease	2	4	1	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	11	12	4	9
6. Rate Increase	0	0	0	0
7. Rate Decrease	1	0	0	0
	272	128		

Table 2 Q5 P

Title:

Q5, Third Chart Reactions

Column 1. is: NDI Men

Column 2. is: NDI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	NDI Men	NDI Women	NDI Men	NDI Women
	1	2	3	4
RESPIRATION	No.	No.	%	%
1. Rate Decrease	1	0	0	0
2. Rate Increase	3	0	2	0
3. I/E Ratio Change	0	0	0	0
4. Amplitude Increase	4	0	2	0
5. Amplitude Decrease/Suppression	5	1	3	2
6. Progressive Increase/Decrease	1	1	0	2
7. Progressive Increase & Return	2	0	1	0
8. Progressive Decrease & Return	4	0	2	0
9. Baseline Change - Temporary	3	5	2	10
10. Baseline Change - Permanent	6	1	3	2
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	2	1	1	2
ELECTRODERMAL				
1. Amplitude Change	47	13	25	26
2. Complex Response	12	2	6	4
3. Response Duration & Return	45	13	24	26
CARDIOVASCULAR				
1. Baseline Increase & Decrease	30	9	16	18
2. Baseline Increase	1	1	0	2
3. Baseline Decrease	6	2	3	4
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	10	1	5	2
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	182	50		

Table 2-66-A

Title: Q 6 , Reactions from the First Three Charts

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	27	11	2	1
2. Rate Increase	21	2	2	0
3. I/E Ratio Change	7	5	1	1
4. Amplitude Increase	51	19	4	3
5. Amplitd Decrease/Suppression	20	19	2	3
6. Progressive Increase/Decrease	4	2	0	0
7. Progressive Increase & Return	6	8	0	1
8. Progressive Decrease & Return	11	11	1	1
9. Baseline Change - Temporary	40	38	3	5
10. Baseline Change - Permanent	32	15	3	2
11. Apnea - Holding (inspiration)	2	2	0	0
12. Apnea - Blocking (Exhalation)	12	5	1	1
ELECTRODERMAL				
1. Amplitude Change	307	188	25	25
2. Complex Response	70	57	6	8
3. Response Duration & Return	296	180	24	24
CARDIOVASCULAR				
1. Baseline Increase & Decrease	183	105	15	14
2. Baseline Increase	29	13	2	2
3. Baseline Decrease	43	32	4	4
4. Amplitude Increase	1	0	0	0
5. Amplitude Decrease	50	39	4	5
6. Rate Increase	1	0	0	0
7. Rate Decrease	0	0	0	0
	1213	751		

Table 2-Q6-B

Title:

Q 6, Reactions from the First Three Charts

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	Men	Women	Men	Women
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	25	9	2	2
2. Rate Increase	12	8	1	2
3. I/E Ratio Change	7	5	1	1
4. Amplitude Increase	45	20	3	4
5. Amplitd Decrease/Suppression	21	14	2	3
6. Progressive Increase/Decrease	6	0	0	0
7. Progressive Increase & Return	9	3	1	1
8. Progressive Decrease & Return	18	4	1	1
9. Baseline Change - Temporary	56	21	4	5
10. Baseline Change - Permanent	23	16	2	3
11. Apnea - Holding (inspiration)	0	2	0	1
12. Apnea - Blocking (Exhalation)	12	2	1	1
ELECTRODERMAL				
1. Amplitude Change	350	110	26	24
2. Complex Response	100	20	7	4
3. Response Duration & Return	339	105	25	23
CARDIOVASCULAR				
1. Baseline Increase & Decrease	196	68	14	15
2. Baseline Increase	28	11	2	2
3. Baseline Decrease	48	20	4	4
4. Amplitude Increase	1	0	0	0
5. Amplitude Decrease	61	24	4	5
6. Rate Increase	1	0	0	0
7. Rate Decrease	0	0	0	0
8.	1358	462		

Table 2-Q6C

Title:

Q 6, First Chart Reactions

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

1st chart

	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION	No	No.	%	%
1. Rate Decrease	8	6	2	2
2. Rate Increase	8	1	2	0
3. I/E Ratio Change	20	2	0	1
4. Amplitude Increase	20	7	5	2
5. Amplitude Decrease/Suppression	12	7	3	2
6. Progressive Increase/Decrease	4	0	1	0
7. Progressive Increase & Return	3	2	1	1
8. Progressive Decrease & Return	1	3	0	1
9. Baseline Change - Temporary	10	18	2	6
10. Baseline Change - Permanent	12	4	3	1
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	3	0	1	0
ELECTRODERMAL	81	50		
1. Amplitude Change	109	78	26	26
2. Complex Response	31	29	7	10
3. Response Duration & Return	107	73	26	24
CARDIOVASCULAR	247	180		
1. Baseline Increase & Decrease	57	38	7	13
2. Baseline Increase	7	3	2	1
3. Baseline Decrease	19	15	4	5
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	13	16	3	5
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	424	302		
	96	72		

Table 2-Q6-D

Title:

Q 6, First Chart Reactions

Column 1. is:

Men

Column 2. is:

Women

Column 3. is:

% Distribution of 1

Column 4. is:

% Distribution of 2

	Men	Women	Men	Women
RESPIRATION	1	2	3	4
1. Rate Decrease	25	9	2	2
2. Rate Increase	12	8	1	2
3. I/E Ratio Change	7	5	1	1
4. Amplitude Increase	45	20	3	4
5. Amplitd Decrease/Suppression	21	14	2	3
6. Progressive Increase/Decrease	6	0	0	0
7. Progressive Increase & Return	9	3	1	1
8. Progressive Decrease & Return	18	4	1	1
9. Baseline Change - Temporary	56	21	4	5
10. Baseline Change - Permanent	23	16	2	3
11. Apnea - Holding (inspiration)	0	2	0	1
12. Apnea - Blocking (Exhalation)	12	2	1	1
ELECTRODERMAL				
1. Amplitude Change	350	110	26	24
2. Complex Response	100	20	7	4
3. Response Duration & Return	339	105	25	23
CARDIOVASCULAR				
1. Baseline Increase & Decrease	196	68	14	15
2. Baseline Increase	28	11	2	2
3. Baseline Decrease	48	28	4	4
4. Amplitude Increase	1	0	0	0
5. Amplitude Decrease	61	24	4	5
6. Rate Increase	1	0	0	0
7. Rate Decrease	0	0	0	0
	1358	462		

Table 2-Q6-E

Title:

Q6, First Chart Reactions

Column 1. is:

DI Men

Column 2. is:

DI Women

Column 3. is:

% Distribution of 1

Column 4. is:

% Distribution of 2

	DI Men	DI Women	DI Men	DI Women
RESPIRATION	1	2	3	4
1. Rate Decrease	no.	no.	%	%
2. Rate Increase	4	2	2	2
3. I/E Ratio Change	6	2	3	2
4. Amplitude Increase	0	0	0	0
5. Amplitd Decrease/Suppression	10	6	4	5
6. Progressive Increase/Decrease	5	6	2	5
7. Progressive Increase & Return	1	0	0	0
8. Progressive Decrease & Return	1	0	0	0
9. Baseline Change - Temporary	1	0	0	0
10. Baseline Change - Permanent	4	5	2	4
11. Apnea - Holding (inspiration)	6	5	3	4
12. Apnea - Blocking (Exhalation)	0	0	0	0
ELECTRODERMAL	2	0	1	0
1. Amplitude Change	71	30	32	23
2. Complex Response	20	9	9	7
3. Response Duration & Return	69	30	31	23
CARDIOVASCULAR				
1. Baseline Increase & Decrease	35	18	16	14
2. Baseline Increase	3	2	1	2
3. Baseline Decrease	10	8	4	6
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	9	8	4	6
6. Rate Increase	1	0	0	0
7. Rate Decrease	0	0	0	0
	258	131		

Table 2-26-F

Q . First Chart Reactions

umn 1. is: NDI Men

umn 2. is: NDI Women

umn 3. is: % Distribution of 1

umn 4. is: % Distribution of 2

	NDI Men	NDI Women	NDI men	NDI Women
	1	2	3	4
	no.	no.	%	%
RESPIRATION				
1. Rate Decrease	5	1	2	2
2. Rate Increase	0	1	0	2
3. I/E Ratio Change	1	1	0	2
4. Amplitude Increase	7	0	7	0
5. Amplitd Decrease/Suppression	3	3	1	5
6. Progressive Increase/Decrease	0	0	0	0
7. Progressive Increase & Return	2	0	1	0
8. Progressive Decrease & Return	3	0	1	0
9. Baseline Change - Temporary	15	2	6	5
10. Baseline Change - Permanent	1	2	0	4
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	0	0	0	0
ELECTRODERMAL				
1. Amplitude Change	58	14	24	25
2. Complex Response	24	3	10	5
3. Response Duration & Return	58	12	23	22
CARDIOVASCULAR				
1. Baseline Increase & Decrease	29	7	12	13
2. Baseline Increase	2	1	1	2
3. Baseline Decrease	10	4	4	7
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	12	3	5	5
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	227	56		

Table 2-Q6-G

Title:

Q6, Second Chart Reactions

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	9	1	2	0
2. Rate Increase	10	0	2	0
3. I/E Ratio Change	5	2	1	1
4. Amplitude Increase	18	8	4	3
5. Amplitd Decrease/Suppression	3	7	1	3
6. Progressive Increase/Decrease	2	1	0	0
7. Progressive Increase & Return	0	2	0	1
8. Progressive Decrease & Return	5	4	1	4
9. Baseline Change - Temporary	21	8	5	8
10. Baseline Change - Permanent	11	8	3	8
11. Apnea - Holding (inspiration)	2	2	0	2
12. Apnea - Blocking (Exhalation)	2	1	0	1
ELECTRODERMAL	88	44		
1. Amplitude Change	100	60	25	24
2. Complex Response	22	18	5	7
3. Response Duration & Return	93	58	23	24
CARDIOVASCULAR	225	136		
1. Baseline Increase & Decrease	59	30	15	12
2. Baseline Increase	12	12	3	5
3. Baseline Decrease	15	7	4	3
4. Amplitude Increase	1	3	0	1
5. Amplitude Decrease	16	13	4	5
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	406	245		

103

65

Table 2-Q6 14

Title: Q6, Second Chart Reactions

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	Men	Women	Men	Women
	1	2	3	4
RESPIRATION	No.	No.	%	%
1. Rate Decrease	7	2	2	1
2. Rate Increase	5	2	1	1
3. I/E Ratio Change	4	2	1	1
4. Amplitude Increase	19	5	4	4
5. Amplitd Decrease/Suppression	7	3	2	2
6. Progressive Increase/Decrease	3	0	1	0
7. Progressive Increase & Return	1	1	0	1
8. Progressive Decrease & Return	7	2	2	1
9. Baseline Change - Temporary	21	8	5	6
10. Baseline Change - Permanent	8	6	2	4
11. Apnea - Holding (inspiration)	6	2	0	1
12. Apnea - Blocking (Exhalation)	3	0	1	0
ELECTRODERMAL				
1. Amplitude Change	115	33	25	24
2. Complex Response	34	3	7	2
3. Response Duration & Return	109	31	24	24
CARDIOVASCULAR				
1. Baseline Increase & Decrease	61	22	13	16
2. Baseline Increase	15	4	3	3
3. Baseline Decrease	16	6	3	4
4. Amplitude Increase	1	0	0	0
5. Amplitude Decrease	22	6	5	4
6. Rate Increase	0	6	0	0
7. Rate Decrease	0	0	0	0
	458	138		

Table 2-Q6-I

Title:

Q 6 Second Chart Reactions

Column 1. is:

NDI Men

Column 2. is:

NDI Women

Column 3. is:

% Distribution of 1

Column 4. is:

% Distribution of 2

	NDI Men	NDI Women	NDI Men	NDI Women
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	1	0	1	0
2. Rate Increase	0	0	0	0
3. I/E Ratio Change	0	1	0	2
4. Amplitude Increase	4	2	2	4
5. Amplitd Decrease/Suppression	4	3	2	4
6. Progressive Increase/Decrease	1	0	1	0
7. Progressive Increase & Return	1	1	1	2
8. Progressive Decrease & Return	3	1	2	2
9. Baseline Change - Temporary	17	4	2	7
10. Baseline Change - Permanent	5	2	1	4
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	2	0	1	0
ELECTRODERMAL				
1. Amplitude Change	72	12	26	22
2. Complex Response	17	1	10	2
3. Response Duration & Return	68	12	25	22
CARDIOVASCULAR				
1. Baseline Increase & Decrease	39	8	13	15
2. Baseline Increase	9	2	4	4
3. Baseline Decrease	12	3	2	4
4. Amplitude Increase	1	0	0	0
5. Amplitude Decrease	12	2	6	4
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	163	54		

Table 2-66-J

Title:

Q.6 Second Chart Reactions

Column 1. is:

DI Men

Column 2. is:

DI Women

Column 3. is:

% Distribution of 1

Column 4. is:

% Distribution of 2

	DI Men	DI Women	DI Men	DI Women
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	6	2	2	2
2. Rate Increase	5	2	2	2
3. I/E Ratio Change	4	1	1	1
4. Amplitd Increase -	15	3	5	4
5. Amplitd Decrease/Suppression	3	0	1	0
6. Progressive Increase/Decrease	2	0	1	0
7. Progressive Increase & Return	0	0	0	0
8. Progressive Decrease & Return	4	1	1	1
9. Baseline Change - Temporary	17	4	6	2
10. Baseline Change - Permanent	7	4	2	1
11. Apnea - Holding (inspiration)	0	2	0	0
12. Apnea - Blocking (Exhalation)	2	0	1	1
ELECTRODERMAL				
1. Amplitude Change	72	21	24	26
2. Complex Response	17	2	4	10
3. Response Duration & Return	68	19	23	25
CARDIOVASCULAR				
1. Baseline Increase & Decrease	39	14	13	13
2. Baseline Increase	9	2	3	4
3. Baseline Decrease	12	3	4	2
4. Amplitude Increase	1	0	0	0
5. Amplitude Decrease	12	4	4	6
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	295	84		

Table 2-062K

Q 6, Third Chart Reactions

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION	ng.	ng.	%	%
1. Rate Decrease	12	1	3	0
2. Rate Increase	7	6	2	0
3. I/E Ratio Change	5	1	1	0
4. Amplitude Increase	18	6	4	3
5. Amplitude Decrease/Suppression	3	7	1	3
6. Progressive Increase/Decrease	2	1	0	0
7. Progressive Increase & Return	2	2	0	1
8. Progressive Decrease & Return	5	4	1	2
9. Baseline Change - Temporary	21	8	5	4
10. Baseline Change - Permanent	12	3	3	1
11. Apnea - Holding (inspiration)	2	0	0	0
12. Apnea - Blocking (Exhalation)	2	1	0	0
ELECTRODERMAL	99	34		
1. Amplitude Change	99	58	24	26
2. Complex Response	19	18	5	8
3. Response Duration & Return	91	56	22	25
CARDIOVASCULAR	209	132		
1. Baseline Increase & Decrease	59	32	15	14
2. Baseline Increase	11	8	3	4
3. Baseline Decrease	16	8	4	4
4. Amplitude Increase	1	0	0	0
5. Amplitude Decrease	18	12	4	5
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	405	226		

105

60

Table 2-06-L

Title: Q 6, Third Chart Reactions

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	Men	Women	Men	Women
	1	2	3	4
	no.	no.	%	%
RESPIRATION				
1. Rate Decrease	9	4	2	2
2. Rate Increase	1	3	0	1
3. I/E Ratio Change	2	0	0	0
4. Amplitude Increase	9	9	2	4
5. Amplitude Decrease/Suppression	6	2	1	1
6. Progressive Increase/Decrease	2	0	0	0
7. Progressive Increase & Return	5	2	1	1
8. Progressive Decrease & Return	7	2	2	1
9. Baseline Change - Temporary	16	5	4	2
10. Baseline Change - Permanent	8	3	2	1
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	7	2	2	1
ELECTRODERMAL				
1. Amplitude Change	106	33	25	14
2. Complex Response	22	5	5	2
3. Response Duration & Return	106	32	25	14
CARDIOVASCULAR				
1. Baseline Increase & Decrease	71	21	17	9
2. Baseline Increase	8	4	2	2
3. Baseline Decrease	12	2	3	1
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	18	7	4	5
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
TOTAL	415	136		

Table 2-86-M

Title:

Q 6, Third Chart Reactions

Column 1. is: DI Men

Column 2. is: DI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI Men	DI Women	DI Men	DI Women
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	6	3	2	3
2. Rate Increase	0	3	0	3
3. I/E Ratio Change	2	0	1	0
4. Amplitude Increase	8	5	3	5
5. Amplitude Decrease/Suppression	3	2	1	2
6. Progressive Increase/Decrease	1	0	0	0
7. Progressive Increase & Return	2	1	1	1
8. Progressive Decrease & Return	3	2	1	2
9. Baseline Change - Temporary	8	1	3	1
10. Baseline Change - Permanent	7	1	3	1
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	6	1	2	1
ELECTRODERMAL				
1. Amplitude Change	69	23	26	25
2. Complex Response	12	5	4	5
3. Response Duration & Return	70	22	26	25
CARDIOVASCULAR				
1. Baseline Increase & Decrease	46	15	17	16
2. Baseline Increase	7	3	3	3
3. Baseline Decrease	6	2	2	2
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	11	4	4	4
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
8. P.V.C.	267	93		

Table 2-Q6-N

Title: Q6, Third Chart Reactions

Column 1. is: NDI Men

Column 2. is: NDI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	NDI Men	NDI Women	NDI Men	NDI Women
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	3	1	2	2
2. Rate Increase	1	0	1	0
3. I/E Ratio Change	0	0	0	0
4. Amplitude Increase	1	4	1	8
5. Amplitd Decrease/Suppression	3	0	2	1
6. Progressive Increase/Decrease	1	0	1	0
7. Progressive Increase & Return	3	1	2	0
8. Progressive Decrease & Return	4	0	3	1
9. Baseline Change - Temporary	8	4	5	4
10. Baseline Change - Permanent	1	2	1	5
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	1	1	1	2
ELECTRODERMAL				
1. Amplitude Change	37	10	25	23
2. Complex Response	10	0	7	0
3. Response Duration & Return	36	10	24	23
CARDIOVASCULAR				
1. Baseline Increase & Decrease	25	6	17	14
2. Baseline Increase	1	1	1	2
3. Baseline Decrease	6	0	4	0
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	7	3	5	4
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
TOTAL	148	43		

Table 2 Q7-A

Title: Q 7 , Reactions from the First Three Charts

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

3 charts	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	27	4	2	1
2. Rate Increase	17	7	1	1
3. I/E Ratio Change	8	1	1	0
4. Amplitude Increase	45	22	3	3
5. Amplitd Decrease/Suppression	22	11	2	2
6. Progressive Increase/Decrease	8	4	1	1
7. Progressive Increase & Return	5	2	0	0
8. Progressive Decrease & Return	18	14	1	2
9. Baseline Change - Temporary	54	24	4	3
10. Baseline Change - Permanent	24	24	2	3
11. Apnea - Holding (inspiration)	1	0	0	0
12. Apnea - Blocking (Exhalation)	16	2	1	0
ELECTRODERMAL	245			
1. Amplitude Change	321	179	25%	26%
2. Complex Response	53	42	4	6
3. Response Duration & Return	304	173	23	25
CARDIOVASCULAR	678			
1. Baseline Increase & Decrease	227	113	17%	17%
2. Baseline Increase	28	16	2	2
3. Baseline Decrease	21	14	2	2
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	43	30	7	4
6. Rate Increase	0	0	0	0
7. Rate Decrease	1	0	0	0
	1303	682		

Table 2-Q7-B

Title: Q 7 , Reactions from the First Three Charts

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

3 charts	Men	Women	Men	Women
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	25	5	2%	1%
2. Rate Increase	17	5	1	1
3. I/E Ratio Change	2	7	0	1
4. Amplitude Increase	51	13	4	2
5. Amplitd Decrease/Suppression	25	10	2	2
6. Progressive Increase/Decrease	7	4	1	1
7. Progressive Increase & Return	3	3	0	1
8. Progressive Decrease & Return	23	8	2	2
9. Baseline Change - Temporary	50	23	4	4
10. Baseline Change - Permanent	30	14	2	3
11. Apnea - Holding (inspiration)	1	0	0	0
12. Apnea - Blocking (Exhalation)	12	5	1	1
ELECTRODERMAL				
1. Amplitude Change	330	133	25%	26%
2. Complex Response	67	18	5	3
3. Response Duration & Return	315	126	24	24
CARDIOVASCULAR				
1. Baseline Increase & Decrease	221	93	17	18
2. Baseline Increase	29	12	2	2
3. Baseline Decrease	26	5	2	1
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	78	37	6	7
6. Rate Increase	0	0	0	0
7. Rate Decrease	1	0	0	0
	1313	521		

Table 2-Q7-Qc

Title: Q 7, First Chart Reactions

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

1st Charts				
	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	9	1	2%	0
2. Rate Increase	8	4	2	1
3. I/E Ratio Change	0	1	0	0
4. Amplitude Increase	19	9	4	3
5. Amplitd Decrease/Suppression	5	4	1	1
6. Progressive Increase/Decrease	2	2	0	1
7. Progressive Increase & Return	1	1	0	0
8. Progressive Decrease & Return	4	4	1	1
9. Baseline Change - Temporary	15	10	3	4
10. Baseline Change - Permanent	8	10	2	4
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	4	1	1	0
ELECTRODERMAL	75	47		
1. Amplitude Change	11	75	25	26%
2. Complex Response	17	17	4	6
3. Response Duration & Return	106	71	24	25
CARDIOVASCULAR	234	163		
1. Baseline Increase & Decrease	76	49	17	17
2. Baseline Increase	14	6	3	2
3. Baseline Decrease	9	6	2	2
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	35	13	8	5
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	443	284		

Table 2-Q7 ⁸⁰

Title:

Q7, First Chart Reactions

Column 1. is:

Men

Column 2. is:

Women

Column 3. is:

% Distribution of 1

Column 4. is:

% Distribution of 2

1st charts	M	W	M	W
	1	2	3	4
RESPIRATION	no	no	%	%
1. Rate Decrease	9	1	2	1
2. Rate Increase	6	4	1	2
3. I/E Ratio Change	0	1	0	1
4. Amplitude Increase	21	6	4	4
5. Amplitude Decrease/Suppression	5	2	1	1
6. Progressive Increase/Decrease	1	2	0	1
7. Progressive Increase & Return	1	1	0	1
8. Progressive Decrease & Return	6	1	1	1
9. Baseline Change - Temporary	19	4	4	2
10. Baseline Change - Permanent	6	9	1	5
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	4	1	1	1
ELECTRODERMAL				
1. Amplitude Change	119	54	25	28
2. Complex Response	27	5	6	3
3. Response Duration & Return	114	51	24	27
CARDIOVASCULAR				
1. Baseline Increase & Decrease	86	31	18	21
2. Baseline Increase	15	4	3	2
3. Baseline Decrease	10	3	2	2
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	34	11	7	6
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	483	191		

$$483 \div 115 = 4.2$$

$$191 \div 46 = 4.2$$

Table 2 Q7 E

Title: Q7. First Chart Reactions

Column 1. is: NDI Men

Column 2. is: NDI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	NDI Men	NDI Women	NDI Men	NDI Women
1st Chart?	1	2	3	4
RESPIRATION	No.	No.	%	%
1. Rate Decrease	1	0	1%	0
2. Rate Increase	3	1	2	1
3. I/E Ratio Change	0	1	0	1
4. Amplitude Increase	6	2	3	3
5. Amplitd Decrease/Suppression	2	0	1	0
6. Progressive Increase/Decrease	1	1	1	1
7. Progressive Increase & Return	1	0	1	0
8. Progressive Decrease & Return	4	0	2	0
9. Baseline Change - Temporary	9	1	5	1
10. Baseline Change - Permanent	3	4	2	6
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	1	0	1	0
ELECTRODERMAL				
1. Amplitude Change	45	24	24%	35%
2. Complex Response	13	2	7	3
3. Response Duration & Return	43	22	23	32
CARDIOVASCULAR				
1. Baseline Increase & Decrease	39	7	20	10
2. Baseline Increase	5	1	3	1
3. Baseline Decrease	8	0	3	0
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	10	2	5	3
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	191	68		

$$191 \div 44 = 4.3$$

$$68 \div 15 = 4.5$$

Table 2.07-F

Title:

Q7, First Chart Reactions

Column 1. is: DI Men

Column 2. is: DI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

1st Charts	DI Men		DI Women	
	No.	No.	%	%
RESPIRATION	1	2	3	4
1. Rate Decrease	8	1	3%	1%
2. Rate Increase	3	3	1	3
3. I/E Ratio Change	0	0	0	0
4. Amplitude Increase	15	4	5	3
5. Amplitd Decrease/Suppression	3	2	1	2
6. Progressive Increase/Decrease	0	1	0	1
7. Progressive Increase & Return	0	1	0	1
8. Progressive Decrease & Return	2	1	1	1
9. Baseline Change - Temporary	10	3	3	3
10. Baseline Change - Permanent	3	5	1	4
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	3	1	1	1
ELECTRODERMAL	47			
1. Amplitude Change	74	30	25	24%
2. Complex Response	14	3	5	2
3. Response Duration & Return	71	29	24	24
CARDIOVASCULAR	159			
1. Baseline Increase & Decrease	47	24	16	20
2. Baseline Increase	10	3	3	2
3. Baseline Decrease	5	3	2	2
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	24	9	8	7
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	292	123		

$$292 \div 71 =$$

$$123 \div 31$$

Table 2-Q7-6

Title:

Q7, Second Chart Reactions

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

2d Charts	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION	No.	No.	%	%
1. Rate Decrease	11	2	3	1
2. Rate Increase	7	2	2	1
3. I/E Ratio Change	2	0	0	0
4. Amplitude Increase	15	9	3	4
5. Amplitude Decrease/Suppression	9	4	2	2
6. Progressive Increase/Decrease	3	0	1	0
7. Progressive Increase & Return	2	1	0	0
8. Progressive Decrease & Return	9	3	2	1
9. Baseline Change - Temporary	17	9	4	4
10. Baseline Change - Permanent	5	2	1	1
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	7	0	0	0
ELECTRODERMAL	87	32		
1. Amplitude Change	111	54	26	26
2. Complex Response	17	13	6	6
3. Response Duration & Return	102	53	24	26
CARDIOVASCULAR	230	120		
1. Baseline Increase & Decrease	72	39	18	17
2. Baseline Increase	8	5	3	2
3. Baseline Decrease	6	3	1	1
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	27	12	6	6
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	430	211		

113

39

Table 2-Q7-H

Title: Q7, Second Chart Reactions

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

2d charts

	Men	Women	Men	Women
	1	2	3	4
	no.	no.	%	%
RESPIRATION				
1. Rate Decrease	9	3	2%	
2. Rate Increase	9	0	2	0
3. I/E Ratio Change	2	0	0	0
4. Amplitude Increase	19	5	4	3
5. Amplitd Decrease/Suppression	8	3	2	2
6. Progressive Increase/Decrease	2	1	0	1
7. Progressive Increase & Return	0	2	6	
8. Progressive Decrease & Return	9	3	2	2
9. Baseline Change - Temporary	15	16	3	10
10. Baseline Change - Permanent	6	1	1	1
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	3	3	1	2
ELECTRODERMAL				
1. Amplitude Change	112	40	25%	25
2. Complex Response	19	6	4	4
3. Response Duration & Return	105	37	19	23
CARDIOVASCULAR				
1. Baseline Increase & Decrease	21	30	17%	19%
2. Baseline Increase	8	4	2	2
3. Baseline Decrease	9	0	2	0
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	24	12	6	8
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	430	160		

Table 2-Q7I

Title: Q 7. Second Chart Reactions

Column 1. is: NDI Men

Column 2. is: NDI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

2d Charts

	NDI Men	NDI Women	NDI Men	NDI Women
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	1	0	1	0
2. Rate Increase	2	0	1	0
3. I/E Ratio Change	0	0	0	0
4. Amplitude Increase	8	1	6	2
5. Amplitd Decrease/Suppression	1	2	1	5
6. Progressive Increase/Decrease	0	0	0	0
7. Progressive Increase & Return	0	1	0	2
8. Progressive Decrease & Return	3	0	2	0
9. Baseline Change - Temporary	4	4	3	10
10. Baseline Change - Permanent	2	0	1	0
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	0	0	0	0
ELECTRODERMAL				
1. Amplitude Change	38	9	27	21
2. Complex Response	8	3	6	7
3. Response Duration & Return	37	9	27	21
CARDIOVASCULAR				
1. Baseline Increase & Decrease	26	8	18	19
2. Baseline Increase	2	2	1	5
3. Baseline Decrease	3	0	2	0
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	7	3	5	7
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	142	42		

Table 2-Q7-J

Title:

Q7. Second Chart Reactions

Column 1. is: DI Men

Column 2. is: DI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

2nd charts

	DI Men	DI Women	DI Men	DI Women
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	8	3	3%	
2. Rate Increase	7	0	2	0
3. I/E Ratio Change	2	0	1	0
4. Amplitude Increase	11	4	4	3
5. Amplitd Decrease/Suppression	7	1	2	1
6. Progressive Increase/Decrease	2	1	1	1
7. Progressive Increase & Return	0	1	0	1
8. Progressive Decrease & Return	6	3	2	3
9. Baseline Change - Temporary	11	6	4	5
10. Baseline Change - Permanent	4	1	1	1
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	3	3	1	3
ELECTRODERMAL				
1. Amplitude Change	74	31	26%	26%
2. Complex Response	11	3	4	3
3. Response Duration & Return	68	28	24	24
CARDIOVASCULAR				
1. Baseline Increase & Decrease	45	22	16	19
2. Baseline Increase	6	2	2	2
3. Baseline Decrease	6	0	2	0
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	17	9	6	8
6. Rate Increase	0	0	0	
7. Rate Decrease	0	0	0	
	288	118		

Table 2-Q7. K

Title: Q 7, Third Chart Reactions

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	3d chart	DI	NDI	DI	NDI
	1	2	3	4	
RESPIRATION	no.	no.	%	%	
1. Rate Decrease	7	1	2	1	
2. Rate Increase	2	1	6	1	
3. I/E Ratio Change	6	0	1	0	
4. Amplitude Increase	11	6	3	3	
5. Amplitude Decrease/Suppression	18	3	4	2	
6. Progressive Increase/Decrease	3	2	1	1	
7. Progressive Increase & Return	2	0	0	0	
8. Progressive Decrease & Return	5	7	1	4	
9. Baseline Change - Temporary	22	5	5	3	
10. Baseline Change - Permanent	11	12	3	6	
11. Apnea - Holding (inspiration)	1	0	0	0	
12. Apnea - Blocking (Exhalation)	5	1	1	1	
ELECTRODERMAL	93	38			
1. Amplitude Change	99	50	23	26	
2. Complex Response	19	12	4	6	
3. Response Duration & Return	96	49	22	26	
CARDIOVASCULAR	214	121			
1. Baseline Increase & Decrease	79	25	18	13	
2. Baseline Increase	6	5	1	3	
3. Baseline Decrease	6	5	1	3	
4. Amplitude Increase	0	0	0	0	
5. Amplitude Decrease	31	5	7	3	
6. Rate Increase	0	0	0	0	
7. Rate Decrease	1	0	0	0	
	430	189			

123 40

Table 2-Q7-L

Title: Q 7, Third Chart Reactions

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

Third Charts				
	Men	Women	Men	Women
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	7	1	2%	1%
2. Rate Increase	2	1	1	1
3. I/E Ratio Change	0	6	0	3
4. Amplitude Increase	11	4	3	2
5. Amplitd Decrease/Suppression	12	6	3	3
6. Progressive Increase/Decrease	4	1	1	1
7. Progressive Increase & Return	2	0	1	0
8. Progressive Decrease & Return	8	4	2	2
9. Baseline Change - Temporary	16	9	4	5
10. Baseline Change - Permanent	18	4	4	2
11. Apnea - Holding (inspiration)	1	0	0	0
12. Apnea - Blocking (Exhalation)	5	1	1	1
ELECTRODERMAL				
1. Amplitude Change	99	39	25%	23%
2. Complex Response	21	7	5	4
3. Response Duration & Return	96	38	24	22
CARDIOVASCULAR				
1. Baseline Increase & Decrease	64	32	16%	19%
2. Baseline Increase	6	4	2	2
3. Baseline Decrease	7	2	2	1
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	20	14	5	8
6. Rate Increase	0	0	0	0
7. Rate Decrease	1	0	0	0
	400	172		

Table 2 Q7-M

Title:

Q 7, Third Chart Reactions

Column 1. is: DI Men

Column 2. is: DI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	3d charts	DI Men	DI Women	DI Men	DI Women
		1	2	3	4
RESPIRATION		no.	no.	%	%
1. Rate Decrease	6	1	2	1%	
2. Rate Increase	2	0	1	0	
3. I/E Ratio Change	0	6	0	5	
4. Amplitude Increase	7	2	3	2	
5. Amplitude Decrease/Suppression	9	5	3	4	
6. Progressive Increase/Decrease	2	1	1	1	
7. Progressive Increase & Return	2	0	1	0	
8. Progressive Decrease & Return	3	2	1	2	
9. Baseline Change - Temporary	15	6	6	5	
10. Baseline Change - Permanent	7	4	3	3	
11. Apnea - Holding (inspiration)	1	0	0	0	
12. Apnea - Blocking (Exhalation)	4	1	1	1	
ELECTRODERMAL					
1. Amplitude Change	64	28	24	21%	
2. Complex Response	12	6	4	4	
3. Response Duration & Return	61	28	23	21	
CARDIOVASCULAR					
1. Baseline Increase & Decrease	47	26	18	20%	
2. Baseline Increase	4	2	1	2	
3. Baseline Decrease	3	2	1	2	
4. Amplitude Increase	0	0	0	0	
5. Amplitude Decrease	17	12	6	9	
6. Rate Increase	0	0	0	0	
7. Rate Decrease	1	0	0	0	
8.	267	131			

Table 2-Q7-N

Title: Q 7, Third Chart Reactions

Column 1. is: NDI Men

Column 2. is: NDI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

3d Charts	NDI Men	NDI Women	NDI Men	NDI Women
	1	2	3	4
	no.	no.	%	%
RESPIRATION				
1. Rate Decrease	1	0	1%	0%
2. Rate Increase	0	1	0	2
3. I/E Ratio Change	0	0	0	0
4. Amplitude Increase	4	2	3	5
5. Amplitude Decrease/Suppression	3	0	2	0
6. Progressive Increase/Decrease	2	0	2	0
7. Progressive Increase & Return	0	0	0	0
8. Progressive Decrease & Return	5	2	4	5
9. Baseline Change - Temporary	1	3	1	7
10. Baseline Change - Permanent	11	0	8	0
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	1	0	1	0
ELECTRODERMAL				
1. Amplitude Change	35	11	26%	27%
2. Complex Response	4	2	7	5
3. Response Duration & Return	35	10	26	24
CARDIOVASCULAR				
1. Baseline Increase & Decrease	17	6	13	15
2. Baseline Increase	2	2	2	5
3. Baseline Decrease	4	0	3	0
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	3	2	2	5
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	133	41		

Table 2-8.0

Title: Q 8, Reactions from the First Three Charts

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	27	3	3%	1%
2. Rate Increase	10	2	1	0
3. I/E Ratio Change	1	4	0	1
4. Amplitude Increase	33	18	3	3
5. Amplitd Decrease/Suppression	41	15	4	2
6. Progressive Increase/Decrease	11	4	1	1
7. Progressive Increase & Return	10	4	1	1
8. Progressive Decrease & Return	16	9	1	2
9. Baseline Change - Temporary	45	21	4	4
10. Baseline Change - Permanent	25	26	2	3
11. Apnea - Holding (inspiration)	2	6	0	0
12. Apnea - Blocking (Exhalation)	16	3	1	1
ELECTRODERMAL				
1. Amplitude Change	283	148	26%	25%
2. Complex Response	48	41	4	7
3. Response Duration & Return	254	142	24	24
CARDIOVASCULAR				
1. Baseline Increase & Decrease	163	91	15	15
2. Baseline Increase	19	16	2	3
3. Baseline Decrease	25	20	2	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	40	28	4	5
6. Rate Increase	1	0	0	0
7. Rate Decrease	1	0	0	0
	1071	589		

Table 2-8-B

Title:

Q 8, Reactions from the First Three Charts

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	Men	Women	Men	Women
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	16	9	1	2
2. Rate Increase	9	2	1	6
3. I/E Ratio Change	2	0	0	0
4. Amplitude Increase	34	11	3	3
5. Amplitd Decrease/Suppression	39	11	3	3
6. Progressive Increase/Decrease	10	2	1	0
7. Progressive Increase & Return	9	2	1	0
8. Progressive Decrease & Return	16	5	1	1
9. Baseline Change - Temporary	48	11	4	3
10. Baseline Change - Permanent	26	10	2	2
11. Apnea - Holding (inspiration)	1	1	0	0
12. Apnea - Blocking (Exhalation)	11	3	1	1
ELECTRODERMAL				
1. Amplitude Change	299	71	26%	17%
2. Complex Response	63	14	6	3
3. Response Duration & Return	273	66	24	16
CARDIOVASCULAR				
1. Baseline Increase & Decrease	176	43	15%	10%
2. Baseline Increase	25	4	2	1
3. Baseline Decrease	26	13	2	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	50	9	4	2
6. Rate Increase	1	0	0	0
7. Rate Decrease	1	0	0	0
	1129	417		

Table 2-8-C

Title:

Q82, First Chart Reactions

Column 1. is:

DI

Column 2. is:

NDI

Column 3. is:

% Distribution of 1

Column 4. is:

% Distribution of 2

1st Charts		DI	NDI	DI	NDI
		1	2	3	4
RESPIRATION		No.	No.	%	%
1. Rate Decrease	9			3%	6
2. Rate Increase	4			1	0
3. I/E Ratio Change	0	2		0	1
4. Amplitude Increase	12	10		3	4
5. Amplitd Decrease/Suppression	10	4		3	2
6. Progressive Increase/Decrease	6	1		2	0
7. Progressive Increase & Return	2	3		1	1
8. Progressive Decrease & Return	4	3		1	1
9. Baseline Change - Temporary	14	9		4	4
10. Baseline Change - Permanent	9	7		0	3
11. Apnea - Holding (inspiration)	0	0		0	0
12. Apnea - Blocking (Exhalation)	6	0		2	0
ELECTRODERMAL		76	41		
1. Amplitude Change	99	54		28%	24%
2. Complex Response	16	16		4	7
3. Response Duration & Return	88	54		25	24
CARDIOVASCULAR		203	124		
1. Baseline Increase & Decrease	51	35		14%	15%
2. Baseline Increase	8	8		2	4
3. Baseline Decrease	8	6		2	3
4. Amplitude Increase	0	0		0	0
5. Amplitude Decrease	11	12		3	5
6. Rate Increase	1	0		0	0
7. Rate Decrease	0	0		0	0
	358	226			

79 61

Table 2-8-D

le:

Q82, First Chart Reactions

Column 1. is:

Men

Column 2. is:

Women

Column 3. is:

% Distribution of 1

Column 4. is:

% Distribution of 2

1st Charts		Men	Women	Men	Women
		1	2	3	4
RESPIRATION		Nr.	Nr.	%	%
1. Rate Decrease		6	3	2	2
2. Rate Increase		3	1	1	0
3. I/E Ratio Change		1	1	0	0
4. Amplitude Increase		14	7	4	5
5. Amplitd Decrease/Suppression		8	5	2	3
6. Progressive Increase/Decrease		4	1	1	0
7. Progressive Increase & Return		4	0	1	0
8. Progressive Decrease & Return		4	3	1	2
9. Baseline Change - Temporary		20	1	5	0
10. Baseline Change - Permanent		8	6	2	4
11. Apnea - Holding (inspiration)		0	0	0	0
12. Apnea - Blocking (Exhalation)		2	1	1	0
ELECTRODERMAL		94			
1. Amplitude Change		102	38	27	25%
2. Complex Response		17	5	5	3
3. Response Duration & Return		94	38	25	25
CARDIOVASCULAR		122			
1. Baseline Increase & Decrease		51	27	14	18
2. Baseline Increase		10	4	3	3
3. Baseline Decrease		8	5	2	3
4. Amplitude Increase		0	0	0	0
5. Amplitude Decrease		16	7	4	5
6. Rate Increase		1	0	0	0
7. Rate Decrease	96	0	0	0	0
		373	153		

Table 2-8-E

Title: Q 8 First Chart Reactions

Column 1. is: NDI Men

Column 2. is: NDI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

Q. 8	1st charts	NDI Men	NDI Women	NDI Men	NDI Women
		1	2	3	4
RESPIRATION		no.	no.	%	%
1. Rate Decrease		0	0	0	0
2. Rate Increase		0	0	0	0
3. I/E Ratio Change		1	1	1	2%
4. Amplitude Increase		8	2	7	4
5. Amplitd Decrease/Suppression		1	2	1	4
6. Progressive Increase/Decrease		1	0	1	0
7. Progressive Increase & Return		3	0	2	0
8. Progressive Decrease & Return		2	1	1	2
9. Baseline Change - Temporary		8	0	7	0
10. Baseline Change - Permanent		3	3	2	6
11. Apnea - Holding (inspiration)		0	0	0	0
12. Apnea - Blocking (Exhalation)		0	0	0	0
ELECTRODERMAL	27				
1. Amplitude Change		36	12	24	24%
2. Complex Response		12	1	8	2
3. Response Duration & Return		36	12	24	24
CARDIOVASCULAR	84				
1. Baseline Increase & Decrease		23	10	15%	20%
2. Baseline Increase		4	2	3	4
3. Baseline Decrease		4	1	3	2
4. Amplitude Increase		0	0	0	0
5. Amplitude Decrease		8	4	7	8
6. Rate Increase		0	0	0	0
7. Rate Decrease	39	0	0	0	0
		150	51		

Table 2-8-F

Title:

Q4, First Chart Reactions

Column 1. is: DI Men

Column 2. is: DI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

1st Charts	DI Men	DI Women	DI Men	DI Women
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	6	3	3	3%
2. Rate Increase	3	1	1	1
3. I/E Ratio Change	0	0	0	0
4. Amplitude Increase	6	5	3	5
5. Amplitd Decrease/Suppression	7	3	3	3
6. Progressive Increase/Decrease	3	1	1	1
7. Progressive Increase & Return	1	0	0	0
8. Progressive Decrease & Return	2	2	1	2
9. Baseline Change - Temporary	12	1	5	1
10. Baseline Change - Permanent	5	3	2	3
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	2	1	1	1
ELECTRODERMAL				
1. Amplitude Change	66	26	29	25%
2. Complex Response	12	4	5	4
3. Response Duration & Return	58	26	25	25
CARDIOVASCULAR				
1. Baseline Increase & Decrease	28	17	12	17%
2. Baseline Increase	6	2	3	2
3. Baseline Decrease	4	4	2	4
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	8	3	3	3
6. Rate Increase	1	0	0	0
7. Rate Decrease	0	0	0	0
	229	102		

Table 2-8-G

Title: Q8, Second Chart Reactions

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

<i>2nd Chart</i>		DI	NDI	DI	NDI
		1	2	3	4
RESPIRATION		no.	no.	%	%
1. Rate Decrease		10	1	3	1
2. Rate Increase		4	0	1	0
3. I/E Ratio Change		0	2	0	1
4. Amplitude Increase		10	3	3	2
5. Amplitd Decrease/Suppression		12	8	3	4
6. Progressive Increase/Decrease		3	1	1	1
7. Progressive Increase & Return		3	0	1	0
8. Progressive Decrease & Return		5	2	1	1
9. Baseline Change - Temporary		17	2	5	1
10. Baseline Change - Permanent		8	8	2	4
11. Apnea - Holding (inspiration)		1	0	0	0
12. Apnea - Blocking (Exhalation)		6	2	2	1
ELECTRODERMAL		79	29		
1. Amplitude Change		91	51	26	27%
2. Complex Response		19	11	5	6
3. Response Duration & Return		80	48	22	25
CARDIOVASCULAR		190	110		
1. Baseline Increase & Decrease		63	28	18	15
2. Baseline Increase		3	4	1	2
3. Baseline Decrease		7	10	2	5
4. Amplitude Increase		0	0	0	0
5. Amplitude Decrease		13	8	4	4
6. Rate Increase		0	0	0	0
7. Rate Decrease		1	0	0	0
		356	189		

87 50

Table 2-8-H

Title: Q8, Second Chart Reactions

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

<i>2d charts</i>		Men	Women	Men	Women
		1	2	3	4
RESPIRATION		no.	no.	%	%
1. Rate Decrease		6	3	2	2%
2. Rate Increase		3	1	1	1
3. I/E Ratio Change		0	1	0	1
4. Amplitude Increase		11	2	3	2
5. Amplitd Decrease/Suppression		16	2	4	2
6. Progressive Increase/Decrease		3	0	1	0
7. Progressive Increase & Return		1	1	0	1
8. Progressive Decrease & Return		5	2	1	2
9. Baseline Change - Temporary		12	5	3	4
10. Baseline Change - Permanent		10	5	3	4
11. Apnea - Holding (inspiration)		0	1	0	1
12. Apnea - Blocking (Exhalation)		5	2	1	2
ELECTRODERMAL					
1. Amplitude Change		101	32	27	25%
2. Complex Response		23	6	6	5
3. Response Duration & Return		91	28	24	22
CARDIOVASCULAR					
1. Baseline Increase & Decrease		61	22	16	17%
2. Baseline Increase		6	0	2	2
3. Baseline Decrease		9	8	2	7
4. Amplitude Increase		0	0	0	0
5. Amplitude Decrease		15	6	4	5
6. Rate Increase		0	0	0	0
7. Rate Decrease		1	0	0	0
Σ		379	127		

Table 2-8-T

Title:

Q 8 Second Chart Reactions

Column 1. is: DI Men

Column 2. is: DI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

2d Chart	DI Men	DI Women	DI Men	DI Women
RESPIRATION	1	2	3	4
1. Rate Decrease	5	3	2	3%
2. Rate Increase	3	1	1	1
3. I/E Ratio Change	0	0	0	0
4. Amplitude Increase	8	2	3	2
5. Amplitd Decrease/Suppression	10	2	4	2
6. Progressive Increase/Decrease	2	0	1	0
7. Progressive Increase & Return	1	1	0	1
8. Progressive Decrease & Return	3	2	1	2
9. Baseline Change - Temporary	11	5	4	6
10. Baseline Change - Permanent	4	4	2	4
11. Apnea - Holding (inspiration)	0	1	0	1
12. Apnea - Blocking (Exhalation)	4	1	.2	1
ELECTRODERMAL				
1. Amplitude Change	66	21	26	24%
2. Complex Response	15	4	6	4
3. Response Duration & Return	59	17	24	19
CARDIOVASCULAR				
1. Baseline Increase & Decrease	43	17	17	19%
2. Baseline Increase	3	0	1	0
3. Baseline Decrease	2	5	1	6
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	10	3	4	3
6. Rate Increase	0	0	0	0
7. Rate Decrease	1	0	0	0
	250	89		

Table 2-8-J

Title:

Q 8: Second Chart Reactions

Column 1. is: NDI Men

Column 2. is: NDI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

2d Charts		NDI Men	NDI Women	AM Men	NDI Women
		1	2	3	4
RESPIRATION					
1. Rate Decrease		1	0	1%	0
2. Rate Increase		0	0	0	0
3. I/E Ratio Change		0	1	0	3%
4. Amplitude Increase		3	0	2	0
5. Amplitd Decrease/Suppression		6	0	5	0
6. Progressive Increase/Decrease		1	0	1	0
7. Progressive Increase & Return		0	0	0	0
8. Progressive Decrease & Return		2	0	2	0
9. Baseline Change - Temporary		1	0	1	0
10. Baseline Change - Permanent		4	1	5	3
11. Apnea - Holding (inspiration)		0	0	0	0
12. Apnea - Blocking (Exhalation)		1	1	1	3
ELECTRODERMAL					
1. Amplitude Change		35	11	27	29%
2. Complex Response		8	2	6	5
3. Response Duration & Return		32	11	25	29
CARDIOVASCULAR					
1. Baseline Increase & Decrease		18	5	14	13
2. Baseline Increase		3	0	2	0
3. Baseline Decrease		7	3	5	8
4. Amplitude Increase		0	0	0	0
5. Amplitude Decrease		5	3	4	8
6. Rate Increase		0	0	0	0
7. Rate Decrease		0	0	0	0
		129	38		

Table 2-8-1K

Title: Q8, Third Chart Reactions

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

3d charts	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	8	1	2	1
2. Rate Increase	2	1	1	1
3. I/E Ratio Change	1	0	0	0
4. Amplitude Increase	11	5	3	3
5. Amplitude Decrease/Suppression	19	3	5	2
6. Progressive Increase/Decrease	2	3	1	2
7. Progressive Increase & Return	5	1	1	1
8. Progressive Decrease & Return	6	3	2	2
9. Baseline Change - Temporary	15	10	4	6
10. Baseline Change - Permanent	9	5	3	3
11. Apnea - Holding (inspiration)	1	0	0	0
12. Apnea - Blocking (Exhalation)	4	1	1	1
ELECTRODERMAL	83	33		
1. Amplitude Change	93	43	26	25%
2. Complex Response	13	14	4	8
3. Response Duration & Return	86	40	24	23
CARDIOVASCULAR	192	97		
1. Baseline Increase & Decrease	49	28	14	16%
2. Baseline Increase	8	4	2	2
3. Baseline Decrease	16	4	3	2
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	16	8	4	5
6. Rate Increase	6	6	0	0
7. Rate Decrease	0	0	0	0
	358	174		

83

44

Table 2.8-L

Title:

Q8, Third Chart Reactions

Column 1. is:

Men

Column 2. is:

Women

Column 3. is:

% Distribution of 1

Column 4. is:

% Distribution of 2

3d Charts

	Men	Women	Men	Women
	No.	No.	%	%
RESPIRATION	1	2	3	4
1. Rate Decrease	4	4	1	3
2. Rate Increase	3	0	1	0
3. I/E Ratio Change	1	0	0	0
4. Amplitude Increase	9	6	2	4
5. Amplitd Decrease/Suppression	15	7	4	5
6. Progressive Increase/Decrease	3	1	1	1
7. Progressive Increase & Return	4	1	1	1
8. Progressive Decrease & Return	7	1	2	1
9. Baseline Change - Temporary	16	9	4	7
10. Baseline Change - Permanent	8	5	2	4
11. Apnea - Holding (inspiration)	1	0	0	0
12. Apnea - Blocking (Exhalation)	4	1	1	1
ELECTRODERMAL				
1. Amplitude Change	96	33	26	24%
2. Complex Response	16	9	4	7
3. Response Duration & Return	88	32	24	23
CARDIOVASCULAR				
1. Baseline Increase & Decrease	58	16	16	12
2. Baseline Increase	9	3	2	2
3. Baseline Decrease	9	4	2	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	19	5	5	4
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	370	137		

Table 2-8-M

Title:

Q8, Third Chart Reactions

Column 1. is: DI Men

Column 2. is: DI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

3d charts		DI Men	DI Women	DI Men	DI Women
		no.	no.	%	%
RESPIRATION					
1. Rate Decrease		4	3	2	3
2. Rate Increase		2	0	1	0
3. I/E Ratio Change		1	0	0	0
4. Amplitude Increase		6	4	2	4
5. Amplitude Decrease/Suppression		13	6	5	6
6. Progressive Increase/Decrease		1	1	0	1
7. Progressive Increase & Return		4	1	2	1
8. Progressive Decrease & Return		4	1	2	1
9. Baseline Change - Temporary		10	5	4	5
10. Baseline Change - Permanent		5	3	2	3
11. Apnea - Holding (inspiration)		1	0	0	0
12. Apnea - Blocking (Exhalation)		3	1	1	1
ELECTRODERMAL					
1. Amplitude Change		66	24	26	25%
2. Complex Response		7	6	3	6
3. Response Duration & Return		61	23	24	24
CARDIOVASCULAR					
1. Baseline Increase & Decrease		38	4	15	9
2. Baseline Increase		6	2	2	2
3. Baseline Decrease		5	4	2	4
4. Amplitude Increase		0	0	0	0
5. Amplitude Decrease		13	3	5	3
6. Rate Increase		0	0	0	0
7. Rate Decrease		6	0	0	0
		250	96		

Table 2-8-N

Title: Q8, Third Chart Reactions

Column 1. is: NDI Men

Column 2. is: NDI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

3d chart

	NDI Men	NDI Women	NDI Men	NDI Women
	1	2	3	4
RESPIRATION				
1. Rate Decrease	0	1	0	2%
2. Rate Increase	1	0	1	0
3. I/E Ratio Change	0	0	0	0
4. Amplitude Increase	3	2	2	5
5. Amplitd Decrease/Suppression	2	1	2	2
6. Progressive Increase/Decrease	2	0	2	0
7. Progressive Increase & Return	0	0	0	0
8. Progressive Decrease & Return	3	0	2	0
9. Baseline Change - Temporary	6	4	5	10
10. Baseline Change - Permanent	3	2	2	5
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	1	0	1	0
ELECTRODERMAL				
1. Amplitude Change	30	9	25	22%
2. Complex Response	9	3	7	7
3. Response Duration & Return	27	9	22	22
CARDIOVASCULAR				
1. Baseline Increase & Decrease	20	7	17	17%
2. Baseline Increase	3	1	2	2
3. Baseline Decrease	4	0	3	0
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	6	2	5	5
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	120	41		

Table 2-9-A

Title: Q 9, Reactions from the First Three Charts

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

1st 3 charts	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	18	9	2	1%
2. Rate Increase	7	10	1	2
3. I/E Ratio Change	4	3	0	0
4. Amplitude Increase	34	22	3	3
5. Amplitd Decrease/Suppression	38	11	4	2
6. Progressive Increase/Decrease	6	2	1	0
7. Progressive Increase & Return	1	3	0	0
8. Progressive Decrease & Return	20	16	2	2
9. Baseline Change - Temporary	44	17	4	2
10. Baseline Change - Permanent	28	13	3	2
11. Apnea - Holding (inspiration)	2	0	0	0
12. Apnea - Blocking (Exhalation)	9	3	1	0
ELECTRODERMAL				
1. Amplitude Change	280	162	26	26%
2. Complex Response	47	44	4	7
3. Response Duration & Return	252	154	24	24
CARDIOVASCULAR				
1. Baseline Increase & Decrease	173	109	16	17
2. Baseline Increase	22	14	2	2
3. Baseline Decrease	27	15	3	2
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	53	27	5	4
6. Rate Increase	2	0	0	0
7. Rate Decrease	2	0	0	0
	1069	634		

Table 2-9-B

Title:

Q 9, Reactions from the First Three Charts

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

1st Three Charts		Men	Women	Men	Women
		1	2	3	4
RESPIRATION		no.	no.	%	%
1. Rate Decrease		19	6	2%	1%
2. Rate Increase		13	4	1	1
3. I/E Ratio Change		3	4	0	1
4. Amplitude Increase		42	11	4	3
5. Amplitd Decrease/Suppression		36	12	3	3
6. Progressive Increase/Decrease		4	4	0	1
7. Progressive Increase & Return		4	0	0	0
8. Progressive Decrease & Return		26	10	2	2
9. Baseline Change - Temporary		37	20	3	5
10. Baseline Change - Permanent		27	14	2	3
11. Apnea - Holding (inspiration)		1	1	0	0
12. Apnea - Blocking (Exhalation)		9	3	1	1
ELECTRODERMAL					
1. Amplitude Change		307	108	26%	25%
2. Complex Response		66	19	6	4
3. Response Duration & Return		294	91	25	21
CARDIOVASCULAR					
1. Baseline Increase & Decrease		184	78	16%	18%
2. Baseline Increase		26	8	2	2
3. Baseline Decrease		26	14	2	3
4. Amplitude Increase		0	0	0	0
5. Amplitude Decrease		53	26	4	6
6. Rate Increase		1	1	0	0
7. Rate Decrease		2	0	0	0
		1178	434		

Table 2-9-C

Title:

Q Q, First Chart Reactions

Column 1. is:

DI

Column 2. is:

NDI

Column 3. is:

% Distribution of 1

Column 4. is:

% Distribution of 2

1st Charts	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION	NO.	NO.	%	%
1. Rate Decrease	3	2	1	1
2. Rate Increase	4	1	1	0
3. I/E Ratio Change	1	2	0	1
4. Amplitude Increase	8	6	2	3
5. Amplitd Decrease/Suppression	20	5	5	2
6. Progressive Increase/Decrease	2	0	0	0
7. Progressive Increase & Return	1	1	0	0
8. Progressive Decrease & Return	6	5	1	2
9. Baseline Change - Temporary	12	5	3	2
10. Baseline Change - Permanent	14	6	3	3
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	2	1	0	0
ELECTRODERMAL	13	34		
1. Amplitude Change	109	60	27	26%
2. Complex Response	15	17	4	7
3. Response Duration & Return	101	54	25	26
CARDIOVASCULAR	225	136		
1. Baseline Increase & Decrease	58	42	14	18
2. Baseline Increase	9	4	2	2
3. Baseline Decrease	14	4	3	2
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	23	9	6	4
6. Rate Increase	1	0	0	0
7. Rate Decrease	0	0	0	0
	403	229		

105 54

Table 2-9-D

Title:

Q 9, First Chart Reactions

Column 1. is:

Men

Column 2. is:

Women

Column 3. is:

% Distribution of 1

Column 4. is:

% Distribution of 2

1st Charts	Men	Women	Men	Women
	1	2	3	4
RESPIRATION	No.	No.	%	%
1. Rate Decrease	4	0	1	0
2. Rate Increase	3	2	1	1
3. I/E Ratio Change	1	2	0	1
4. Amplitude Increase	12	1	3	1
5. Amplitd Decrease/Suppression	18	7	4	4
6. Progressive Increase/Decrease	0	2	0	1
7. Progressive Increase & Return	2	0	0	0
8. Progressive Decrease & Return	6	5	1	3
9. Baseline Change - Temporary	11	5	3	3
10. Baseline Change - Permanent	12	7	3	4
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	3	0	1	0
ELECTRODERMAL				
1. Amplitude Change	119	40	27	25%
2. Complex Response	22	7	5	4
3. Response Duration & Return	117	36	27	22
CARDIOVASCULAR				
1. Baseline Increase & Decrease	66	29	15	18
2. Baseline Increase	9	2	2	0
3. Baseline Decrease	9	8	2	5
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	22	10	5	6
6. Rate Increase	1	0	0	0
7. Rate Decrease	0	0	0	0
	437	163		

Table 2-9-E

Title: Q 9. First Chart Reactions

Column 1. is: NDI Men

Column 2. is: NDI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

	NDI Men	NDI Women	NDI Men	NDI Women
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	2	0	1	0
2. Rate Increase	1	0	1	0
3. I/E Ratio Change	0	2	0	4
4. Amplitude Increase	6	0	4	0
5. Amplitd Decrease/Suppression	5	0	3	0
6. Progressive Increase/Decrease	0	0	0	0
7. Progressive Increase & Return	1	0	1	0
8. Progressive Decrease & Return	3	2	2	2
9. Baseline Change - Temporary	3	2	2	4
10. Baseline Change - Permanent	3	2	2	4
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	1	0	1	0
ELECTRODERMAL				
1. Amplitude Change	40	14	26%	26%
2. Complex Response	13	1	8	2
3. Response Duration & Return	40	13	26%	26%
CARDIOVASCULAR				
1. Baseline Increase & Decrease	26	13	17	24
2. Baseline Increase	2	1	1	2
3. Baseline Decrease	3	1	2	2
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	6	3	4	6
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	155	54		

Table 2-9-F

Title:

Q 9, First Chart Reactions

Column 1. is: DI Men

Column 2. is: DI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

1st Charts	DI Men	DI Women	DI Men	DI Women
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	2	0	1	0
2. Rate Increase	2	2	1	2
3. I/E Ratio Change	1	0	0	0
4. Amplitude Increase -	6	1	2	1
5. Amplitd Decrease/Suppression	13	7	5	6
6. Progressive Increase/Decrease	0	2	0	2
7. Progressive Increase & Return	1	0	0	0
8. Progressive Decrease & Return	3	3	1	3
9. Baseline Change - Temporary	8	3	3	3
10. Baseline Change - Permanent	9	5	3	5
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	2	0	1	0
ELECTRODERMAL				
1. Amplitude Change	79	26	28	24%
2. Complex Response	9	6	3	6
3. Response Duration & Return	77	23	27	21
CARDIOVASCULAR				
1. Baseline Increase & Decrease	40	16	14	15
2. Baseline Increase	7	1	2	1
3. Baseline Decrease	6	7	2	6
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	16	7	6	6
6. Rate Increase	1	0	0	0
7. Rate Decrease	0	0	0	0
	282	109		

Table 2-9-6

Title:

Q 9, Second Chart Reactions

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

2d Charts		DI	NDI	DI	NDI
		1	2	3	4
RESPIRATION		no.	no.	%	%
1. Rate Decrease		13	1	6	0
2. Rate Increase		1	0	0	0
3. I/E Ratio Change		2	1	1	0
4. Amplitude Increase		6	0	3	0
5. Amplitd Decrease/Suppression		8	0	3	0
6. Progressive Increase/Decrease		2	0	1	0
7. Progressive Increase & Return		0	0	0	0
8. Progressive Decrease & Return		9	0	4	0
9. Baseline Change - Temporary		18	2	8	1
10. Baseline Change - Permanent		5	1	2	0
11. Apnea - Holding (inspiration)		2	1	1	0
12. Apnea - Blocking (Exhalation)		4	1	2	0
ELECTRODERMAL		no.	no.	%	%
1. Amplitude Change		90	114	11	36%
2. Complex Response		20	52	72	16
3. Response Duration & Return		79	9	88	3
CARDIOVASCULAR		no.	no.	%	%
1. Baseline Increase & Decrease		64	87	2	28%
2. Baseline Increase		9	12	4	4
3. Baseline Decrease		10	30	4	10
4. Amplitude Increase		0	0	0	0
5. Amplitude Decrease		10	4	4	1
6. Rate Increase		0	6	0	0
7. Rate Decrease		0	0	0	0
		352	315		

93

123

Table 2-9-H

Title: Q9, Second Chart Reactions

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

2d Chart	Men	Women	Men	Women
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	12	4	3	3
2. Rate Increase	5	0	1	0
3. I/E Ratio Change	1	2	0	0
4. Amplitude Increase	16	4	4	3
5. Amplitd Decrease/Suppression	9	2	2	2
6. Progressive Increase/Decrease	2	1	0	0
7. Progressive Increase & Return	1	0	0	0
8. Progressive Decrease & Return	10	3	7	2
9. Baseline Change - Temporary	14	8	3	5
10. Baseline Change - Permanent	6	4	1	3
11. Apnea - Holding (inspiration)	1	1	0	0
12. Apnea - Blocking (Exhalation)	4	2	1	0
ELECTRODERMAL				
1. Amplitude Change	101	38	25	26%
2. Complex Response	20	5	5	12
3. Response Duration & Return	95	32	24	18
CARDIOVASCULAR				
1. Baseline Increase & Decrease	68	27	17%	18%
2. Baseline Increase	8	3	2	2
3. Baseline Decrease	10	2	7	0
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	16	7	4	5
6. Rate Increase	0	1	0	0
7. Rate Decrease	2	0	2	0
	401	146		

Table 2-9-I

Title:

Q 9 Second Chart Reactions

Column 1. is: DI Men

Column 2. is: DI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

2d Charts

	DI Men	DI Women	DI Men	DI Women
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	10	3	4	3%
2. Rate Increase	1	0	0	0
3. I/E Ratio Change	1	1	0	1
4. Amplitude Increase -	11	4	4	4
5. Amplitd Decrease/Suppression	6	2	2	2
6. Progressive Increase/Decrease	1	1	0	1
7. Progressive Increase & Return	0	0	0	0
8. Progressive Decrease & Return	6	3	2	3
9. Baseline Change - Temporary	10	6	4	6
10. Baseline Change - Permanent	2	3	1	3
11. Apnea - Holding (inspiration)	1	1	0	1
12. Apnea - Blocking (Exhalation)	3	1	1	1
ELECTRODERMAL 52	28			
1. Amplitude Change	66	25	26	24%
2. Complex Response	15	4	6	4
3. Response Duration & Return	60	19 1/2	23	18
CARDIOVASCULAR 141				
1. Baseline Increase & Decrease	41	20	16	19
2. Baseline Increase	6	3	2	3
3. Baseline Decrease	6	1	2	1
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	10	5	4	5
6. Rate Increase	0	1	0	0
7. Rate Decrease 65	2	0 30	6	0
	258	103		

Table 2-9-5

Title:

Q q Second Chart Reactions

Column 1. is: NDI Men

Column 2. is: NDI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

2nd Charts		NDI Men	NDI Women	NDI Men	NDI Women
		1	2	3	4
RESPIRATION					
1. Rate Decrease		2	2	1	4
2. Rate Increase		4	1	3	2
3. I/E Ratio Change		0	0	0	0
4. Amplitude Increase		5	4	3	8
5. Amplitude Decrease/Suppression		3	0	2	0
6. Progressive Increase/Decrease		1	0	1	0
7. Progressive Increase & Return		1	0	1	0
8. Progressive Decrease & Return		4	1	3	1
9. Baseline Change - Temporary		4	1	3	1
10. Baseline Change - Permanent		4	1	3	1
11. Apnea - Holding (inspiration) 29		0	0	0	0
12. Apnea - Blocking (Exhalation) 19		1	0	1	1
ELECTRODERMAL					
1. Amplitude Change		35	11	24	23%
2. Complex Response		5	3	3	6
3. Response Duration & Return		35	11	24	23
CARDIOVASCULAR					
1. Baseline Increase & Decrease		27	6	19	13
2. Baseline Increase		2	2	1	4
3. Baseline Decrease		4	2	3	4
4. Amplitude Increase		0	0	0	0
5. Amplitude Decrease		6	2	4	4
6. Rate Increase		0	0	0	0
7. Rate Decrease		6	0	0	0
		143	47		

Table 2-9-K

Title: Q 9, Third Chart Reactions

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

<i>3rd Charts</i>		DI	NDI	DI	NDI
		1	2	3	4
RESPIRATION		no.	no.	%	%
1. Rate Decrease		2	4	1	2
2. Rate Increase		2	5	1	2
3. I/E Ratio Change		1	0	0	0
4. Amplitude Increase		11	10	4	5
5. Amplitd Decrease/Suppression		10	2	4	1
6. Progressive Increase/Decrease		2	1	1	0
7. Progressive Increase & Return		0	1	0	0
8. Progressive Decrease & Return		5	7	2	3
9. Baseline Change - Temporary		14	5	5	2
10. Baseline Change - Permanent		9	2	3	1
11. Apnea - Holding (inspiration)		0	0	0	0
12. Apnea - Blocking (Exhalation)		3	0	1	0
ELECTRODERMAL		59	37		
1. Amplitude Change		77	48	27%	24%
2. Complex Response		13	19	5	7
3. Response Duration & Return		59	47	21	23%
CARDIOVASCULAR		149	114		
1. Baseline Increase & Decrease		51	29	18	10
2. Baseline Increase		4	8	1	4
3. Baseline Decrease		6	5	2	2
4. Amplitude Increase		0	0	0	0
5. Amplitude Decrease		15	9	5	4
6. Rate Increase		0	0	0	0
7. Rate Decrease		0	0	0	0
		284	202		

76

51

Table 2-9-L

Title: Q 4, Third Chart Reactions

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

3d Chart

	Men	Women	Men	Women
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	3	2	1	2
2. Rate Increase	5	2	1	2
3. I/E Ratio Change	1	0	0	0
4. Amplitude Increase -	14	6	4	5
5. Amplitd Decrease/Suppression	9	3	3	2
6. Progressive Increase/Decrease	2	1	1	1
7. Progressive Increase & Return	1	0	0	0
8. Progressive Decrease & Return	10	2	3	2
9. Baseline Change - Temporary	12	7	4	5
10. Baseline Change - Permanent	7	3	2	2
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	2	1	1	0
ELECTRODERMAL				
1. Amplitude Change	87	30	26	23%
2. Complex Response	24	7	7	5
3. Response Duration & Return	82	29	24	22
CARDIOVASCULAR				
1. Baseline Increase & Decrease	50	22	15	17%
2. Baseline Increase	9	3	3	2
3. Baseline Decrease	7	4	2	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	15	9	4	7
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	340	131		

Table 2-9-M

Title:

Q 9, Third Chart Reactions

Column 1. is: DI Men

Column 2. is: DI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

3d Chrts	DI Men	DI Women	DI Men	DI Women
RESPIRATION	1	2	3	4
1. Rate Decrease	no	no	%	%
2. Rate Increase	2	0	1	0
3. I/E Ratio Change	1	1	1	1
4. Amplitude Increase	1	0	1	0
5. Amplitd Decrease/Suppression	9	2	5	3
6. Progressive Increase/Decrease	7	3	4	3
7. Progressive Increase & Return	1	1	1	1
8. Progressive Decrease & Return	0	0	0	0
9. Baseline Change - Temporary	4	1	2	1
10. Baseline Change - Permanent	8	6	4	7
11. Apnea - Holding (inspiration)	6	2	3	3
12. Apnea - Blocking (Exhalation)	0	0	0	0
ELECTRODERMAL	2	1	1	1
1. Amplitude Change				
2. Complex Response	53	19	27	23%
3. Response Duration & Return	4	4	2	5
CARDIOVASCULAR	48	18	24	21
1. Baseline Increase & Decrease				
2. Baseline Increase	30	16	15	19
3. Baseline Decrease	3	1	2	1
4. Amplitude Increase	4	2	2	3
5. Amplitude Decrease	0	0	6	0
6. Rate Increase	8	7	4	8
7. Rate Decrease	0	0	0	0
	0	0	0	0
	196	84		

Table 2-9-N

Title: Q 9, Third Chart Reactions

Column 1. is: NDI Men

Column 2. is: NDI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

<i>3d charts</i>		NDI Men	NDI Women	NDI Men	NDI Women
		1	2	3	4
RESPIRATION		nr.	no.	%	%
1. Rate Decrease		1	2	1	4%
2. Rate Increase		4	1	3	2
3. I/E Ratio Change		0	0	0	0
4. Amplitude Increase		5	4	3	8
5. Amplitd Decrease/Suppression		2	0	1	0
6. Progressive Increase/Decrease		1	0	1	0
7. Progressive Increase & Return		1	0	1	0
8. Progressive Decrease & Return		6	1	4	2
9. Baseline Change - Temporary		4	1	3	2
10. Baseline Change - Permanent		1	1	1	2
11. Apnea - Holding (inspiration)		0	0	0	0
12. Apnea - Blocking (Exhalation)		0	0	0	0
ELECTRODERMAL					
1. Amplitude Change		34	11	24	23%
2. Complex Response		15	3	10	6
3. Response Duration & Return		34	11	24	23
CARDIOVASCULAR					
1. Baseline Increase & Decrease		20	6	14	13
2. Baseline Increase		6	2	4	4
3. Baseline Decrease		3	2	2	4
4. Amplitude Increase		0	0	0	0
5. Amplitude Decrease		7	2	5	4
6. Rate Increase		0	0	0	0
7. Rate Decrease		0	0	0	0
		144	47		

Table 2-10-A

Title: Q 10, Reactions from the First Three Charts

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

Question 10	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	19	6	2	2
2. Rate Increase	6	2	1	1
3. I/E Ratio Change	2	3	0	1
4. Amplitude Increase	35	17	3	5
5. Amplitd Decrease/Suppression	35	6	3	2
6. Progressive Increase/Decrease	4	2	0	1
7. Progressive Increase & Return	4	4	0	1
8. Progressive Decrease & Return	17	6	2	2
9. Baseline Change - Temporary	46	12	4	3
10. Baseline Change - Permanent	26	5	2	1
11. Apnea - Holding (inspiration)	1	0	0	0
12. Apnea - Blocking (Exhalation)	8	6	1	2
ELECTRODERMAL				
1. Amplitude Change	279	90	26	25%
2. Complex Response	43	27	4	8
3. Response Duration & Return	262	79	24	22%
CARDIOVASCULAR				
1. Baseline Increase & Decrease	192	61	17	17%
2. Baseline Increase	25	4	2	1
3. Baseline Decrease	20	18	2	5
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	69	9	6	3
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
TOTAL	1087	357		

Table 2-10-B

Title: Q10, Reactions from the First Three Charts

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

Q. 10	Men	Women	Men	Women
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	14	7	1	2%
2. Rate Increase	5	3	1	1
3. I/E Ratio Change	3	2	0	0
4. Amplitude Increase	34	15	3	4
5. Amplitude Decrease/Suppression	26	14	3	3
6. Progressive Increase/Decrease	3	2	0	0
7. Progressive Increase & Return	4	2	0	0
8. Progressive Decrease & Return	17	4	2	1
9. Baseline Change - Temporary	37	18	4	4
10. Baseline Change - Permanent	17	7	2	2
11. Apnea - Holding (inspiration)	0	1	0	0
12. Apnea - Blocking (Exhalation)	10	4	1	1
ELECTRODERMAL				
1. Amplitude Change	251	99	26	25%
2. Complex Response	50	19	5	5
3. Response Duration & Return	236	91	24	23
CARDIOVASCULAR				
1. Baseline Increase & Decrease	167	74	17	18
2. Baseline Increase	24	4	2	1
3. Baseline Decrease	23	13	2	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	53	22	5	5
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	969	401		

Table 2-10-C

Title:

Q10, First Chart Reactions

Column 1. is:

DI

Column 2. is:

NDI

Column 3. is:

% Distribution of 1

Column 4. is:

% Distribution of 2

Chart Q10	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	9	6	2	2
2. Rate Increase	1	0	0	0
3. I/E Ratio Change	0	0	0	0
4. Amplitude Increase	17	8	4	3
5. Amplitude Decrease/Suppression	14	5	3	2
6. Progressive Increase/Decrease	1	1	0	0
7. Progressive Increase & Return	2	1	0	0
8. Progressive Decrease & Return	9	2	2	1
9. Baseline Change - Temporary	18	9	4	4
10. Baseline Change - Permanent	10	6	2	2
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	2	3	0	1
ELECTRODERMAL	83	41		
1. Amplitude Change	102	59	25	26%
2. Complex Response	14	12	3	5
3. Response Duration & Return	101	57	25	25
CARDIOVASCULAR	217	128		
1. Baseline Increase & Decrease	64	39	16	17
2. Baseline Increase	6	2	1	1
3. Baseline Decrease	9	6	2	2
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	25	12	6	5
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
8. ...	406	228		

106 59
634

Table 2-10-D

Q 10 First Chart Reactions

Column 1. is:

Men

Column 2. is:

Women

Column 3. is:

% Distribution of 1

Column 4. is:

% Distribution of 2

1st Chnts Q16	Men	Women	Men	Women
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	5	8	1	4
2. Rate Increase	1	0	0	0
3. I/E Ratio Change	6	0	2	0
4. Amplitude Increase	13	8	4	4
5. Amplitd Decrease/Suppression	9	10	3	4
6. Progressive Increase/Decrease	2	0	1	0
7. Progressive Increase & Return	1	0	0	0
8. Progressive Decrease & Return	7	0	2	0
9. Baseline Change - Temporary	15	12	4	5
10. Baseline Change - Permanent	8	8	2	4
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	3	2	1	1
ELECTRODERMAL				
1. Amplitude Change	99	54	28	24%
2. Complex Response	0	0	0	0
3. Response Duration & Return	98	54	28	24
CARDIOVASCULAR				
1. Baseline Increase & Decrease	59	42	17	19
2. Baseline Increase	8	0	2	0
3. Baseline Decrease	9	6	3	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	19	18	5	8
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
TOTAL	356	222		

Table 2-10-E

Title: Q 10 First Chart Reactions

Column 1. is: NDI Men

Column 2. is: NDI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

1st charts

	NDI Men	NDI Women	NDI Men	NDI Women
	1	2	3	4.
RESPIRATION				
1. Rate Decrease	1	4	1	4%
2. Rate Increase	0	0	0	0
3. I/E Ratio Change	0	0	0	0
4. Amplitude Increase	2	4	2	4
5. Amplitd Decrease/Suppression	0	5	0	5
6. Progressive Increase/Decrease	1	0	1	0
7. Progressive Increase & Return	1	6	1	0
8. Progressive Decrease & Return	0	0	0	0
9. Baseline Change - Temporary	3	6	3	6
10. Baseline Change - Permanent	2	4	2	4
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	2	1	2	1
ELECTRODERMAL				
1. Amplitude Change	28	27	29	23%
2. Complex Response	7	5	7	4
3. Response Duration & Return	27	27	28	23
CARDIOVASCULAR				
1. Baseline Increase & Decrease	16	21	16	18
2. Baseline Increase	2	0	2	0
3. Baseline Decrease	3	3	3	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	3	9	3	8
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	98	116		

$$98 \div 44 = 2.2$$

$$116 \div 15 = 7.7$$

Table 2-10-F

Title: Q 10, First Chart Reactions

Column 1. is: DI Men

Column 2. is: DI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

1st Charts	DI Men	DI Women	DI Men	DI Women
RESPIRATION	1	2	3	4
1. Rate Decrease	4	4	1	3
2. Rate Increase	1	0	6	0
3. I/E Ratio Change	0	0	0	0
4. Amplitude Increase	11	4	4	3
5. Amplitd Decrease/Suppression	9	5	3	4
6. Progressive Increase/Decrease	1	0	6	0
7. Progressive Increase & Return	0	0	6	0
8. Progressive Decrease & Return	7	0	3	0
9. Baseline Change - Temporary	12	6	4	1
10. Baseline Change - Permanent	6	4	3	3
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	1	1	0	1
ELECTRODERMAL				
1. Amplitude Change	71	27	25	23
2. Complex Response	9	5	3	4
3. Response Duration & Return	71	27	26	23
CARDIOVASCULAR				
1. Baseline Increase & Decrease	43	21	22	18
2. Baseline Increase	6	0	3	0
3. Baseline Decrease	6	3	3	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	16	9	1	6
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	274	116		

$$274 \div 71 = 3.9$$

$$116 \div 31 = 3.5$$

Table 2-10-G

Title: Q 10, Second Chart Reactions

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

2d Charts	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	7	3	2	3
2. Rate Increase	3	0	1	0
3. I/E Ratio Change	1	2	0	2
4. Amplitude Increase	5	9	1	8
5. Amplitude Decrease/Suppression	11	2	3	2
6. Progressive Increase/Decrease	1	0	0	0
7. Progressive Increase & Return	2	0	1	0
8. Progressive Decrease & Return	4	2	1	2
9. Baseline Change - Temporary	13	5	4	4
10. Baseline Change - Permanent	4	1	1	1
11. Apnea - Holding (inspiration)	1	0	0	0
12. Apnea - Blocking (Exhalation)	3	2	1	2
ELECTRODERMAL	55	26		
1. Amplitude Change	90	28	26	25%
2. Complex Response	5	8	4	7
3. Response Duration & Return	20	24	24	21
CARDIOVASCULAR	55	60		
1. Baseline Increase & Decrease	62	20	18	18%
2. Baseline Increase	7	1	2	1
3. Baseline Decrease	6	6	2	5
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	25	1	7	1
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	340	114		

Table 2-10-H

Title: Q10 Second Chart Reactions

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

2nd chart	Men	Women	Men	Women
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	5	2	2	2
2. Rate Increase	2	1	1	1
3. I/E Ratio Change	3	0	1	0
4. Amplitude Increase	11	3	4	3
5. Amplitd Decrease/Suppression	8	5	3	4
6. Progressive Increase/Decrease	0	1	0	1
7. Progressive Increase & Return	1	1	0	1
8. Progressive Decrease & Return	5	1	2	1
9. Baseline Change - Temporary	12	6	4	5
10. Baseline Change - Permanent	3	1	1	1
11. Apnea - Holding (inspiration)	0	1	0	1
12. Apnea - Blocking (Exhalation)	3	1	1	1
ELECTRODERMAL	53			
1. Amplitude Change	78	29	26%	24%
2. Complex Response	17	5	6	4
3. Response Duration & Return	69	27	23	23
CARDIOVASCULAR				
1. Baseline Increase & Decrease	49	24	16%	20%
2. Baseline Increase	5	2	2	1
3. Baseline Decrease	8	3	3	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	19	6	6	5
6. Rate Increase	1	0	1	0
7. Rate Decrease	0	0	0	0
	299	119		

Table 2-10-I

Title:

Q. Second Chart Reactions

Column 1. is:

NDI Men

Column 2. is:

NDI Women

Column 3. is:

% Distribution of 1

Column 4. is:

% Distribution of 2

<i>2nd Charts</i>		NDI Men	NDI Women	NDI Men	NDI Women
		1	2	3	4
RESPIRATION		no.	no.	%	%
1. Rate Decrease		3	0	4	0
2. Rate Increase		0	0	0	0
3. I/E Ratio Change		2	0	3	0
4. Amplitude Increase		7	2	9	9
5. Amplitd Decrease/Suppression		1	1	1	5
6. Progressive Increase/Decrease		0	0	0	0
7. Progressive Increase & Return		0	0	0	0
8. Progressive Decrease & Return		1	1	1	5
9. Baseline Change - Temporary		5	0	6	0
10. Baseline Change - Permanent		0	0	0	0
11. Apnea - Holding (inspiration)		0	0	0	0
12. Apnea - Blocking (Exhalation)		2	0	3	0
ELECTRODERMAL					
1. Amplitude Change		17	6	22	27%
2. Complex Response		7	0	9	0
3. Response Duration & Return		15	5	19	23
CARDIOVASCULAR					
1. Baseline Increase & Decrease		11	5	14	23
2. Baseline Increase		1	0	1	0
3. Baseline Decrease		4	2	5	9
4. Amplitude Increase		0	0	0	0
5. Amplitude Decrease		1	0	1	0
6. Rate Increase		0	0	0	0
7. Rate Decrease		0	0	0	0
		77	22		

Table 2-10-J

Title:

Q .10 Second Chart Reactions

Column 1. is:

DI Men

Column 2. is:

DI Women

Column 3. is:

% Distribution of 1

Column 4. is:

% Distribution of 2

2nd Chart		DI Men	DI Women	DI Men	DI Women
		no.	no.	%	%
RESPIRATION		1	2	3	4
1. Rate Decrease		2	2	1	2
2. Rate Increase		2	1	1	1
3. I/E Ratio Change		1	0	1	0
4. Amplitude Increase		4	1	2	1
5. Amplitd Decrease/Suppression		7	4	3	4
6. Progressive Increase/Decrease		0	1	0	1
7. Progressive Increase & Return		1	1	1	1
8. Progressive Decrease & Return		4	0	2	0
9. Baseline Change - Temporary		7	6	3	6
10. Baseline Change - Permanent		3	1	1	1
11. Apnea - Holding (inspiration)		0	1	0	1
12. Apnea - Blocking (Exhalation)		1	1	1	1
ELECTRODERMAL					
1. Amplitude Change		61	25	27	25%
2. Complex Response		10	5	5	5
3. Response Duration & Return		54	22	24	22
CARDIOVASCULAR					
1. Baseline Increase & Decrease		38	19	17	19%
2. Baseline Increase		4	2	2	2
3. Baseline Decrease		4	1	2	1
4. Amplitude Increase		0	0	0	0
5. Amplitude Decrease		18	6	8	6
6. Rate Increase		1	0	1	0
7. Rate Decrease		0	0	0	0
		222	99		

Table 2-10-k

Title: Q 10 Third Chart Reactions

Column 1. is: DI

Column 2. is: NDI

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

<i>3d charts</i>	DI	NDI	DI	NDI
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	3	1	1	1
2. Rate Increase	2	1	1	1
3. I/E Ratio Change	1	0	0	0
4. Amplitude Increase	13	6	4	6
5. Amplitd Decrease/Suppression	10	2	3	2
6. Progressive Increase/Decrease	2	0	1	0
7. Progressive Increase & Return	2	2	1	2
8. Progressive Decrease & Return	4	3	1	3
9. Baseline Change - Temporary	14	3	4	3
10. Baseline Change - Permanent	6	2	2	2
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	4	2	1	2
ELECTRODERMAL	61	22		
1. Amplitude Change	87	21	25	22
2. Complex Response	14	8	4	8
3. Response Duration & Return	81	19	24	20
CARDIOVASCULAR	182	48		
1. Baseline Increase & Decrease	64	16	19	2
2. Baseline Increase	12	1	3	1
3. Baseline Decrease	5	7	1	7
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	19	2	6	2
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
TOTAL	343	96		

100

26

Table 2-10-L

Title: Q10, Third Chart Reactions

Column 1. is: Men

Column 2. is: Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

3d charts

	Men	Women	Men	Women
	no.	no.	%	%
RESPIRATION				
1. Rate Decrease	4	0		
2. Rate Increase	2	1	1	0
3. I/E Ratio Change	0	1	0	1
4. Amplitude Increase	10	8	3	6
5. Amplitd Decrease/Suppression	9	3	3	2
6. Progressive Increase/Decrease	1	1	0	1
7. Progressive Increase & Return	2	1	1	1
8. Progressive Decrease & Return	5	2	2	2
9. Baseline Change - Temporary	10	6	3	5
10. Baseline Change - Permanent	6	2	2	2
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	4	2	1	2
ELECTRODERMAL				
1. Amplitude Change	74	31	25	25%
2. Complex Response	17	5	6	4
3. Response Duration & Return	69	29	23	23
CARDIOVASCULAR				
1. Baseline Increase & Decrease	54	22	18	17%
2. Baseline Increase	11	2	4	2
3. Baseline Decrease	6	5	2	4
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	15	5	5	4
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	299	126		

Table 2-10-M

Title: Q 10, Third Chart Reactions

Column 1. is: NDI Men

Column 2. is: NDI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

3d Chart				
	NDI Men	NDI Women	NDI Men	NDI Women
	1	2	3	4
RESPIRATION				
1. Rate Decrease	1	0	1	0
2. Rate Increase	0	1	0	10
3. I/E Ratio Change	0	0	0	0
4. Amplitude Increase	4	1	5	10
5. Amplitude Decrease/Suppression	2	0	2	0
6. Progressive Increase/Decrease	0	0	0	0
7. Progressive Increase & Return	1	0	1	0
8. Progressive Decrease & Return	3	0	4	0
9. Baseline Change - Temporary	3	0	4	0
10. Baseline Change - Permanent	2	0	2	0
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	2	0	2	0
ELECTRODERMAL				
1. Amplitude Change	18	2	22	20%
2. Complex Response	7	1	9	10
3. Response Duration & Return	17	2	21	20
CARDIOVASCULAR				
1. Baseline Increase & Decrease	14	1	17	10%
2. Baseline Increase	1	0	1	0
3. Baseline Decrease	5	2	6	20
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	2	0	2	0
6. Rate Increase	0	0	0	0
7. Rate Decrease	0	0	0	0
	82	10		

Table 2-10-N

Title: Q 10, Third Chart Reactions

Column 1. is: DI Men

Column 2. is: DI Women

Column 3. is: % Distribution of 1

Column 4. is: % Distribution of 2

3d chart	DI Men	DI Women	DI Men	DI Women
	1	2	3	4
RESPIRATION	no.	no.	%	%
1. Rate Decrease	3	0	1	0
2. Rate Increase	2	0	1	0
3. I/E Ratio Change	0	1	0	1
4. Amplitude Increase	6	7	3	6
5. Amplitude Decrease/Suppression	7	3	3	3
6. Progressive Increase/Decrease	1	1	1	1
7. Progressive Increase & Return	1	1	1	1
8. Progressive Decrease & Return	2	2	1	2
9. Baseline Change - Temporary	7	6	3	5
10. Baseline Change - Permanent	4	2	2	2
11. Apnea - Holding (inspiration)	0	0	0	0
12. Apnea - Blocking (Exhalation)	2	2	1	2
ELECTRODERMAL				
1. Amplitude Change	56	29	26	25%
2. Complex Response	10	4	4	3
3. Response Duration & Return	52	27	24	23
CARDIOVASCULAR				
1. Baseline Increase & Decrease	40	21	18	18%
2. Baseline Increase	10	2	4	2
3. Baseline Decrease	1	3	1	3
4. Amplitude Increase	0	0	0	0
5. Amplitude Decrease	13	5		4
6. Rate Increase	6	6	0	0
7. Rate Decrease	6	0	0	0
8. Total	217	116		

Table 3-1

NDI WOMEN / NDI MEN

Average reactions from sets of charts

Source of reactions from sets of charts

Average heart rate from sets of charts







Table 3-2

NDI WOMEN / DI WOMEN

Average reactions from
sets of charts

Source of reactions from
sets of charts.

Average heart rate
from sets of charts



n. 01 sets, 31 DI sets

Table 3-3

NDI MEN / DI MEN

Average reactions
from sets of charts

Sources of reactions
from sets of charts

Average heart rate
from sets of charts







Table 3-4

D1 WOMEN/D1 MEN

Average reactions
from sets of charts

Source of reactions
from sets of charts

Average heart rate from
sets of charts

No. Women
sets, Men 69 sets





Table 3-5

WOMEN / MEN

Average reactions from sets of charts

Source of reactions from sets of charts

Average Heart Rate from sets of charts



Women 47, men 113 sets

Average Reactions
on DI and NDI Sets
of Charts

Source of Reactions
on DI and NDI Sets
of Charts

DI/NDI

Average Heart Rate
Responses on DI and NDI
sets of charts




TABLE 4 SERIES

DATA FROM THE SETS OF CHARTS

Note on the tables. The \$\$ number/letter group is the Axciton/DoD number; the set number is the FRI file; 10, 8, 7, etc. with Q is the number of questions on a chart; 3C means 3 comparative questions, 3R is the number of relevant questions on a chart, 3 charts is the number of charts run but not counting stim charts; DI is deception indicated; NDI is no deception indicated (both confirmed by independent means; M and F for Male and Female; under Asked is R for Relevant questions, C for comparative questions and T is for technical questions (irrelevant, symptomatic, sacrifice relevant) and the total number of questions asked in that set; (from the left) T is the total number of reactions on each chart and in the set; TR is the total number of reactions in each chart and the set to relevant questions; TC is the same but reactions to the comparative questions; R is the number of reactions by chart and set from the respiration channels; GSR is the number of reactions by chart and set from the electrodermal channel; C is the number of reactions by chart and set from the cardio channel; HR is the heart rate from the beginning and end of each chart and below the average rates for the charts; RR is the respiration rates from the beginning and end of each chart and below the average rate for the charts in the set (not all sets have the RR data on the form); stim data on the lower left if known; notes on fast or slow HR or RR.

Table 4AA

\$\$\$ GROUP Set no. 1 9 No. Test, 3 C 2 R, 3 charts DI ☒, NDI ☒ M ☐ F ☐

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	29	9	8	3	17	9	92/92	na	6 R
b.	34	11	6	5	22	7	90/88		9 C
c.	28	9	8	4	20	4	92/64		12 T
T.	<u>91</u>	<u>29</u>	<u>22</u>	<u>12</u>	<u>59</u>	<u>20</u>	<u>91/81 av.</u>		<u>27</u>

Table 4AB

\$\$\$ 362VRS Set no. 2 10 No. Test, 3 C 3 R, 2 charts DI ☐, NDI ☒ M ☒ F ☐

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	32	9	10	5	20	7	94/92	na	9 R
b.	25	10	9	3	20	2	96/92		9 C
c.	38	11	12	7	24	7	90/90		12 T
T.	<u>95</u>	<u>30</u>	<u>31</u>	<u>15</u>	<u>64</u>	<u>16</u>	<u>93/91 av.</u>		<u>30</u>

Table 4AE

\$\$ 2# 3Rk2 Set no. 5 10 No. Test, 2 C 4 R, 3 charts DI , NDI ☒ M ☒ F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	3i	8	11	3	21	7	122/112	na	12 R
b.	34	9	11	3	21	10	118/110		6 C
c.	36	16	14	5	24	7	118/104		12 T
T.	<u>101</u>	<u>33</u>	<u>36</u>	<u>11</u>	<u>66</u>	<u>24</u>	<u>119/104</u>		<u>30</u>

Table 4AF

\$\$ 2# HS% Y Set no. 6 9 No. Test, 4 C 3 R, 3 charts DI , NDI ☒ M ☒ F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	28	13	11	0	21	7	84/86	na	9 R
b.	36	17	11	5	22	9	78/88		12 C
c.	37	16	12	7	21	9	86/88		6 T
T.	<u>101</u>	<u>46</u>	<u>34</u>	<u>12</u>	<u>64</u>	<u>25</u>	<u>83/87</u>		<u>27</u>

Table 4AG

\$\$\$ MAF Set no. 8 100 Test, 3 C 3 R, 2 charts DI , NDI ✓ M ✓ F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 35	11	11	1	25	9	72/76	na	6 R
b. 39	12	12	5	27	7	74/84		6 C
c.								8 T
<u>74</u>	<u>23</u>	<u>23</u>	<u>6</u>	<u>52</u>	<u>16</u>	<u>73/80 av</u>		<u>20</u>
T.								

Table 4AH

\$\$\$ \$OMLK Set no. 9 100 Test, 3 C 3 R, 3 charts DI , NDI ✓ M ✓ F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 29	8	10	3	18	8	72/76	na	9 R
b. 24	7	5	2	16	6	74/74		9 C
c. 33	10	10	3	22	8	70/76		12 T
<u>86</u>	<u>25</u>	<u>25</u>	<u>8</u>	<u>56</u>	<u>22</u>	<u>72/75 av</u>		<u>30</u>
T.								

Table 4AJ

\$\$\$ 90c Set no. 10. 10 Q-Test, 3 C 3 R, 3 charts DI , NDI ✓ M ✓ F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	32	10	9	2	20	10	76/72	na.	9 ^R
b.	37	12	11	8	20	9	74/78		9 ^C
c.	39	11	11	4	25	10	70/76		12 ^T
T.	<u>108</u>	<u>33</u>	<u>31</u>	<u>14</u>	<u>65</u>	<u>29</u>	<u>73/75</u> av.		<u>30</u>

Table 4AJ

\$\$\$ 32NOLD Set no. 11 10 Q-Test, 3 C 3 R, 3 charts DI , NDI ✓ M ✓ F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	41	16	10	9	22	10	96/102	na.	9 ^R
b.	40	13	11	9	21	10	116/102		9 ^C
c.	43	15	11	11	22	10	98/100		12 ^T
T.	<u>124</u>	<u>44</u>	<u>32</u>	<u>29</u>	<u>65</u>	<u>30</u>	<u>101/101</u> av.		<u>30</u>

Table 4AK

\$\$\$vc8Y Set No. 12 108 No. Test, 3 C 3 R, 4 Charts, DI NDI ☒ M ☒ F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	35	12	12	8	19	8	80/70	na	12 R
b.	35	9	12	7	20	8	80/68		12 C
c.	36	9	12	7	20	9	66/70		<u>16</u> T
d.	35	12	12	8	20	7	68/70		46 Total

e.

F.

<u>Totals</u>	141	42	48	30	79	32	73/69 Av.		
---------------	-----	----	----	----	----	----	-----------	--	--

Table 4 AL

\$\$\$ 96PLM7 Set no. 14 10 Q. Test, 3 C 3 R, 3 charts DI ✓, NDI ✓ M ✓ F ✓

[illegible]

Table 4 A M

\$\$\$
47 Set no. 15 100. Test, 3 C3 R, 3 charts DI ☒, NDI M/F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	25	7	7	2	20	3	90/90	na.	9 ^R
b.	27	9	7	3	21	3	92/88		9 ^C
c.	27	10	6	4	22	1	92/92		12 ^T
T.	<u>79</u>	<u>26</u>	<u>20</u>	<u>9</u>	<u>63</u>	<u>7</u>	<u>91/90 av.</u>		<u>30</u>

Table 4AP

\$\$\$LB k05 Set no. 18 10 Q. Test, 3 C 3 R, 3 charts DI ✓, NDI M F ✓

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	40	12	11	7	22	11	108/104	na	9 R
b.	37	10	9	5	22	16	110/96		9 C
c.	42	14	11	9	23	10	98/98		12 T
T.	<u>119</u>	<u>36</u>	<u>31</u>	<u>21</u>	<u>67</u>	<u>31</u>	<u>105/97</u> av		<u>30</u>

Table 4AQ

\$\$\$K% B1Y Set no. 19 10 Q. Test, 2 C 4 R, 3 charts DI ✓, NDI M F ✓
MCAr

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	37	8	13	7	20	10	80/80	na	12 R
b.	29	2	15	11	11	7	82/78		6 C
c.	24	5	16	3	14	7	84/82		12 T
T.	<u>90</u>	<u>15</u>	<u>44</u>	<u>21</u>	<u>45</u>	<u>24</u>	<u>82/80</u> av		<u>30</u>

Table 4AR

\$\$\$1ES4D Set no. 20 10 Test, 3 C 3 R, 3 charts DI /, NDI M/F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	39	11	12	4	25	10	94/90	n.a.	9 R
b.	40	12	12	5	26	9	92/90		9 C
c.	36	13	12	8	20	8	90/88		12 T
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>
T.	115	36	36	17	71	27	92/89 av.		30

Table 4AS

\$\$\$40136x Set no. 21 10 Test, 3 C 3 R, 3 charts DI /, NDI M/F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	27	7	9	9	9	9	74/82	n.a.	9 R
b.	23	7	9	4	10	9	76/82		9 C
c.	31	9	9	1	22	8	74/80		12 T
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>
T.	81	23	27	14	41	26	75/81 av.		30

Table 4AT

\$\$ 485V \$M Set no. 22 10 Q. Test, 3 C 3 R, 3 charts DI , NDI ✓ M ✓ F
 2 C 3 R on 3rd chart

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 19	4	9	0	16	3	98/94	ha.	9 R
b. 33	10	10	2	26	5	108/94		8 C
c. 31	10	10	4	26	1	98/100		13 T
<u>83</u>	<u>24</u>	<u>29</u>	<u>6</u>	<u>68</u>	<u>9</u>	<u>101/96 av.</u>		<u>30</u>
T.								

Table 4AU

\$\$ 8507V1 Set no. 23 10 Q. Test, 3 C 3 R, 3 charts DI ✓, NDI M ✓ F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 37	10	13	5	24	8	128/124		9 R
b. 36	11	13	5	23	8	122/120		9 C
c. 32	9	11	2	26	10	122/120		12 T
<u>105</u>	<u>30</u>	<u>37</u>	<u>12</u>	<u>67</u>	<u>26</u>	<u>124/121 av.</u>		<u>30</u>
T.								

Table 4AV

\$\$\$4\$J\$ Set no. 24 10 G. Test, 3 C 3 R, 3 charts DI ☒, NDI M ☒ F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 36	11	9	10	21	5	100/96		9 R
b. 37	8	12	12	17	8	104/100		9 C
c. 35	8	10	14	12	9	98/90		12 T
<u>108</u>	<u>27</u>	<u>31</u>	<u>36</u>	<u>50</u>	<u>22</u>	<u>101/95 av</u>		<u>30</u>
T.								

Table 4AW

\$\$\$7MA\$3V Set no. 25 11 G. Test, 4 C 4 R, 3 charts DI ☒, NDI M ☒ F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 30	11	11	7	15	8	102/108		12 R
b. 25	9	12	6	12	7	108/116		12 C
c. 31	14	11	6	18	7	118/92		9 T
<u>86</u>	<u>34</u>	<u>34</u>	<u>19</u>	<u>45</u>	<u>22</u>	<u>109/103 av</u>		<u>33</u>
T.								

Table 4AX

\$\$ 7LL485 Set no. 26 70 Test, 3 C 2 R, 3 charts DI , NDI ✓ M F ✓

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	23	11	6	2	15	6	104/110		6 R
b.	25	8	11	4	16	5	104/102		9 C
c.	25	9	7	6	14	5	102/108		6 T
T.	<u>73</u>	<u>28</u>	<u>24</u>	<u>12</u>	<u>45</u>	<u>16</u>	<u>103/107</u>		<u>21</u>

Table 4AY

\$\$ 7D865 Set no. 27 90 Test, 4 C 3 R, 3 charts DI ✓, NDI M ✓ F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	37	17	13	6	25	6	118/126		9 R
b.	35	13	13	4	23	8	118/110		12 C
c.	33	14	10	5	23	5	108/114		6 T
T.	<u>105</u>	<u>44</u>	<u>36</u>	<u>15</u>	<u>71</u>	<u>19</u>	<u>115/117 Av</u>		<u>27</u>

Table 4AZ

\$\$2#kFTI Set no. 28 9 Test, 4 C 3 R, 3 charts DI , NDI M F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	32	17	8	7	21	4	80/78		9 R
b.	22	8	7	6	10	6	82/76		12 C
c.	25	11	8	4	16	5	80/76		6 T
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>
T.	79	36	23	17	47	15	81/77		27

Table 4BA

\$\$20JQ96 Set no. 29 90 Test, 3 C 2 R, 3 charts DI , NDI M F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	32	11	7	5	18	9	104/94		6 R
b.	34	12	7	6	20	8	98/90		9 C
c.	34	11	8	6	20	8	96/96		12 T
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>
T.	100	34	22	17	58	25	99/93		27

Table 4BB

\$\$201B7M Set no. 30 10 Q. Test, 3 C 3 R, 3 charts DI , NDI / M / F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	39	13	13	7	24	8	114/112		9 R
b.	34	10	10	5	20	9	102/100		9 C
c.	34	10	11	5	20	9	98/106		12 T
T.	<u>107</u>	<u>33</u>	<u>34</u>	<u>17</u>	<u>64</u>	<u>26</u>	<u>105/106</u>		<u>30</u>

Table 4Br

\$\$2013kP Set no. 31 10 Q. Test, 3 C 3 R, 3 charts DI , NDI / M / F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	35	11	9	3	23	9	94/88		9 R
b.	30	8	16	1	21	8	90/86		9 C
c.	31	9	16	1	24	6	90/92		12 T
T.	<u>96</u>	<u>28</u>	<u>29</u>	<u>5</u>	<u>68</u>	<u>23</u>	<u>91/84</u>		<u>30</u>

Table 4BD

\$\$2TD&CA Set no. 32 9 Test, 3 C 2 R, 3 charts DI , NDI /M/F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	36	14	7	16	19	7	62/64		6 R
b.	36	13	8	9	19	8	60/60		9 C
c.	36	10	7	13	17	6	62/66		12 T
T.	<u>108</u>	<u>37</u>	<u>22</u>	<u>32</u>	<u>55</u>	<u>21</u>	<u>61/63</u>		

Table 4BE

\$\$27IMDS Set no. 33 10 Test, 3 C 3 R, 3 charts DI , NDI /M F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	35	9	11	6		5	122/118		9 R
b.	42	13	13	5		10	116/108		9 C
c.	41	10	13	8		10	100/98		12 T
T.	<u>118</u>	<u>32</u>	<u>37</u>	<u>19</u>	<u>74</u>	<u>25</u>	<u>113/108</u>		<u>30</u>

Table 48F

\$\$\$4441 Set no. 34 90 Test, 3 C 2 R, 2 charts DI , NDI ✓ M ✓ F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	35	11	8	6	20	9	82/76		6 R
b.	32	8	7	5	20	7	80/86		9 C
c.									12 T
T.	<u>67</u>	<u>19</u>	<u>15</u>	<u>11</u>	<u>40</u>	<u>16</u>	<u>81/81</u>		<u>27</u>

Table 48G

\$\$\$4441 Set no. 35 11 Test, 5 C 4 R, 3 charts DI , NDI ✓ M ✓ F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	42	18	17	8	24	16	84/90		12 R
b.	37	14	13	6	24	7	88/90		15 C
c.	45	22	16	7	30	8	82/88		6 T
T.	<u>124</u>	<u>54</u>	<u>46</u>	<u>21</u>	<u>78</u>	<u>25</u>	<u>85/89</u>		<u>33</u>

Table 4B11

\$\$\$ 6N61W4 Set no. 36 9 Q₁₀ Test, 4 C 3 R, 3 charts DI /, NDI M / F —

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	33	9	14	9	16	8	124/128		9 ^R
b.	35	11	14	12	16	7	118/116		12 ^C
c.	37	17	13	11	19	7	118/106		6 ^T
T.	<u>105</u>	<u>37</u>	<u>41</u>	<u>32</u>	<u>51</u>	<u>22</u>	<u>120/117</u>		<u>27</u>

Table 4BI

Set no. 27 11Q. Test, 4 C 3 R, 2 charts DI /, NDI M F /

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	41	11	12	13	21	7	88/80		6 R
b.	34	13	8	4	- 17	8	84/82		8 C
c.									8 T
T.	<u>75</u>	<u>24</u>	<u>20</u>	<u>22</u>	<u>38</u>	<u>15</u>	<u>86/81</u>	<u> </u>	<u>22</u>

Table 4BJ

\$\$EVMSK Set no. 38 11 Q. Test, 4 C 3 R, 3 charts DI /, NDI M / F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	38	13	13	5	25	8	98/92		9 R
b.	33	13	10	1	21	11	96/92		12 C
c.	33	13	11	4	21	8			12 T
T.	<u>104</u>	<u>39</u>	<u>37</u>	<u>10</u>	<u>67</u>	<u>27</u>	<u>94/92</u>		<u>33</u>

Table 4BK

\$\$D3DVSL Set no. 39 11 Q. Test, 4 C 3 R, 3 charts DI /, NDI M / F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	40	13	12	5	25	10	138/136		9 R
b.	31	6	10	4	-17	10	142/144		12 C
c.	48	18	15	11	25	12	132/132		12 T
T.	<u>119</u>	<u>37</u>	<u>37</u>	<u>20</u>	<u>67</u>	<u>32</u>	<u>137/137</u>		<u>33</u>

Note Required HR

Table 4BL

\$\$ 51666 Set no. 40 10 Test, 3 C 3 R, 3 charts DI , NDI ✓ M ✓ F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	33	10	10	8	20	5	74/66		9 R
b.	28	9	8	10	15	3	68/62		9 C
c.	39	15	10	10	18	11	64/62		12 T
	<u>100</u>	<u>34</u>	<u>28</u>	<u>28</u>	<u>53</u>	<u>19</u>	<u>69/63</u>		<u>30</u>
T.									

Table 4BM

\$\$ 51666 APA Set no. 41 100 Test, 3 C 3 R, 3 charts DI , NDI M F ✓

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	36	9	12	5	24	7	124/114		9 R
b.	37	12	10	6	23	8	116/110		9 C
c.	28	7	11	4	17	7	116/106		12 T
	<u>101</u>	<u>28</u>	<u>33</u>	<u>15</u>	<u>64</u>	<u>22</u>	<u>119/110</u>		<u>30</u>
T.									

note rapid HR

Table 4BN

Set no. 42 10 Test, 3 C 3 R, 3 charts DI , NDI ✓ M F ✓

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 32	9	8	5	22	5	72/74		9 R
b. 31	8	11	5	19	7	72/76		9 C
c. 25	7	7	9	8	8	72/76		12 T
<u>88</u>	<u>24</u>	<u>26</u>	<u>19</u>	<u>49</u>	<u>20</u>	<u>72/75</u>		<u>30</u>
T.								

Table 4B0

Set no. 43 8 Test, 3 C 2 R, 3 charts DI ✓, NDI M F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 25	10	6	3	15	7	72/74		6 R
b. 29	12	6	4	18	7	72/76		9 C
c. 25	6	9	3	16	6	72/76		9 T
<u>79</u>	<u>28</u>	<u>21</u>	<u>10</u>	<u>49</u>	<u>20</u>	<u>72/75</u>		<u>24</u>
T.								

Table 4BP

\$\$9%2DxD Set no. 44 100 Test, 3 C 3 R, 3 charts DI , NDI M F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	40	13	11	6	26	8	64/68		9 R
b.	41	13	12	7	25	9	64/64		9 C
c.	40	12	12	8	25	7	68/70		12 T
T.	<u>121</u>	<u>38</u>	<u>35</u>	<u>21</u>	<u>76</u>	<u>24</u>	<u>65/68</u>		<u>30</u>

Table 4BQ

\$\$4Q0M75 Set no. 45 100 Test, 3 C 3 R, 3 charts DI , NDI M F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	29	8	11	2	22	5	100/100		9 R
b.	32	11	8	9	18	5	102/98		9 C
c.	31	10	9	5	19	7	94/102		12 T
T.	<u>92</u>	<u>29</u>	<u>28</u>	<u>16</u>	<u>59</u>	<u>17</u>	<u>99/100</u>		<u>30</u>

Table 4BR

\$\$312FSA Set no. 46 10 G. Test, 3 C 3 R, 3 charts DI , NDI M F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	40	13	11	6	25	9	128/132		9 R
b.	40	12	12	8	22	10	152/138		9 C
c.	35	11	12	4	22	9	132/128		12 T
T.	<u>115</u>	<u>36</u>	<u>35</u>	<u>18</u>	<u>69</u>	<u>28</u>	<u>137/133</u>		<u>30</u>

Note rapid HR

Table 4BS

\$\$3HEZV Set no. 47 10 G. Test, 3 C 3 R, 3 charts DI , NDI M F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	47	16	11	9	28	10	98/98		9 R
b.	43	13	13	5	29	9	94/96		9 C
c.	40	12	11	6	25	9	92/92		12 T
T.	<u>130</u>	<u>41</u>	<u>35</u>	<u>20</u>	<u>82</u>	<u>28</u>	<u>95/95</u>		<u>30</u>

Table 4BT

Set no. 48 10 Test, 3 C 3 R, 2 charts DI , NDI ✓ M F ✓

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	37	12	12	8	20	9	94/86		6 R
b.	40	12	11	9	21	10	96/88		6 C
c.									8 T
T.	<u>77</u>	<u>24</u>	<u>23</u>	<u>17</u>	<u>41</u>	<u>19</u>	<u>92/87</u>		<u>20</u>

Table 4BU

Set no. 49 10 Test, 3 C 3 R, 3 charts DI ✓, NDI M F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	33	16	10	0	17	16	68/68		9 R
b.	41	16	12	3	26	12	70/76		9 C
c.	36	9	15	4	19	13	70/68		12 T
T.	<u>110</u>	<u>29</u>	<u>37</u>	<u>7</u>	<u>62</u>	<u>41</u>	<u>69/69</u>		<u>30</u>

Table 4BV

\$\$\$46CUN₄ Set no. 52 10 Q₂ Test, 3 C 3 R, 3 charts DI , NDI ✓ M ✓ F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	35	10	10	4	27	4	102/100		9 R
b.	38	12	11	8	24	6	98/100		9 C
c.	30	10	6	3	24	3	98/96		12 T
T.	<u>103</u>	<u>32</u>	<u>27</u>	<u>15</u>	<u>75</u>	<u>13</u>	<u>99/99</u>		<u>30</u>

Table 4BW

\$\$\$4\$QQ₂ Set no. 53 9 Q₂ Test, 4 C 3 R, 3 charts DI , NDI ✓ M F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	29	14	10	3	19	7	84/90		9 R
b.	26	13	9	2	17	7	90/88		12 C
c.	24	13	9	5	18	3	84/90		6 T
T.	<u>81</u>	<u>40</u>	<u>28</u>	<u>10</u>	<u>54</u>	<u>17</u>	<u>86/89</u>		<u>27</u>

Table 4BX

\$\$\$4%FCVs Set no. 54 9 Test, 4 C 3 R, 3 charts DI , NDI ✓ M F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	28	14	10	3	20	5	90/104		9 R
b.	36	13	10	3	18	9	94/88		12 C
c.	33	14	10	3	23	7	92/90		6 T
	<u>91</u>	<u>41</u>	<u>30</u>	<u>9</u>	<u>61</u>	<u>21</u>	<u>92/94</u>		<u>27</u>
T.									

Table 4BY

\$\$\$4B2225 Set no. 55 10 Q. Test, 4 C 3 R, 4 charts DI , NDI ✓ M F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	39	13	12	10	22	7	96/96		12 R
b.	37	15	10	6	26	11	88/102		16 C
c.	34	16	8	7	19	10	84/86		12 T
d.	<u>46</u>	<u>20</u>	<u>14</u>	<u>12</u>	<u>21</u>	<u>13</u>	<u>90/88</u>		<u> </u>
T.	<u>158</u>	<u>64</u>	<u>44</u>	<u>35</u>	<u>82</u>	<u>41</u>	<u>89/93</u>		<u>40</u>

Table 4BZ

\$\$ 4110RV Set no. 56 9 Test, 3 C 2 R, 3 charts DI , NDI ✓ M ✓ F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 44	14	11	13	23	8	72/72		6 R
b. 44	16	16	12	24	8	74/66		9 C
c. 40	14	7	10	21	9	76/66		12 T
<u>128</u>	<u>44</u>	<u>28</u>	<u>35</u>	<u>68</u>	<u>25</u>	<u>72/68</u>		<u>27</u>
T.								

Table 4 CA

\$\$ ^{6&PVM} Set no. 58 104 Test, 3 C 3 R, 3 charts DI , NDI M F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 41	13	11	4	20	17	102/112		9 R
b. 39	12	10	8	19	12	106/106		9 C
c. 40	11	12	6	21	13	96/100		12 T
<u>120</u>	<u>36</u>	<u>33</u>	<u>18</u>	<u>60</u>	<u>42</u>	<u>101/106</u>		<u>30</u>
T.								

Table 4CB

670225
 \$\$ Set no. 59 10 .Test, 3 C 3 R, 3 charts DI , NDI M/F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	37	11	10	7	21	9	62/60		9 R
b.	30	13	8	8	15	7	56/62		9 C
c.	30	7	11	3	19	8	64/58		12 T
T.	<u>97</u>	<u>31</u>	<u>29</u>	<u>18</u>	<u>55</u>	<u>24</u>	<u>61/60</u>		<u>30</u>

Table 4CC

\$\$\$ AKLWP Set no. 61 100 .Test, 3 C 3 R, 3 charts DI , NDI M/F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	41	13	12	6	21	14	98/104		9 R
b.	40	12	13	3	22	15	108/110		9 C
c.	31	7	11	3	19	9	106/106		12 T
T.	<u>112</u>	<u>32</u>	<u>36</u>	<u>12</u>	<u>62</u>	<u>38</u>	<u>104/107</u>		<u>30</u>

Note HR for Stim only 78/76

Table 4CD

\$54775 Set no. 62 100 Test, 3 C 3 R, 3 charts DI , NDI M F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 19	5	6	3	7	9	64/68		9 R
b. 14	4	5	6	0	8	66/68		9 C
c. 13	5	4	4	0	9	70/68		12 T
<u>46</u>	<u>14</u>	<u>15</u>	<u>13</u>	<u>7</u>	<u>26</u>	<u>67/68</u>		<u>30</u>
T.								

GSR faulty

Table: 4CE

\$\$\$TCovs Set no. 63 10 Q. Test, 3 C 3 R, 3 charts DI , NDI M/F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	25	5	10	1	15	9	86/86		9 R
b.	25	7	4	1	11	13	86/86		9 C
c.	24	8	5	5	13	6	86/82		12 T
T.	<u>74</u>	<u>20</u>	<u>19</u>	<u>7</u>	<u>39</u>	<u>28</u>	<u>86/85</u>		

Table 4 CF

\$\$38AV36 Set no. 64 10 Q. Test, 3 C 3 R, 3 charts DI /, NDI M /F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	39	9	13	2	21	16	78/84		9 R
b.	33	12	11	5	26	8	78/82		9 C
c.	43	13	14	7	22	14	78/70		12 T
T.	<u>115</u>	<u>34</u>	<u>38</u>	<u>14</u>	<u>63</u>	<u>38</u>	<u>78/79</u>		<u>30</u>

Table 4 CG

\$\$40%88A Set no. 65 7 Q. Test, 3 C 2 R, 3 charts DI , NDI M /F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	30	15	9	5	16	9	54/54		6 R
b.	33	14	10	5	15	13	56/56		9 C
c.	33	16	9	2	16	15	56/54		6 T
T.	<u>96</u>	<u>45</u>	<u>28</u>	<u>12</u>	<u>47</u>	<u>37</u>	<u>55/55</u>		<u>21</u>

Note: show HR

Table 4CH\$\$\$T2654 Set no. 66 10 Q. Test, 3 C 3 R, 3 charts DI ☒, NDI M ☒ F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	36	8	11	2	19	9	78/80		9 R
b.	30	6	10	5	16	9	74/72		9 C
c.	44	10	18	9	19	16	74/64		12 T
T.	<u>104</u>	<u>24</u>	<u>39</u>	<u>16</u>	<u>54</u>	<u>34</u>	<u>75/72</u>		<u>30</u>

Table 4CI\$\$\$T8X1 Set no. 67 10 Q. Test, 3 C 2 R, 2 charts DI ☒, NDI M ☒ F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	42	12	14	10	21	11	134/136		6 R
b.	56	19	15	19	21	16	122/142		6 C
c.									8 T
T.	<u>98</u>	<u>31</u>	<u>29</u>	<u>29</u>	<u>42</u>	<u>27</u>	<u>128/136</u>		<u>20</u>

Note rapid H.R.

Table 4CJ

\$\$\$450K26 Set no. 69 100 Test, 3 C 3 R, 3 charts DI , NDI ✓ M ✓ F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 41	11	12	8	16	17	72/68		9 R
b. 40	14	11	2	19	19	74/80		9 C
c. 44	15	13	8	19	17	74/76		12 T
<u>125</u>	<u>40</u>	<u>36</u>	<u>18</u>	<u>54</u>	<u>53</u>	<u>73/76</u>		<u>30</u>
T.								

Stim 92/92

Note large cards output of reactions

Table 4CK

\$\$1%W9T6 Set no. 70 100 Test, 3 C 3 R, 3 charts DI ✓, NDI M ✓ F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 34	9	11	2	22	10	112/108		9 R
b. 34	10	11	3	19	12	98/102		9 C
c. 36	13	10	5	21	10	100/104		12 T
<u>104</u>	<u>32</u>	<u>32</u>	<u>10</u>	<u>62</u>	<u>32</u>	<u>103/105</u>		<u>30</u>
T.								

Stim 92/92

Table 4 CL

\$\$1%3% Mv Set no. 71 9 Q. Test, 3 C 2 R, 3 charts DI , NDI ✓ M F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	32	12	6	4	19	9	112/118		6 R
b.	32	11	7	5	19	8	116/128		9 C
c.	34	11	7	6	20	8	112/128		12 T
T.	<u>98</u>	<u>34</u>	<u>20</u>	<u>15</u>	<u>58</u>	<u>25</u>	<u>113/125</u>		<u>27</u>

Note rapid HR.

Table 4 CM

\$\$1CQ58K Set no. 73 9 Q. Test, 3 C 2 R, 4 charts DI ✓, NDI M F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	27	12	7	6	14	7	80/82		8 R
b.	14	5	5	1	7	6	80/86		12 C
c.	28	8	7	8	17	3	80/82		16 T
d.	<u>22</u>	<u>7</u>	<u>6</u>	<u>7</u>	<u>11</u>	<u>4</u>	<u>86/84</u>		
T.	<u>91</u>	<u>32</u>	<u>25</u>	<u>22</u>	<u>49</u>	<u>20</u>	<u>81/83</u>		<u>36</u>

Table 4CN

\$\$7HRF7A Set no. 74 100 Test, 3 C 3 R, 4 charts DI ☒ NDI M ☒ F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	33	9	8	2	21	10	82/78		12 R
b.	29	11	8	2	22	5	74/78		12 C
c.	30	11	11	2	22	6	82/80		16 T
d.	<u>31</u>	<u>12</u>	<u>8</u>	<u>4</u>	<u>18</u>	<u>9</u>			
T.	123	43	35	10	83	30	78/78		40

Table 4C6

\$\$15CMV Set no. 76 100 Test, 3 C 3 R, 3 charts DI ☒ NDI M ☒ F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	30	10	7	8	17	5	104/108		9 R
b.	31	9	10	5	17	9	104/110		9 C
c.	28	9	10	3	18	7	108/102		12 T
	<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>
T.	89	28	27	16	52	21	105/107		30

Stim 108/108

Net rapid HR average 106

Table 4CP

\$\$IPUGS Set no. 77 11 Q. Test, 4 C 3 R, 3 charts DI /, NDI M F /

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	34	16	9	8	16	16	110/104		9 R
b.	32	12	9	7	18	7	102/108		12 C
c.	27	9	13	6	12	9	102/98		12 T
T.	<u>93</u>	<u>37</u>	<u>31</u>	<u>21</u>	<u>46</u>	<u>26</u>	<u>105/103</u>		<u>33</u>

note rapid LR

Table 4CQ

\$\$IRAGSS Set no. 78 10 Q. Test, 3 C 3 R, 3 charts DI /, NDI M F /

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	35	11	9	4	22	9	78/80		9 R
b.	27	7	8	2	-20	5	82/86		9 C
c.	16	4	3	2	11	3	84/86		12 T
T.	<u>78</u>	<u>22</u>	<u>20</u>	<u>8</u>	<u>53</u>	<u>17</u>	<u>81/84</u>		<u>30</u>

STIM 82/82

Table 4CR

\$\$\$69NMC Set no. 79 106 Test, 3C3R, 3 charts DI , NDI ✓ M F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 39	11	14	5	14	20	64/66	18/18	9 R
b. 40	13	13	5	23	12	66/68	20/18	9 C
c. 28	7	9	5	14	9	64/68	20/18	12 T
<u>107</u>	<u>31</u>	<u>36</u>	<u>15</u>	<u>51</u>	<u>41</u>	<u>65/67</u>	<u>19/18</u>	<u>30</u>
T.						av.	av.	

Note Respiration added
" high out put of cardio

Table 4CS

\$\$\$648SIN Set no. 80 90 Test, 4C3R, 3 charts DI , NDI ✓ M F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 45	18	16	6	23	14	88/92	15/15	9 R
b. 31	14	10	5	16	10	92/94	15/14	12 C
c. 34	17	10	11	12	11	98/94	16/14	6 T
<u>110</u>	<u>49</u>	<u>36</u>	<u>22</u>	<u>51</u>	<u>37</u>	<u>93/93</u>	<u>15/14</u>	<u>27</u>
T.								

Table 4CT

\$\$2400 Set no. 81 9 Q. Test, 3 C 2 R, 3 charts DI /, NDI M / F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	48	16	11	13	18	17	106/122	15/19	6 R
b.	43	16	10	16	19	8	114/120	13/13	9 C
c.	43	14	11	16	20	7	114/108	13/13	12 T
T.	<u>134</u>	<u>46</u>	<u>32</u>	<u>45</u>	<u>57</u>	<u>32</u>	<u>111/117</u>	<u>14/16</u>	<u>27</u>
							AV	AV	

Note large Respiration output of reactions
Note rapid HR

Table 4CU

\$\$H485\$ Set no. 86 10 Q. Test, 4 C 3 R, 3 charts DI /, NDI M / F /

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	47	20	15	6	24	17	100/102	25/24	9 R
b.	46	19	15	6	24	16	102/104	25/25	12 C
c.	43	19	11	9	22	12	102/102	26/25	9 T
T.	<u>136</u>	<u>58</u>	<u>41</u>	<u>21</u>	<u>70</u>	<u>45</u>	<u>101/103</u>	<u>25/25</u>	<u>30</u>
							AV	AV	

Note high cardiac output
Note HR
Note high Respiration Rate

Table 4cv

Set no. 87-9 Test, 4C3R, 3 charts DI NDI M F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 42	20	15	8	21	13	82/88	14/16	9 R
b. 33	15	12	4	21	8	80/84	18/16	12 C
c. 36	16	12	7	20	9	80/82	16/17	9 T
<u>111</u>	<u>51</u>	<u>39</u>	<u>19</u>	<u>62</u>	<u>30</u>	<u>81/85</u>	<u>16/16</u>	<u>30</u>
T.								

Table 4cw

Set no. Test, C R, charts DI NDI M F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 58	18	18	23	26	9	108/108	28/28	9 R
b. 44	14	12	16	21	9	112/106	23/25	12 C
c. 42	15	13	16	20	6	116/106	23/25	6 T
<u>144</u>	<u>47</u>	<u>43</u>	<u>55</u>	<u>67</u>	<u>22</u>	<u>112/107</u>	<u>25/26</u>	<u>27</u>
T.						AV.	AV.	

Note rapid respiration
Note large respiration output of reaction

no more

Table 4EX

\$\$85A3M Set no. 94 10 Test, 3 C 3 R, 3 charts DI , NDI M / F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	44	15	14	7	21	16	68/66	15/15	9 R
b.	49	16	10	6	25	18	60/62	13/15	9 C
c.	54	18	15	12	22	20	62/62	14/15	12 T
T.	<u>147</u>	<u>48</u>	<u>39</u>	<u>25</u>	<u>68</u>	<u>54</u>	<u>63/61</u>	<u>14/16</u>	<u>30</u>

Table 4CY

\$\$2N6V56V Set no. 96 104 Test, 3 C 3 R, 3 charts DI /, NDI M / F /

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	33	11	12	3	13	17	110/102	19/15	9 R
b.	46	10	12	13	19	14	104/104	12/15	9 C
c.	32	11	10	5	18	9	104/102	12/15	12 T
T.	<u>111</u>	<u>32</u>	<u>34</u>	<u>21</u>	<u>50</u>	<u>40</u>	<u>106/103</u>	<u>15/15</u>	<u>30</u>

Table 4C2

\$\$\$C190Y Set no. 97 10 Test, 3 C 3 R, 3 charts DI , NDI M F ✓

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 38	13	11	8	24	6	106/104	22/24	9 R
b. 32	8	12	5	21	6	108/108	22/20	9 C
c. 30	8	9	6	21	3	106/106	21/20	12 T
<u>100</u>	<u>19</u>	<u>32</u>	<u>19</u>	<u>66</u>	<u>15</u>	<u>107/106</u>	<u>22/21</u>	<u>30</u>
T.								

Table 4DA

\$\$\$K139Y Set no. 98 10 Test, 3 C 3 R, 3 charts DI , NDI M F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 48	11	17	10	22	16	88/78	13/17	9 R
b. 47	12	15	14	-13	14	80/88	11/15	9 C
c. 39	8	12	9	15	16	80/90	10/17	12 T
<u>134</u>	<u>31</u>	<u>44</u>	<u>33</u>	<u>55</u>	<u>46</u>	<u>83/85</u>	<u>11/16</u>	<u>30</u>
T.								

STIM 82/86, 16/16

Table 4DB

8 LYJUP

\$\$\$ Set no. 99 10 Test, 3 C 3 R, 3 charts DI ✓, NDI ✓ M ✓ F ✓

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	44	15	12	14	22	8	90/96	22/14	9 R
b.	31	7	10	11	13	7	88/88	16/14	9 C
c.	39	11	13	19	15	5	84/92	18/8	12 T
T.	<u>114</u>	<u>33</u>	<u>35</u>	<u>44</u>	<u>50</u>	<u>20</u>	<u>87/92</u>	<u>19/12</u>	<u>30</u>

STIM 92/86, 16/22

Note unusual output of respiration (44)

Table 4DC\$\$\$ QALXG Set no. 106 10 Test, 3 C 3 R, 3 charts DI ✓, NDI ✓ M ✓ F ✓

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	53	16	15	12	26	15	84/74	22/22	9 R
b.	56	15	15	6	27	18	80/82	21/22	9 C
c.	57	18	17	12	26	14	86/86	21/21	12 T
T.	<u>166</u>	<u>39</u>	<u>47</u>	<u>29</u>	<u>79</u>	<u>52</u>	<u>83/81</u>	<u>21/22</u>	<u>30</u>

Note rapid respiration

Table 4DD

\$\$\$QASW Set no. 101 100 Test, 3 C 3 R, 3 charts DI ☒, NDI M/F F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	34	13	7	12	19	3	92/92	16/19	9 R
b.	26	11	6	8	15	3	94/102	17/15	9 C
c.	33	11	9	14	14	5	104/94	15/18	12 T
	<u>93</u>	<u>35</u>	<u>22</u>	<u>34</u>	<u>48</u>	<u>11</u>	<u>97/96</u>	<u>16/17</u>	<u>30</u>
T.									

STIM 92/88, 23/22

Table 4DE

\$\$\$QSVW4 Set no. 102 100 Test, 3 C 3 R, 3 charts DI ☒, NDI M/F ☒

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	37	13	11	1	23	13	118/116	18/19	9 R
b.	42	11	13	4	24	14	122/110	18/18	9 C
c.	34	12	10	4	19	11	120/120	18/19	12 T
	<u>113</u>	<u>36</u>	<u>34</u>	<u>9</u>	<u>66</u>	<u>38</u>	<u>120/115</u>	<u>18/19</u>	<u>30</u>
T.									

STIM 86/88, 19/23

Note Rapid HR

Table 4DF\$\$\$57Q91K Set no. 103 10 Q Test, 3 C 3 R, 3 charts DI /, NDI M/F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	36	9	16	2	20	8	96/86	17/18	9 R
b.	27	7	7	3	22	2	90/88	14/17	9 C
c.	26	7	9	3	21	2	88/88	15/16	12 T
	<u>83</u>	<u>23</u>	<u>26</u>	<u>8</u>	<u>63</u>	<u>12</u>	<u>91/87</u>	<u>15/17</u>	<u>30</u>
T.									

Stim 86/88, 17/15

Table 4DG\$\$\$V#v7M Set no. 105 10 Q Test, 3 C 3 R, 3 charts DI /, NDI M/F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	37	12	13	4	21	12	84/76	20/16	9 R
b.	42	16	11	6	17	19	78/74	19/16	9 C
c.	47	16	15	8	19	20	76/76	17/16	12 T
	<u>126</u>	<u>44</u>	<u>39</u>	<u>18</u>	<u>57</u>	<u>51</u>	<u>79/75</u>	<u>19/16</u>	<u>30</u>
T.									

Note large output of cardio channel

Stim 70/76, 19/20

Table 4DH

\$\$\$V%CEA Set no. 106 10.4 Test, 3 C 3 R, 3 charts DI /, NDI M /F

[illegible]

Note slow respiration

Table: 401

\$\$\$1%6002 Set no. 108 7 Q. Test, 3 C 2 R, 3 charts DI , NDI /M/F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	22	12	5	2	15	5	108/106	15/18	6 R
b.	19	9	5	1	17	1	112/104	16/17	9 C
c.	25	11	7	5	14	6	104/103	16/18	6 T
	<u>66</u>	<u>32</u>	<u>17</u>	<u>8</u>	<u>46</u>	<u>12</u>	<u>108/103</u>	<u>16/18</u>	<u>21</u>

Table 4DJ

\$\$150BY1 Set no. 109 100 Test, 3 C 3 R, 3 charts DI ☒, NDI M/F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 33	10	11	7	20	6	74/72	18/16	9 R
b. 30	9	8	3	22	5	78/72	15/16	9 C
c. 27	8	8	1	22	4	72/70	16/16	12 T
<u>T. 90</u>	<u>27</u>	<u>27</u>	<u>11</u>	<u>64</u>	<u>15</u>	<u>75/71</u>	<u>16/16</u>	<u>30</u>

Table 4DK

\$\$17RB% Set no. 110 100 Test, 3 C 3 R, 3 charts DI ☒, NDI M/F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 29	8	11	4	20	5	94/88	12/13	9 R
b. 21	6	9	6	8	7	84/84	14/13	9 C
c. 26	8	7	7	12	7	80/82	13/13	12 T
<u>T. 76</u>	<u>22</u>	<u>27</u>	<u>17</u>	<u>40</u>	<u>19</u>	<u>86/85</u>	<u>13/13</u>	<u>30</u>

Table 4DL

\$\$\$146cz Set no. 111 10670 Test, 3C 3R, 3 charts DI /, NDI M / F.

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	28	7	8	2	23	3	100/80	23/25	9 R
b.	29	9	7	9	18	2	96/84	23/24	9 C
c.	39	15	12	10	21	8	80/74	20/26	12 T
	<hr/>	<hr/>	<hr/>	<hr/>	<hr/>	<hr/>	<hr/>	<hr/>	<hr/>
T.	96	31	27	21	62	13	92/79	22/25	30

Table 4DM

\$\$\$ 1061PY Set no. 112 100. Test, 3 C 3 R, 3 charts DI /, NDI M / F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 29	11	7	7	12	10	66/66	20/20	9 R
b. 26	10	11	5	12	9	66/62	17/20	9 C
c. 24	4	9	8	9	7	66/60	14/19	12 T
<u>79</u>	<u>25</u>	<u>27</u>	<u>20</u>	<u>33</u>	<u>26</u>	<u>66/63</u>	<u>17/20</u>	<u>30</u>

Table 4DN

\$\$ | For 2% Set no. 114 ¹⁰ ~~12~~ Test, 3 C 3 R, 3 charts DI /, NDI M F /

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	35	6	12	2	17	16	96/94	19/18	9 R
b.	29	7	9	1	19	4	92/92	15/17	9 C
c.	37	12	12	8	21	8	90/84	17/16	12 T
T.	<u>101</u>	<u>25</u>	<u>33</u>	<u>11</u>	<u>57</u>	<u>33</u>	<u>93/90</u>	<u>17/17</u>	<u>30</u>

STIM 90/86 16/17

Table 4D0

\$\$ H9PVA Set no. 115 10 ~~12~~ Test, 3 C 3 R, 3 charts DI /, NDI M F /

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	46	14	15	2	24	20	98/96	17/16	9 R
b.	31	9	11	1	21	9	94/88	13/13	9 C
c.	36	7	10	3	19	8	96/90	13/14	12 T
T.	<u>107</u>	<u>30</u>	<u>36</u>	<u>6</u>	<u>64</u>	<u>37</u>	<u>96/91</u>	<u>14/14</u>	<u>30</u>

STIM 96/92, 17/14

Table 4DP

\$\$108%31 Set no. 116 10 A. Test, 3 C 3 R, 3 charts DI /, NDI M / F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	22	5	8	5	11	6	82/78	15/12	9 R
b.	16	3	5	3	8	5	78/76	14/13	9 C
c.	23	5	8	7	7	9	78/74	16/13	12 T
T.	<u>61</u>	<u>13</u>	<u>21</u>	<u>15</u>	<u>26</u>	<u>20</u>	<u>79/76</u>	<u>15/13</u>	<u>30</u>

Table 4DQ

\$\$108%31 Set no. 117 10 A. Test, 3 C 3 R, 3 charts DI /, NDI M / F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	37	12	13	6	18	13	86/86	19/14	9 R
b.	41	15	14	18	14	9	88/90	14/18	9 C
c.	32	7	18	12	11	9	84/84	15/19	12 T
T.	<u>110</u>	<u>34</u>	<u>35</u>	<u>36</u>	<u>43</u>	<u>31</u>	<u>86/87</u>	<u>16/17</u>	<u>30</u>

STIM 86/84, 18/17

Table 4DR

\$\$122&N3 Set no. 118 10 Test, 3 C 3 R, 3 charts DI 1, NDI M/F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	22	4	8	2	16		102/106	26/35	9 R
b.	25	7	8	5	20		112/114	31/36	9 C
c.	29	9	10	8	18		116/114	32/34	12 T
	<u>76</u>	<u>20</u>	<u>26</u>	<u>15</u>	<u>54</u>	<u>7</u>	<u>110/110</u>	<u>30/33</u>	<u>30</u>
T.									

Note rapid respiration
Stim 100/108, 30/31

Table 4DS

\$\$2#226T Set no. 119 Test, C R, charts DI 1, NDI M/F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	32	10	8	5	25	2	76/74	18/16	9 R
b.	30	11	10	5	21	4	72/76	17/15	9 C
c.	31	12	11	8	19	4	70/70	15/17	12 T
	<u>93</u>	<u>33</u>	<u>29</u>	<u>18</u>	<u>65</u>	<u>10</u>	<u>73/73</u>	<u>17/16</u>	<u>30</u>
T.									

Handwritten signature

Table 4DT\$2#3R11 Set no. 120 100 Test, 3 C 3 R, 3 charts DI /, NDI M/F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	37	11	8	7	25	5	70/68	17/16	9 R
b.	42	15	13	6	26	10	70/72	17/17	9 C
c.	40	9	11	10	19	11	68/70	15/17	12 T
T.	<u>119</u>	<u>35</u>	<u>32</u>	<u>23</u>	<u>70</u>	<u>26</u>	<u>69/70</u>	<u>16/17</u>	<u>30</u>

Table 4DU\$2#5411 Set no. 121 100 Test, 3 C 3 R, 3 charts DI /, NDI M/F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	37	9	11	7	24	6	88/84	18/19	9 R
b.	34	11	12	7	21	6	84/82	18/19	9 C
c.	39	10	16	9	25	5	88/88	18/17	12 T
T.	<u>110</u>	<u>30</u>	<u>39</u>	<u>23</u>	<u>70</u>	<u>17</u>	<u>87/85</u>	<u>18/18</u>	<u>30</u>

STIM 86/86, 21/20

Table 4DV

\$\$22KMwv Set no. 124 100. Test, 3 C 3 R, 3 charts DI /, NDI M/F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 45	12	15	14	23	8	76/74	11/14	9 R
b. 33	9	11	16	20	3	80/72	10/10	9 C
c. 36	11	9	7	20	9	78/76	10/11	12 T
<u>T. 114</u>	<u>32</u>	<u>35</u>	<u>31</u>	<u>63</u>	<u>20</u>	<u>78/74</u>	<u>10/12</u>	<u>30</u>

note slow respiration

Table 4DW

\$\$29#N4V Set no. 125 100. Test, 3 C 3 R, 3 charts DI /, NDI M/F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 30	6	9	8	18	4	146/144	24/31	9 R
b. 27	7	12	6	17	4	140/128	24/26	9 C
c. 39	8	17	16	17	6	126/122	21/25	12 T
<u>T. 96</u>	<u>21</u>	<u>38</u>	<u>30</u>	<u>52</u>	<u>14</u>	<u>135/131</u>	<u>23/27</u>	<u>30</u>

note rapid HR and RR

Table 4DX

\$\$19N5MY Set no. 126 10 Q. Test, 3 C 3 R, 4 charts DI /, NDI M/F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 31	11	9	5	21	5	88/78	8/8	12 R
b. 40	15	13	11	17	12	68/68	10/7	12 C
c. 19	7	4	1	12	6	68/64	9/8	16 T
d. 34	7	13	6	21	7	66/66	12/10	
<u>124</u>	<u>40</u>	<u>39</u>	<u>23</u>	<u>71</u>	<u>30</u>	<u>72/69</u>	<u>10/8</u>	<u>40</u>
T.								

Stim 72/70 10/4

Note slow respiration

Table 4DY

\$\$20AWKS Set no. 127 10 Q. Test, 3 C 3 R, 3 charts DI /, NDI M/F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 42	10	14	5	26	17	84/90	22/24	9 R
b. 42	12	16	4	24	14	88/90	18/23	9 C
c. 52	17	16	8	26	18	94/94	19/21	12 T
<u>136</u>	<u>39</u>	<u>46</u>	<u>17</u>	<u>70</u>	<u>49</u>	<u>89/91</u>	<u>20/22</u>	<u>30</u>
T.								

STIM 96/96, 18/15

Table 4DZ-1

Set no. 127 100 Test, 3 C 3 R, 3 charts DI /, NDI M/F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 35	12	10	8	21	6	98/100	12/16	9 R
b. 39	14	14	9	19	11	94/94	19/16	9 C
c. 45	15	15	13	19	13	100/94	11/18	12 T
<u>T.</u>	<u>41</u>	<u>39</u>	<u>30</u>	<u>59</u>	<u>30</u>	<u>97/96</u>	<u>14/15</u>	<u>30</u>

STIM 92/86 18/15

Table 4DZ-2

Set no. 128 100 Test, 3 C 3 R, 3 charts DI /, NDI M/F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 35	16	16	7	26	8	88/76	23/23	9 R
b. 39	11	11	8	20	11	72/78	21/21	9 C
c. 40	12	13	11	19	10	74/72	22/19	12 T
<u>114</u>	<u>33</u>	<u>34</u>	<u>26</u>	<u>59</u>	<u>29</u>	<u>78/75</u>	<u>22/24</u>	<u>30</u>
T.								

STIM 84/86 23/24

Table 402-3

\$\$2HS\$Ag Set no. 130 100 Test, 3 C 3 R, 3 charts DI ☒, NDI M F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	30	8	10	5	19	6	104/94	20/22	9 R
b.	24	8	8	2	18	4	80/84	22/19	9 C
c.	31	8	9	5	21	5	82/84	17/18	12 T
T.	<u>85</u>	<u>24</u>	<u>27</u>	<u>12</u>	<u>58</u>	<u>15</u>	<u>89/87</u>	<u>20/20</u>	<u>30</u>

Stim 84/86, 23/22

Table 402-4

\$\$2Hwwsv Set no. 131 100 Test, 3 C 3 R, 3 charts DI ☒, NDI M F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	29	4	11	4	18	7	84/84	20/20	9 R
b.	24	3	3	4	14	6	78/78	15/19	9 C
c.	26	2	4	7	14	5	80/76	16/14	12 T
T.	<u>79</u>	<u>9</u>	<u>18</u>	<u>15</u>	<u>46</u>	<u>18</u>	<u>81/79</u>	<u>17/18</u>	<u>30</u>

Table 4EA

\$\$2K5V47 Set no. 132 10 a. Test, 3 C 3 R, 3 charts DI ☒, NDI M / F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	26	4	11	6	10	10	72/70	17/17	9 R
b.	12	3	3	3	3	6	78/72	21/17	9 C
c.	10	2	4	4	1	5	76/74	18/19	12 T
T.	<u>48</u>	<u>9</u>	<u>18</u>	<u>13</u>	<u>14</u>	<u>21</u>	<u>75/72</u>	<u>19/18</u>	<u>30</u>

Table 4EB

\$\$2M6AR0 Set no. 133 10 a. Test, 3 C 3 R, 3 charts DI ☒, NDI M / F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	42	16	12	8	23	11	72/72	16/17	9 R
b.	49	17	15	12	21	16	80/74	18/15	9 C
c.	40	10	14	5	21	14	76/74	16/18	12 T
T.	<u>131</u>	<u>43</u>	<u>41</u>	<u>25</u>	<u>65</u>	<u>41</u>	<u>76/73</u>	<u>17/17</u>	<u>30</u>

Table 4EC

\$2TELVS Set no. 135 100 Test, 3 C 3 R, 3 charts DI /, NDI M / F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 22	6	7	2	20	0	84/92	11/9	9 R
b. 23	5	8	3	15	5	94/88	9/10	9 C
c. 27	8	9	5	17	5	90/82	10/11	12 T
<u>72</u>	<u>19</u>	<u>24</u>	<u>10</u>	<u>52</u>	<u>10</u>	<u>89/87</u>	<u>10/10</u>	<u>30</u>
T.								

Note slow respiration
stim 96/96, 10/9

Table 4ED

\$20WP8s Set no. 139 100 Test, 3 C 3 R, 3 charts DI /, NDI M / F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 49	17	14	13	26	10	74/60	23/18	9 R
b. 46	12	12	6	24	16	62/66	20/19	9 C
c. 52	19	16	16	24	12	60/66	14/19	12 T
<u>147</u>	<u>48</u>	<u>42</u>	<u>35</u>	<u>74</u>	<u>38</u>	<u>65/64</u>	<u>19/19</u>	<u>30</u>
T.								

Two stim tests 62/60, 22/21 and 62/64, 20/21

Table 4EE

Set no. 140 100 Test, 3 C 3 R, 3 charts DI /, NDI M / F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	25	7	11	3	13	9	104/98	20/23	9 R
b.	19	4	7	6	2	11	20/22	20/22	9 C
c.	21	4	7	6	5	10	20/21	20/21	12 T
T.	<u>65</u>	<u>15</u>	<u>25</u>	<u>15</u>	<u>20</u>	<u>30</u>	<u>99/93</u>	<u>20/22</u>	<u>30</u>

Table 4EF

Set no. 141 100 Test, 3 C 3 R, 3 charts DI /, NDI M / F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	36	12	13	7	20	9	90/88	17/15	9 R
b.	34	10	12	3	21	10	90/82	17/15	9 C
c.	41	10	12	12	20	9	84/82	15/12	12 T
T.	<u>111</u>	<u>32</u>	<u>37</u>	<u>22</u>	<u>61</u>	<u>28</u>	<u>88/84</u>	<u>16/14</u>	<u>30</u>

STIM 80/78, 16/14

Table 4EG

\$\$3&R&Z Set no. 143 8Q Test, 3 C 3 R, 3 charts DI , NDI M F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	35	12	13	4	16	15	70/72	22/21	9 R
b.	31	12	12	2	16	13	72/72	21/20	9 C
c.	19	8	6	5	6	8	78/76	22/21	6 T
T.	<u>85</u>	<u>32</u>	<u>31</u>	<u>11</u>	<u>38</u>	<u>36</u>	<u>73/73</u>	<u>22/21</u>	<u>24</u>

Table 4EH

\$\$3&RR&S Set no. 144 10&T Test, 3 C 3 R, 3 charts DI , NDI M F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	39	12	12	10	23	6	72/74	17/16	9 R
b.	28	9	9	1	21	6	74/74	19/21	9 C
c.	29	6	8	7	18	4	74/74	21/21	12 T
T.	<u>96</u>	<u>27</u>	<u>29</u>	<u>18</u>	<u>62</u>	<u>16</u>	<u>73/74</u>	<u>19/19</u>	<u>30</u>

STIM 74/74 25/22

Table 4ET

\$\$\$302HWY Set No. 146 100 No. Test, 3 C 3 R, 6 Charts, DI ☒ NDI ☐ M ☒ F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	32	9	8	5	23	4	102/100	26/24	18 ^R
b.	29	7	8	5	21	3	98/100	18/20	18 ^C
c.	32	12	8	7	21	4	96/96	24/21	<u>24</u> ^T
d.	33	9	10	5	23	5	96/96	26/23	60 Total
e.	40	10	13	9	24	7	98/96	15/22	
F.	32	11	10	7	21	4	94/94	23/22	
<u>Totals</u>	<u>198</u>	<u>58</u>	<u>57</u>	<u>38</u>	<u>133</u>	<u>27</u>	<u>97/97</u>	<u>21/22</u>	
							AV.	AV.	

STIM 100/102, 26/26

Table 4EI

\$\$34042 Set no. 145 7 Q. Test, 3 C 2 R, 3 charts DI , NDI M/F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	26	12	8	3	16	7	88/82	18/16	6 R
b.	29	13	9	3	19	7	96/86	17/16	9 C
c.	24	11	8	1	17	6	96/88	17/18	6 T
T.	<u>79</u>	<u>36</u>	<u>25</u>	<u>7</u>	<u>52</u>	<u>20</u>	<u>93/85</u>	<u>17/17</u>	<u>21</u>

Table 4EK

\$\$31624 Set no. 147 10 Q. Test, 3 C 3 R, 3 charts DI , NDI M/F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	34	11	14	2	22	10	76/76	20/20	9 R
b.	37	10	13	2	22	13	74/78	18/21	9 C
c.	33	10	13	4	17	12	72/76	19/20	12 T
T.	<u>104</u>	<u>31</u>	<u>40</u>	<u>8</u>	<u>61</u>	<u>35</u>	<u>74/77</u>	<u>19/19</u>	<u>30</u>

STIM 74/74, 17/18

Table 4EL

\$\$\$QDDP Set no. 148 10 Test, 3 C 3 R, 3 charts DI /, NDI M/F /

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	39	11	11	1	22	14	88/86	20/20	9 R
b.	37	11	12	2	22	13	88/90	18/21	9 C
c.	39	13	13	1	21	17	84/86	19/20	12 T
T.	<u>115</u>	<u>35</u>	<u>36</u>	<u>4</u>	<u>65</u>	<u>46</u>	<u>87/88</u> Av	<u>19/20</u> Av	<u>30</u>

STIM 88/84, 23/22

Table 4EM

\$\$\$HPENI Set no. 149 10 Test, 3 C 3 R, 3 charts DI /, NDI M/F /

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	24	7	6	8	14	2	72/66	15/18	9 R
b.	31	9	8	16	16	11	66/76	15/12	9 C
c.	29	11	10	13	9	7	66/64	11/10	12 T
T.	<u>84</u>	<u>27</u>	<u>24</u>	<u>31</u>	<u>33</u>	<u>20</u>	<u>68/69</u> Av	<u>14/13</u> Av	<u>30</u>

Table 4EN

\$\$\$310135 Set no. 150 10 @ Test, 3 C 3 R charts DI /, NDI M F /

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	30	5	12	2	16	12	86/78	16/11	9 R
b.	36	9	10	3	20	13	82/80	9/11	9 C
c.	36	6	13	4	17	14	74/80		12 T
T.	<u>101</u>	<u>20</u>	<u>35</u>	<u>9</u>	<u>53</u>	<u>39</u>	<u>81/79</u>	<u>10/13</u> <u>10/12</u>	<u>30</u>

STIM 82/80, 16/12

Table 4EO

\$\$\$314% F7 Set no. 152 Test, 3 C 3 R, 2 charts DI /, NDI M F /

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	32	10	12	6	18	8	126/126	21/22	6 R
b.	33	10	11	17	12	4	124/124	17/17	6 C
c.									8 T
T.	<u>65</u>	<u>20</u>	<u>23</u>	<u>23</u>	<u>30</u>	<u>12</u>	<u>125/125</u> AV	<u>19/19</u> AV	<u>20</u>

STIM 128/126 24/24

Rapid HR and RR

Table 4EP

\$\$\$T&DUG Set no. 153 100 Test, 3C3R, 3 charts DI __, NDI ☒ M ☒ F ☒

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	36	11	7	6	22	8	162/110	24/23	9 R
b.	35	13	9	3	19	13	162/108	23/22	9 C
c.	39	10	11	6	18	15	100/104	22/20	12 T
T.	<u>110</u>	<u>34</u>	<u>27</u>	<u>15</u>	<u>59</u>	<u>36</u>	<u>101/107</u>	<u>23/22</u>	<u>30</u>

Table: 4EQ

\$\$\$TL9RG Set no. 154 10:00 Test, 3 C 3 R, 3 charts DI /, NDI M F /

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	42	12	14	2	20	20	68/68	17/16	9 R
b.	34	13	11	1	18	15	64/70	16/18	9 C
c.	26	7	9	1	12	13	66/66	18/18	12 T
T.	<u>102</u>	<u>32</u>	<u>34</u>	<u>4</u>	<u>50</u>	<u>48</u>	<u>66/68</u>	<u>17/17</u>	<u>30</u>
							AV.	AV.	

Table. 4ER

\$\$\$WZ8EP Set no. 155 100 Test, 3 C 3 R, 3 charts DI ☒, NDI M F ☒

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	45	10	19	13	21	11	76/80	21/17	9 R
b.	27	5	10	9	10	8	82/74	17/17	9 C
c.	29	7	9	5	13	11	74/70	16/17	12 T
	<u>101</u>	<u>22</u>	<u>38</u>	<u>27</u>	<u>44</u>	<u>30</u>	<u>77/75</u>	<u>18/17</u>	<u>30</u>
T.							Av	Av	

STIM 68/68, 18/18

Table: 4ES

Set no. _____ Test, 4 C 4 R, 2 charts DI __, NDI ✓ M F *Gender unknown*

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	36	16	13	5	18	13	72/74	14/13	8 R
b.	33	16	10	7	17	9	72/70	13/13	8 C
c.									4 T
T.	69	32	23	12	35	22	72/72	13/13	20

Table 46rGender
unknown

\$\$ 4% 1424 Set no. 159 9 Q Test, 4 C 3 R, 2 charts DI , NDI M F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	35	16	11	6	19	10	74/70	12/13	6 R
b.	40	20	10	11	14	15	70/72	10/13	8 C
c.									4 T
T.	<u>75</u>	<u>36</u>	<u>21</u>	<u>17</u>	<u>33</u>	<u>25</u>	<u>72/71</u> av.	<u>11/13</u> av.	<u>18</u>

Table 460Gender
unknown

\$\$ 4% 1425 Set no. 160 9 Q Test, 4 C 3 R, 2 charts DI , NDI M F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	40	19	13	6	26	8	104/106	14/18	6 R
b.	38	16	14	6	23	9	106/104	17/17	8 C
c.									4 T
T.	<u>78</u>	<u>35</u>	<u>27</u>	<u>12</u>	<u>49</u>	<u>17</u>	<u>105/105</u> av.	<u>15/17</u> av.	<u>18</u>

Table 4EY

\$\$\$468461 Set no. 161 90 Test, 3C2R, 3 charts DI__, NDI✓M✓F__

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	34	14	2	4	14	16	86/86	18/17	6 R.
b.	34	11	6	4	14	16	82/84	17/17	9 C.
c.	38	13	8	4	16	18	78/90	17/18	12 T.
	<u>106</u>	<u>38</u>	<u>16</u>	<u>12</u>	<u>44</u>	<u>50</u>	<u>82/87</u> Av.	<u>17/17</u> Av.	<u>27</u>

Note high production for Cardio

Table 4EW

\$410090 Set no. 162 9A Test, 3C2R, 3 charts DI___, NDI___ M F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	42	14	10	9	18	15	82/76	13/13	6 R
b.	39	13	10	6	19	14	78/76	11/12	9 C
c.	39	12	8	5	17	17	76/78	13/14	12 T
	<u>120</u>	<u>39</u>	<u>28</u>	<u>20</u>	<u>54</u>	<u>46</u>	<u>79/77</u>	<u>12/13</u>	<u>27</u>
T.							AV.	AV.	

Table 4Ex

\$\$\$4276YP Set no. 164 100 Test, 3 C 3 R, 3 charts DI /, NDI M F ✓

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 22	8	9	3	17	2	94/98	15/17	9 R
b. 13	2	5	4	5	4	96/94	17/17	9 C
c. 22	5	7	4	14	4	94/96	18/17	12 T
<u>57</u>	<u>15</u>	<u>21</u>	<u>11</u>	<u>36</u>	<u>10</u>	<u>95/96</u>	<u>17/17</u>	<u>30</u>
T.						AV	AV	

Table 4EY

\$\$\$4675Z1 Set no. 165 90 Test, 3 C 4 R, 3 charts DI /, NDI M F /

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 38	12	17	3	24	11	78/78	17/16	12 R
b. 30	11	14	4	22	4	76/80	17/15	9 C
c. 30	11	13	2	20	8	76/80	15/16	6 T
<u>98</u>	<u>34</u>	<u>44</u>	<u>9</u>	<u>66</u>	<u>23</u>	<u>77/79</u>	<u>16/16</u>	<u>27</u>
T.						AV	AV	

Table 4EZ

\$\$4QF6AW Set no. 166 100 Test, 3 C 3 R, 3 charts DI ✓, NDI M F ✓

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	33	13	9	4	22	7	92/90.	13/13	9 R
b.	34	11	10	1	23	10	92/90	12/13	9 C
c.	36	9	14	5	21	10	96/88	13/13	12 T
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>
T.	103	33	33	10	66	27	93/89 AV.	13/13 AV	30

Table 4FA

\$\$4kmpyx Set no. 167 100 Test, 3 C 3 R, 3 charts DI ✓, NDI M F ✓

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	41	9	12	4	19	18	104/94		9 R
b.	37	10	13	3	16	18	96/104		9 C
c.	42	13	12	8	16	18	102/96		12 T
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>
T.	120	32	37	15	51	54	101/98 AV.	13/15 AV	30

note large cardio output.

Table 4FB

\$\$456RZH Set no. 169 10Q Test, 3 C 3 R, 3 charts DI /, NDI M/F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 47	12	17	7	24	16	78/76	18/17	9 R
b. 45	15	13	10	24	11	80/78	18/19	9 C
c. 46	12	15	9	22	15	76/76	15/17	12 T
<u>138</u>	<u>39</u>	<u>45</u>	<u>26</u>	<u>70</u>	<u>42</u>	<u>78/77</u>	<u>17/18</u>	<u>30</u>
T.						Av.	Av.	

Table 4FC

\$\$4068yp Set no. 171 8Q Test, 3 C 3 R, 3 charts DI /, NDI M/F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 41	19	15	13	18	10	58/56	9/9	9 R
b. 37	14	12	8	29	10	56/54	9/9	9 C
c. 35	13	13	11	18	6	54/52	13/10	6 T
<u>113</u>	<u>46</u>	<u>40</u>	<u>32</u>	<u>55</u>	<u>26</u>	<u>56/55</u>	<u>10/9</u>	<u>24</u>
T.						Av.	Av.	

Note slow HR and RR

Table 4FD

\$\$401YNM Set no. 172 10Q Test, 3 C 3 R, 3 charts DI ✓, NDI ✓, M ✓, F ✓

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 56	17	13	9	25	16	94/116	17/16	9 R
b. 42	15	12	7	20	15	94/92	16/16	9 C
c. 37	14	13	5	22	10	98/46	15/17	12 T
<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>
T. 129	46	38	21	67	41	95/99 AV	16/16 AV	30

Table 4FE

\$\$40K#CV Set no. 173 8Q Test, 3 C 3 R, 3 charts DI ✓, NDI ✓, M ✓, F ✓

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 30	14	11	3	21	6	48/48	15/14	9 R
b. 25	10	9	2	17	6	48/56	14/15	9 C
c. 30	12	12	6	19	5	50/48	16/14	6 T
<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>
T. 85	36	32	11	57	17	49/49 AV	15/14 AV	24

Not slow HR

Table 4 FF

\$\$\$40YCP\$ Set no. 174 10Q Test, 3C3 R, 3 charts DI /, NDI M / F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	45	14	15	10	22	13	74/78	11/12	9 R.
b.	44	16	12	11	21	12	78/76	11/12	9 C.
c.	38	12	12	13	21	4	76/74	9/11	12 T
	<u>127</u>	<u>42</u>	<u>39</u>	<u>34</u>	<u>64</u>	<u>29</u>	<u>76/74</u>	<u>10/12</u>	<u>30</u>
T.							AV	AV	

Table 4FG

\$540275M Set no. 175 10^G Test, 3 C 3 R, 3 charts DI /, NDI M / F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	42	12	13	6	19	17	78/78	14/15	9 R
b.	34	9	16	3	18	13	74/74	18/19	9 C
c.	32	7	10	4	19	9	76/78	15/16	12 T
	<u>108</u>	<u>28</u>	<u>33</u>	<u>13</u>	<u>56</u>	<u>39</u>	<u>76/77</u> AV	<u>16/17</u>	<u>30</u>

Table FH

\$\$4VB93J Set no. 176 8 Q Test, 3 C 3 R, 3 charts DI , NDI M/F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 29	14	6	4	14	11	66/66	17/17	9 R
b. 36	14	7		12	13	70/62	14/14	9 C
c. 24	11	7		8	13	64/62	16/15	6 T
<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>
T. 83	39	20	12	34	37	67/61 AV	16/15 AV	24

Table 4FI

\$\$4WH68M Set no. 177 10 Q Test, 3 C 3 R, 3 charts DI , NDI M/F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 32	13	13	3	20	9	124/126	25/20	9 R
b. 33	14	15	7	16	10	114/108	22/22	9 C
c. 28	7	12	3	16	9	110/108	22/22	12 T
<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>
T. 93	24	31	13	52	28	116/114 an	23/21 an	30

4FL

\$\$4YM&3D Set no. 186 10Q Test, 3C3R 3 charts DI ☒, NDI M ☒ F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	39	12	14	6	19	14	74/74	18/17	9 R
b.	43	12	14	9	20	14	70/70	15/18	9 C
c.	44	16	12	7	22	15	68/70	14/17	12 T
T.	<u>126</u>	<u>40</u>	<u>40</u>	<u>22</u>	<u>61</u>	<u>43</u>	<u>71/71</u> AV	<u>16/17</u> AV	<u>30</u>

Tabl 4FM

\$\$51Q%WP Set no. 181 10Q Test, 3C3R 3 charts DI ☒, NDI M ☒ F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	41	11	18	11	24	6	104/108	26/24	9 R
b.	41	12	13	9	20	12	96/104	20/21	9 C
c.	45	17	14	12	21	12	90/100	24/24	12 T
T.	<u>127</u>	<u>40</u>	<u>45</u>	<u>32</u>	<u>65</u>	<u>30</u>	<u>97/104</u> AV	<u>23/23</u> AV	<u>30</u>

Tabl 4FN

\$\$59W25L Set no. 182 100 Test, 3 C 3 R 3 charts DI /, NDI M F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	42	14	11	6	27	9	110/110	24/27	9 R
b.	43	14	12	15	19	9	94/90	17/23	9 C
c.	49	16	17	13	24	12	102/94	21/22	12 T
T.	<u>134</u>	<u>44</u>	<u>40</u>	<u>34</u>	<u>70</u>	<u>30</u>	<u>102/98</u> av	<u>21/24</u> av	<u>30</u>

Tabl 4FD

\$\$59W25L Set no. 183 100 Test, 3 C 3 R 3 charts DI /, NDI M F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	41	15	12	12	21	8	86/82	19/19	9 R
b.	43	15	14	16	17	10	88/84	14/20	9 C
c.	43	13	16	17	17	9	86/86	17/17	12 T
T.	<u>127</u>	<u>43</u>	<u>42</u>	<u>45</u>	<u>55</u>	<u>27</u>	<u>87/84</u> av	<u>17/19</u> av	<u>30</u>

Table 4FP

\$\$CZY7KJ Set no. 184 9Q. Test, 3 C 2 R 3 charts DI , NDI M F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	36	16	7	10	18	8	104/102	13/14	6 R
b.	44	17	8	8	24	12	106/100	15/14	9 C
c.	35	11	9	7	21	7	100/106	11/15	12 T
T.	<u>115</u>	<u>44</u>	<u>24</u>	<u>25</u>	<u>63</u>	<u>27</u>	<u>103/103</u> av	<u>13/14</u> av	<u>27</u>

Table 4FQ

\$\$SDW41D Set no. 185 10Q. Test, 3 C 3 R 3 charts DI , NDI M F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	36	11	11	6	26	10	146/140	21/23	9 R
b.	45	14	15	10	20	9	146/132	16/15	9 C
c.	37	11	12	10	20	7	130/136	16/20	12 T
T.	<u>118</u>	<u>36</u>	<u>38</u>	<u>32</u>	<u>60</u>	<u>26</u>	<u>141/136</u> av	<u>18/19</u> av	<u>30</u>

note rapid HR

Tabl 4FR

\$\$51114A Set no. 186 9 Q. Test, 3 C2 R 3 charts DI, NDI M F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	37	12	10	8	19	10	80/78	19/16	6 R
b.	32	9	7	4	19	9	84/82	17/15	9 C
c.	40	11	8	8	22	10	78/78	16/16	12 T
T.	109	32	25	20	60	29	81/79 av	17/16 av	27

Table 4FS

\$\$5VWK%P Set no. 187 10 Q. Test, 3 C3 3 charts DI, NDI M F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	22	7	5	7	5	10	72/76	14/16	9 R
b.	25	5	12	12	4	9	80/78	14/14	9 C
c.	15	5	6	4	7	4	82/82	12/11	12 T
T.	62	17	23	23	16	23	78/79 av	13/14 av	30

Table 4 F T

\$\$65VPC Set no. 188 9 Q Test, 3 C 2 R 3 charts DI, NDI/M F✓

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 30	10	8	2	19	9	92/88	13/12	6 R
b. 26	7	2	4	13	3	86/84	12/12	9 C
c. 24	8	5	4	18	2	84/84	14/14	12 T
<u>T.</u> 74	<u>25</u>	<u>15</u>	<u>10</u>	<u>50</u>	<u>14</u>	<u>87/85</u> av	<u>13/13</u> av	<u>27</u>

Table 4 FU

\$\$6248XD Set no. 189 10 Q Test, 3 C 3 R 3 charts DI✓, NDI M F✓

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 46	13	17	14	19	7	102/100	22/18	9 R
b. 27	2	15	6	13	8	106/98	15/22	9 C
c. 40	12	9	10	21	9	102/100	21/26	12 T
<u>T.</u> 107	<u>27</u>	<u>41</u>	<u>30</u>	<u>53</u>	<u>24</u>	<u>103/99</u> av	<u>19/26</u> av	<u>30</u>

Table 4FV

Set No. 190 10 No. Test, 6 ln 3, 9 QTY, 3, 3CR3, 3C2R, 6 charts DI F NDI M F

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	28	8	4	3	14	11	88/86	17/16	18 R
b.	3	7	8	5	15	11	92/86	13/17	15 C
c.	21	6	8	4	11	6	92/90	16/15	<u>24</u> T
d.	38	7	19	8	21	9	92/96	16/17	57 Total
e.	35	8	12	9	17	9	94/90	15/13	
f.	29	6	15	6	15	8	92/92	13/15	
<u>Totals</u>	182	42	66	35	93	54	92/90 av.	15/15 av.	

Table 4 GA

\$\$\$760CB Set no. 195-100 Test, 3 C 3 R, 3 charts DI ☒, NDI M F ☒

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	33	10	12	4	20	9	98/104	13/16	9 R
b.	37	11	11	6	20	11	100/102	14/16	9 C
c.	44	13	14	9	20	15	98/102	14/16	12 T
	<u>114</u>	<u>34</u>	<u>37</u>	<u>19</u>	<u>60</u>	<u>35</u>	<u>99/103</u>	<u>14/16</u>	<u>30</u>
T.							AV	AV	

Table: 4GB

\$\$\$840DR Set no. 199 10 Q. Test, 3. C 3 R, 3 charts DI ✓, NDI M F ✓

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 33	12	12	5	21	7	106/104	21/22	9 R
b. 44	12	16	6	24	14	108/106	21/22	9 C
c. 33	10	10	8	20	5	104/108	22/24	12 T
<u>110</u>	<u>34</u>	<u>38</u>	<u>19</u>	<u>65</u>	<u>26</u>	<u>106/106</u>	<u>21/23</u>	<u>30</u>
T.						AV	AV	

Table 4GC

\$\$94244# Set no. 200 10 Q Test, 3 C 3 R, 3 charts DI ☒, NDI M F ☒

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	48	15	18	9	23	16	86/92	17/17	9 R
b.	49	16	15	9	23	17	98/92	17/18	9 C
c.	39	13	12	8	25	6	92/98	19/21	12 T
T.	<u>136</u>	<u>44</u>	<u>45</u>	<u>26</u>	<u>71</u>	<u>39</u>	<u>94/94</u> AV	<u>187/19</u> AV	<u>30</u>

Table 4GD

\$\$A%UGYU Set no. 201 10 Q Test, 3 C 3 R, 3 charts DI ☒, NDI M F ☒

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	46	16	13	0	25	15	80/80	22/20	9 R
b.	42	11	13	4	23	15	86/86	23/21	9 C
c.	40	14	16	4	22	14	82/80	21/20	12 T
T.	<u>122</u>	<u>35</u>	<u>42</u>	<u>8</u>	<u>70</u>	<u>44</u>	<u>83/82</u> AV	<u>22/20</u>	<u>30</u>

Table 46E

\$\$\$GNKZHO Set no. 204-90 Test, 4 C 3 R, 3 charts DI __, NDI ☒ M / F __

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	39	19	11	8	18	13	100/98	18/20	9 R.
b.	38	16	14	5	18	15	98/100	18/24	12 C.
c.	41	17	14	9	18	14	94/98	21/24	6 T.
	<u>118</u>	<u>52</u>	<u>39</u>	<u>22</u>	<u>54</u>	<u>42</u>	<u>97/99</u>	<u>19/23</u>	<u>27</u>
T.							AV	AV	

Table: 46F

\$\$\$MSGD Set no. 267 10 Q Test, 3 C 3 R, 3 charts DI __, NDI ✓ M ✓ F ✓

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 26	8	8	15	3	2	82/82	14/12	9 R
b. 17	6	5	13	0	4	88/80	11/13	9 C
c. 13	7	4	9	0	4	84/82	13/14	12 T
<u>50</u>	<u>21</u>	<u>17</u>	<u>37</u>	<u>3</u>	<u>10</u>	<u>85/81</u>	<u>13/13</u>	<u>30</u>
T.						AV	AV	

Table 466

\$\$317CRP Set no. 57 10 Q Test, 4 C 4 R, 3 charts DI ☒, NDI M F Gender Unknown

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	47	20	20	17	20	10	124/122		12 R
b.	49	17	18	13	20	10	132/128		12 C
c.	40	16	18	10	20	10	114/120		6 T
T.	<u>136</u>	<u>53</u>	<u>56</u>	<u>40</u>	<u>66</u>	<u>30</u>	<u>123/123</u>	<u>n/a</u>	<u>30</u>

note rapid HR

Table 464

\$\$2V\$A\$A Set no. 57 10 Q Test, 3 C 3 R, 3 charts DI ☒, NDI M F Gender Unknown

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	27	8	11	4	16	7	84/88		9 R
b.	29	9	9	1	21	7	88/96		9 C
c.	29	8	9	4	14	11	82/90		12 T
T.	<u>85</u>	<u>25</u>	<u>29</u>	<u>9</u>	<u>51</u>	<u>25</u>	<u>85/91</u>	<u>n/a</u>	<u>30</u>

AV

STIM 88/88

gender unknown

	T	TC	TR	R	GSR	C	HR	RR	Asked
a.	29	8	17	8	16	17	98/106		12 R
b.	22	5	14	8	19	17	104/96		12 C.
c.	26	9	13	6	19	17	104/96		6 T
T.	<u>77</u>	<u>22</u>	<u>44</u>	<u>22</u>	<u>54</u>	<u>53</u>	<u>102/99</u>	<u>n/a</u>	<u>30</u>
							av.		

gondes
un horn

T	TC	TR	R	GSR	C	HR	RR	Asked
a.	26	16	6	2	21	3	72/76	9 R
b.	33	12	10	6	23	4	74/78	9 C
c.	22	7	8	4	12	6	70/76	12 T
T.	81	29	24	12	56	13	72/77	30

Table 46K

\$\$2FZAV4 Set no. 84 106 Test, 3 C 3 R, 3 charts DI ✓, NDI M F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 35	9	11	10	21	4	74/72		9 R
b. 37	11	11	10	21	6	70/66		9 C
c. 49	13	15	9	26	9	72/68		12 T
<u>116</u>	<u>33</u>	<u>37</u>	<u>29</u>	<u>68</u>	<u>19</u>	<u>72/69</u>	<u>77</u>	<u>30</u>
T.						AV		

STIM 68/72

Table 46L

\$\$2FZE#A Set no. 85 70 Test, 3 C 2 R, 3 charts DI ✓, NDI M F

Gender unknown

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 23	8	9	2	13	8	86/96	17/16	6 R
b. 23	12	5	3	15	5	90/90	17/17	9 C
c. 21	7	8	3	14	4	84/92	16/15	6 T
<u>67</u>	<u>27</u>	<u>22</u>	<u>8</u>	<u>42</u>	<u>17</u>	<u>87/93</u>	<u>17/16</u>	<u>21</u>
T.						AV	AV	

Table 460Gender
Unknown\$\$21LORJ Set no. 92 80 Test, 3 C 3 R, 3 charts DI ☒, NDI M F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 30	8	8	7	15	8	120/114	15/15	9 R
b. 32	9	14	8	16	8	116/120	15/15	9 C
c. 35	15	11	10	16	9	120/118	13/12	6 T
<u>97</u>	<u>32</u>	<u>33</u>	<u>25</u>	<u>47</u>	<u>25</u>	<u>119/117</u>	<u>14/14</u>	<u>24</u>
T.						AV	AV	

JmTHR

Table 461Gender
Unknown\$\$21LRY a Set no. 93 7 Q Test, 3 C 2 R, 3 charts DI ☒, NDI M F

T	TC	TR	R	GSR	C	HR	RR	Asked
a. 26	8	11	6	13	7	114/116	14/13	6 R
b. 29	11	11	6	17	6	116/120	14/14	9 C
c. 21	7	8	6	9	6	122/114	14/15	6 T
<u>76</u>	<u>25</u>	<u>30</u>	<u>18</u>	<u>39</u>	<u>19</u>	<u>117/117</u>	<u>14/14</u>	<u>21</u>
T.								

Rapid HR

Tabl 4 GG

\$\$\$2K1E2Y Set no. 95 100 Test, 3 C 3 R 3 charts DI ☒, NDI M ☒ F ☐

	T	TC	TR	R	GSR	HR	RR	Asked
a.	44	15	14	9	22	13	92/88 - 21/15	9 Relevant Q.
b.	50	14	16	13	25	12	78/80 10/15	4 Comparative Q.
c.	50	16	14	14	26	10	80/80 19/12	12 Technical Q.
	<u>144</u>	<u>45</u>	<u>44</u>	<u>36</u>	<u>73</u>	<u>35</u>	<u>83/83</u> <u>17/14</u>	<u>30</u> Total Q. asked

2014

Table 1

Set no. _____ Test, C Parts DI , NDI M F

T	TC	TR	R	GSR	C	HR	RR	Asked
---	----	----	---	-----	---	----	----	-------

2. R

b. C

C. T

T.

Table 5-1

Electrodermal

Q. 1	509 reactions/amplitude	590 questions asked	86%
Q. 2.	503 " "	590 " "	85%
Q. 3.	492 " "	590 " "	83%
Q. 4.	489 " "	590 " "	83%
Q. 5.	506 " "	590 " "	86%
Q. 6.	482 " "	590 " "	82%
Q. 7.	493 " "	590 " "	84%
Q. 8.	450 " "	585 " "	77%
Q. 9.	440 " "	579 " "	76%
Q. 10.	439 " "	572 " "	77%

Table 5-2

Electrodermal

Q.	1.	489	reactions/duration	590	questions asked	83%
Q.	2.	479	"	590	"	81%
Q.	3.	454	"	590	"	77%
Q.	4	451	"	590	"	76%
Q.	5.	481	"	590	"	82%
Q.	6	458	"	590	"	78%
Q.	7.	463	"	590	"	78%
Q.	8.	450	"	585	"	77%
Q.	9.	440	"	579	"	76%
Q.	10.	439	"	572	"	77%

Table 5-3

Electrodermal

Q.	1.	59	Reactions/Complex	590	Questions asked	10%
Q.	2.	117	" "	590	" "	20%
Q.	3.	128	" "	590	" "	22%
Q.	4.	122	" "	590	" "	21%
Q.	5.	102	" "	590	" "	17%
Q.	6.	170	" "	590	" "	29%
Q.	7.	109	" "	590	" "	18%
Q.	8.	95	" "	585	" "	16%
Q.	9.	105	" "	579	" "	18%
Q.	10.	74	" "	572	" "	13%

Table 5-4

FREQUENCY OF ELECTRODERMAL RESPONSES

	Electro. Amplitude	Electro. Duration	Electro. Complex	Amplitude Frequency
Q, 1	1	2	7	86%
Q. 2	1	2	4	85%
Q. 3	1	2	4	83%
Q. 4	1	2	4	83%
Q. 5	1	2	5	86%
Q. 6	1	2	4	82%
Q. 7	1	2	5	84%
Q 8	1	2	4	79%
Q 9	1	2	4	79%
Q 10	1	2	5	84%

Table 5-5

AVERAGE HEART RATES IN THIS STUDY

	1st	2nd	3d
Male White DI n.9	87/95	96/96	91/89
Male White NDI n.16	83/81	84/82	81/82
Male Black DI n.9	100/99	97/98	95/94
Male Black NDI n.5	74/74	71/73	73/73
Female White DI n.7	107/103	105/103	105/102
Female White NDI n.9	87/88	87/89	87/87
Female Black DI n.3	114/112	115/111	108/111
Female Black NDI n.3	100/99	97/96	97/97
Average	94/94	94/93	93/92

Table 5-6

Gender and Outcome of Tests

Men Tested	115	DI 71 (62%)	NDI 44 (38%)
Women Tested	46	DI 31 (67%)	NDI 15 (39%)
Gender Unknown	16	DI 9 (56%)	NDI 7 (44%)
Total Tested	177	DI 111 (63%)	NDI 66 (37%)

Of 161 tested whose gender is known, 115 are men (71%) and 46 are women (29%). To compare reactivity of men and women on question 2 of the first chart, you divide the total number of reactions by men, 449, by the number of men tested and get 3.9. The total for women is 182, divided by 46, and get 4.0. These are reasonable results, see Table 1-1. If you are going to compare reactivity of DI Men with DI Women, you divide by 71 for Men and 31 for women, from table 5-6 (supra).

	1	2	3	4	6	7	8	9	10	TAV	IC
RESTIRATION										0.1	NDI
1. Rate Decrease	1	2	2	2	2	2	3	2	2	2	1.1
2. Rate Increase	0	1	2	1	0	1	1	1	1	1	.7
3. I/E Ratio Change	0	0	1	1	1	1	0	0	0	.5	.3
4. Amplitude Increase	4	4	4	4	4	3	3	3	3	3.6	3.3
5. Amplitd Decrease/Suppression	1	2	3	3	2	2	4	4	3	2.6	2.6
6. Progressive Increase/Decrease	1	0	1	1	1	1	1	1	0	.7	.6
7. Progressive Increase & Return	1	0	1	1	0	0	1	0	0	.4	.8
8. Progressive Decrease & Return	1	1	1	1	1	1	1	2	2	1.3	1.7
9. Baseline Change - Temporary	4	3	5	4	3	4	4	4	4	4	3.2
10. Baseline Change - Permanent	2	2	2	2	3	2	2	3	2	2.2	2.6
11. Apnea - Holding (Inspiration)	0	0	0	0	0	0	0	0	0	0	.1
12. Apnea - Blocking (Exhalation)	1	2	1	2	1	1	1	1	1	1.2	.5
ELECTRODERMAL										19.5	17.5
1. Amplitude Change	29	26	25	24	24	25	26	26	26	25.6	25.2
2. Complex Response	2	5	5	5	5	4	4	4	4	4.4	6.1
3. Response Duration & Return	27	25	23	21	23	24	24	24	24	23.8	24.1
CARDIOVASCULAR										53.8	55.4
1. Baseline Increase & Decrease	13	15	13	16	18	15	15	16	17	15.5	15.5
2. Baseline Increase	5	5	4	3	2	2	2	2	2	2.9	3.0
3. Baseline Decrease	2	1	2	3	2	2	2	3	2	2.3	2.9
4. Amplitude Increase	0	0	0	0	0	0	0	0	0	0	0
5. Amplitude Decrease	5	6	5	7	6	4	4	5	6	5.5	4.5
6. Rate Increase	0	0	0	0	0	0	0	0	0	0	0
7. Rate Decrease	0	0	0	0	0	0	0	0	0	0	0
99%, 100%											26.2 25.9

Age:

Comments:

5-7A

Deceptive Charts: Distribution of responses by Percentage

	1	2	3	4	5	6	7	8	9	10	T	IC
RESPIRATION											ND1	
1. Rate Decrease	1	1	1	1	1	1	1	1	1	2	1,1	
2. Rate Increase	0	1	0	1	1	0	1	0	2	1	1,7	
3. I/E Ratio Change	0	0	0	0	0	1	0	1	0	1	1,3	
4. Amplitude Increase	4	4	2	4	2	3	3	3	3	5	3,3	
5. Amplitude Decrease/Suppression	4	3	4	2	2	3	2	2	2	2	2,6	
6. Progressive Increase/Decrease	1	1	0	1	0	0	1	1	0	1	1,6	
7. Progressive Increase & Return	1	1	1	1	1	1	0	1	0	1	1,8	
8. Progressive Decrease & Return	1	2	2	2	2	1	2	2	2	1	1,7	
9. Baseline Change - Temporary	2	3	4	3	5	3	3	4	2	2	3,2	
10. Baseline Change - Permanent	3	2	2	3	2	3	3	3	2	3	2,6	
11. Apnea - Holding (Inspiration)	0	0	0	0	0	0	0	0	0	1	1,1	
12. Apnea - Blocking (Exhalation)	1	1	0	1	0	1	0	1	0	0	1,5	
ELECTRODERMAL											17,5	
1. Amplitude Change	2,6	2,5	2,4	2,4	2,6	2,5	2,6	2,5	2,6	2,5	2,5,2	
2. Complex Response	3	1	8	7	6	8	6	7	7	8	6,1	
3. Response Duration & Return	2,6	2,5	2,3	2,3	2,5	2,4	2,5	2,4	2,4	2,2	2,4,1	
CARDIOVASCULAR											55,4	
1. Baseline Increase & Decrease	12	14	17	15	17	14	17	15	17	17	15,5	
2. Baseline Increase	7	3	3	4	3	2	2	3	2	1	3,0	
3. Baseline Decrease	2	3	2	3	3	4	2	3	2	5	2,9	
4. Amplitude Increase	0	0	0	0	0	0	0	0	0	0	0	
5. Amplitude Decrease	4	8	5	5	5	5	4	5	4	3	4,5	
6. Rate Increase	0	0	0	0	0	0	0	0	0	0	0	
7. Rate Decrease	0	1	0	0	0	0	0	0	0	0	1,1	
											25,9	

Age: _____

Comments: _____

Table 5-7B

Non-deceptive charts: Distribution of responses by percentage.

Table 5-8

CHART SERIAL EFFECT - ELECTRODERMAL

DI	1st 2d	3d	chart	1st 2d	3d	NDI
1.	222 210	-12 191	-31	136 136	-0 120	-16
2.	234 213	-21 216	-18	155 137	-18 120	-35
3.	231 221	-10 190	-41	172 131	-41 94	-78
4.	185 199	+14 193	+8	141 129	-12 121	-20
5.	223 229	+6 224	+1	155 125	-141 141	-14
6.	247 215	-32 209	-38	180 136	-44 132	-48
7.	234 230	-4 214	-20	163 120	-43 111	-52
8.	203 190	-13 192	-11	124 110	-14 97	-27
9.	225 189	-36 149	-76	136 175	+39 114	-22
10.	217 185	-32 182	-35	128 60	-68 48	-80
	2221 2081	1960		1490 1259	1098	
	-140	-261		-231	-392	

CHART SERIAL EFFECT - RESPIRATION

NDI

DI

	1st	2d	3d	chart	1st	2d	3d
1.	56	54	-2	60 +4	38	41	+3 38 0
2.	63	73	+10	77 +14	46	42	-4 47 +1
3.	77	86	+9	89 +12	48	33	-15 40 -8
4.	69	86	+17	92 +13	56	43	-13 38 -18
5.	82	84	+2	97 +15	47	38	-9 37 -10
6.	81	88	+7	91 +10	50	44	-6 34 -16
7.	75	87	+12	93 +18	47	32	-15 38 -9
8.	76	78	+2	83 +7	41	29	-12 33 -8
9.	73	70	-3	59 -14	34	7	-27 37 +3
10.	83	55	-28	61 -22	41	26	-15 22 -19
	745	761	+26	802 +57	448	335	-113 364 -84

CHART SERIAL EFFECT - CARDIO

	DI				NDI			
1.	105	106	+1	77	-28	61	71	+10 55 -6
2.	114	112	-2	99	-15	67	64	-3 56 -11
3.	103	101	-2	98	-5	83	72	-11 50 -33
4.	98	119	+21	122	+24	77	63	-14 50 -27
5.	136	129	-7	101	-35	68	62	-6 63 -5
6.	96	103	+7	105	+9	72	65	-7 60 -12
7.	134	113	-21	123	-11	74	59	-15 40 -34
8.	79	87	+8	83	+4	61	50	-11 44 -17
9.	105	93	-12	76	-29	59	133	+74 51 -8
10.	106	100	-6	100	-6	59	28	-31 26 -33
	<u>1076</u>	<u>1063</u>	<u>-13</u>	<u>984</u>	<u>-92</u>	<u>681</u>	<u>667</u>	<u>495</u> <u>-14</u> <u>-186</u>

Table 5-11

CHART SERIAL EFFECT BY CHANNEL

DI charts	1st	2d	3d	NDI 1st	2d	2d
Respiration	745	761	802	448	335	364
Electrodermal	2221	2081	1960	1490	1259	1098
Cardiovascular	1076	1063	984	681	667	495
Average	1347	1302	1249	873	754	652

Data from tables in 2 Series

Table 5-42

TWO CARDIO FREQUENCY TABLES

This is a comparison of Carl Jensen's study of the frequency of cardio responses taken from 66 specific issue tests in his files with the frequency of cardio responses from the 176 specific issue sets of files in this study. The lists are in descending order. We have changed his terminology to match ours .

THIS STUDY		JENSEN'S STUDY	
Baseline increase & decrease	2778	Baseline increase & decrease	363
Pulse amplitude decrease	940	Pulse amplitude decrease	326
Baseline increase	578	Baseline increase	172
Baseline decrease	400	Pulse amplitude increase	52
Pulse rate increase	25	Baseline decrease	48
Pulse rate decrease	23	Pulse rate increase	43
Pulse amplitude increase	5	Baseline decrease	42
		Pulse rate decrease	20

See Jensen Carl W. (1981) Frequency of occurrence of specific reaction criteria as observed in the cardio tracing. Academy Journal 4 (2) 5, 7.

Table 5-13

PERCENTAGE PROFILE OF Q.5 from 1st, 2nd, & 3rd CHARTS

RESPIRATION	1ST DI %	2nd DI %	3rd DI %
R1	2	2	2
R2	1	0	0
R3	0	1	2
R4	6	4	3
R5	1	1	4
R6	0	1	2
R7	0	0	0
R8	2	2	1
R9	3	4	4
R10	3	2	3
R11	0	0	0
R12	0	1	2

ELECTRODERMAL

	1st DI	2d DI	3d DI
E1	24	24	24
E2	4	5	5
E3	23	23	22

CARDIO

C1	19	19	16
C2	3	1	2
C3	1	2	1
C4	0	0	0
C5	7	7	5
C6	0	0	0
C7	0	0	0

	1st NDI %	2d NDI %	3d NDI %
RESPIRATION			
R1	0	1	0
R2	1	1	1
R3	0	0	0
R4	2	4	2
R5	4	0	1
R6	0	1	1
R7	1	0	1
R8	2	2	2
R9	4	3	3
R10	2	4	3
R11	0	0	0
R12	0	0	1

5-13

ELECTRODERMAL

	1st NDI %	2d NDI %	3d NDI %
E1	26	25	26
E2	7	5	6
E3	24	24	25

CARDIO

C1	16	17	18
C2	3	3	1
C3	3	3	3
C4	0	0	0
C5	4	5	4
C6	0	0	0
C7	0	0	0